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Cancer immunotherapy is designed to boost the body’s immune system, 
promoting immune cells to recognize and attack cancer cells. It is typically used 
as an adjuvant method for cancer treatment. In this PhD project, we explored the 
potential of stem cell- and dendritic cell-based cancer immunotherapy. 
Neural stem/progenitor cells (NSCs) with the ability to target tumors have 
emerged as a potential delivery vehicle for cancer gene therapy. The breakthrough 
in derivation of human-induced pluripotent stem cells (hiPSCs) provides an 
approach that may help overcome ethical and allergenic challenges posed in 
numerous medical applications involving the use of human cells, including NSCs. 
We employed three in vitro methods to generate NSCs from hiPSCs. Then we 
attempted to enhance the tropism by manipulation of proteins that are involved in 
regulating the migration of NSCs toward cancer cells. We compared gene 
expression profiles between migratory and non-migratory hiPSC-NSCs towards 
cancer cells and observed that the gene encoding human nitric oxide synthase 1 
(neuronal), also known as nNOS or NOS1, was down-regulated in migratory 
hiPSC-NSCs. Using nNOS inhibitors and nNOS siRNAs, we demonstrated that 
this protein was a relevant regulator in controlling migration of hiPSC-NSCs 
towards cancer cells, and that inhibition of its activity or down-regulation of its 
expression could sensitize poorly migratory NSCs, hence improving their tumor 
tropism. These findings suggest a novel application of nNOS inhibitors in neural 
stem cell-mediated cancer therapy.  
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The interaction between CD40 ligand (CD40L) and CD40 can directly 
inhibit growth of CD40-positive carcinoma cells and may indirectly inhibit tumor 
growth through co-ordination of immune responses. We report herein an 
alternative means of using the tumor homing property of neural stem cells (NSCs) 
to deliver CD40L molecules into tumor tissues. hiPSC-NSCs were transduced in 
vitro with a baculoviral vector encoding CD40L, and intravenously injected into 
mice with orthotopic and metastatic breast cancers in immune-competent mice. 
Through a bystander mechanism of intercellular transfer of CD40L from the 
donor NSCs to tumor target cells, the treatment impeded the tumor growth, 
leading to the prolonged survival of the tumor bearing mice. This new approach 
of employing NSC-based CD40L immunogene therapy may be particularly 
valuable for metastatic cancer treatments following systemic stem cell 
administration. 
Growing evidence suggests that cancer stem cells (CSCs) are responsible 
for tumorigenesis, cancer recurrence, metastasis, and the failure of cancer 
treatment. CSCs are demonstrated to be resistant to traditional chemo- and radio-
therapies. However, whether CSCs are sensitive to immune cell-mediated cell 
killing still needs to be explored. Here we confer certain CSC-like properties to 
human glioma cells by reprogramming. The reprogramming genes were inserted 
into the AAVS1 locus in glioma cell genome using zinc-finger nuclease (ZFN) 
technology for stable and long-term transgene expression. Human dendritic cells 
loaded with lysates of cancer stem-like cells were capable of eliciting CSC 
antigen specific T-cell response after in vitro priming autologous T cells. 
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Therefore, we envision that OSKM-expressing glioma cell lines can be used as a 
readily accessible source to provide CSC-related antigens for dendritic cell 
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1.1 Neural Stem/Progenitor Cells  
Neural stem/progenitor cells (NSCs) are self-renewing and multi-potent cells that 
give rise to three fundamental neural lineages, namely, neurons, astrocytes, and 
oligodendrocytes (Fig. 1.1). NSCs exist in the developing fetal brain, as well as in 
the mature adult brain. In the latter, NSCs are predominately located in the sub-
ventricular zone (SVZ) and the hippocampus (Kosztowski et al. 2009, Massa & 
Seliger 2013). NSCs are important candidates for the treatment of 
neurodegenerative diseases, such as stroke and Alzheimer’s disease (Srivastava et 
al. 2008). Transplanted NSCs are capable of repairing and replacing injured cells 
and tissues in the nervous system. On the other hand, because of their intrinsic 
tumor homing properties, NSCs are of great interest in cancer gene therapy. In 
recent years, progress has been demonstrated in NSC-mediated gene therapy in 
different tumor models, such as glioma and breast cancer (Shimato et al. 2007, 
Aboody et al. 2000, Yang et al. 2012b). The increasing potential of NSCs 
necessitates the availability of a reliable and continuous source of uniform human 
NSCs for clinical applications.  
 
Fig. 1.1 NSC differentiation (Cited from Sigma-Aldrich) 
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1.1.1 Source of NSCs  
NSCs can be isolated from fetal- or adult-derived central nervous system (CNS) 
(Cai & Grabel 2007). However, primary human NSCs are limited in quantity, 
exhibit variable quality, and are difficult to expand in vitro. Although oncogene-
mediated immortalization provides a solution to the limited life span of NSCs, 
this method causes various safety concerns regarding the transforming and 
oncogenic potential of the oncogenes used (Aboody et al. 2008, Kosztowski et al. 
2009, Taupin 2007). Thus, it poses a great challenge in the large-scale preparation 
of NSCs with stable properties.  
  Several candidate sources have been proposed for the generation of these 
cells. Considering their unlimited self-renewing capability and pluripotency, 
embryonic stem cells are an attractive alternative to fetal- or adult-derived CNS 
tissue. Many studies have reported the successful induction of NSCs from human 
and mouse embryonic stem cells (Wilson & Stice 2006, Dottori & Pera 2008, 
Parisi et al. 2010, Ying et al. 2003, Swistowski et al. 2009, Axell et al. 2009). 
After the introduction of iPSCs that were reprogrammed from somatic cells in 
2006 (Yu et al. 2007, Takahashi & Yamanaka 2006), which exhibit functional 
similarities to embryonic stem cells (ESCs), iPSCs have also been considered a 
candidate for NSC production. However, only a small number of studies have 
demonstrated the possibility of NSC generation from iPSCs (Swistowski et al. 
2010, Chambers et al. 2009, Dimos et al. 2008). Although hiPSCs could provide a 
stable and reliable source for the large-scale generation of human NSCs and 
decrease the probability of immune rejection, hiPSC reprogramming is time-
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consuming and labor-intensive.  
  Recently, several studies have demonstrated the possibility of direct 
conversion from one cell type, such as fibroblasts, to other cell types, such as 
neurons (Caiazzo et al. 2011), blood cells (Szabo et al. 2010), cardiomyocytes 
(Efe et al. 2011), and hepatocytes (Huang et al. 2011). Furthermore, several 
researchers have successfully reprogrammed mouse fibroblasts to expandable and 
tri-potent NSCs through the insertion and over-expression of certain transcription 
factors (Han et al. 2012, Kim et al. 2011, Lujan et al. 2012, Thier et al. 2012). 
However, these protocols used randomly integrated lentiviruses or retroviruses, 
which preferentially integrate into coding or regulatory regions of genes within 
the host genomes; this approach increases the likelihood of oncogene activation, 
gene silencing, and insertional mutagenesis (Schroder et al. 2002, Hacein-Bey-
Abina et al. 2003). The use of lentiviruses or retroviruses, which are infectious to 
humans, is a biosafety concern that cannot be ignored. Moreover, most neural 
transdifferentiation studies have been conducted on mouse fibroblasts with low 
efficiency, while direct conversion from human fibroblasts to NSCs is less well 
documented. 
1.1.2 Tumor tropism of human NSCs 
A lot of research has indicated that NSCs possess innate tumor tropism towards 
glioma and can track these tumor cells through existing or non-typical migration 
routes (Flax et al. 1998, Aboody et al. 2000). In in vivo studies on mice, NSCs 
were observed to surround the tumor border as well as “chasing down” infiltrating 
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tumor cells regardless of NSCs injection location and its distance to the tumor. 
Lin et al. demonstrated that NSCs transplanted intracranially into a mouse glioma 
model infiltrated the entire tumor mass and tracked migratory glioma cells foci 
(Lin et al. 2007). When administrated intravenously, NSCs were also able to 
migrate to various extra-cranial locations, such as the liver, ovaries, and bone 
marrow, to target disseminated tumor cells of neural origin (Aboody et al. 2000, 
Aboody et al. 2006, Brown et al. 2003, Yang et al. 2012b). Furthermore, NSCs 
also display extensive migratory properties towards other types of solid tumors, 
such as non-glial tumor in the brain (Dickson et al. 2007), breast cancer, and 
colon cancer (Yang et al. 2012b). These findings have suggested a powerful 
therapeutic approach of using NSCs to target not only the major tumor mass but 
also distant tumor outgrowths. 
1.1.3 NSCs as gene delivery vehicle  
Systemic administration of stem cells with tumor tropic migratory properties for 
cancer treatment is attractive, given that the injected cells may home to multiple 
metastases in different sites through circulation. Adult stem cells, including 
mesenchymal stem cells (MSCs), NSCs and endothelia progenitor cells (EPCs), 
recently have emerged as cellular vehicles for targeted delivery of therapeutic 
genes to treat primary and disseminated cancers (Wei et al. 2004, Aboody et al. 
2008, Cihova et al. 2011, Binello & Germano 2012, Shah 2012). However, it 
have been broadly recognized that MSCs that reach tumor stroma can contribute 
to tumor growth by promoting angiogenesis, creating a niche to support the 
survival of cancer stem cells, suppressing immune responses against tumor cells, 
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and/or promoting cancer metastasis (Karnoub et al. 2007, Galderisi et al. 2010, 
Klopp et al. 2011, Arap & Pasqualini 2004, Debatin et al. 2008). EPCs might play 
roles in vasculogenesis (formation of blood vessels by in situ differentiation of 
EPCs), angiogenesis (expansion of pre-existing blood vessels), and possibly 
promoting solid tumor growth. NSCs also effectively function as vehicles for 
tracking tumor cells and delivering anti-cancer agents (Aboody et al. 2008, 
Cihova et al. 2011, Shah 2012). In particular, after the systemic administration of 
NSCs via intravenous injection, injected cells may home in on multiple 
intracranial tumor foci and disseminated tumors outside the brain to inhibit tumor 
growth (Aboody et al. 2006, Danks et al. 2007, Kim et al. 2012, Tang et al. 2003, 
Yang et al. 2012b, Zhao & Wang 2010b, Zhao et al. 2012a). Another important 
advantage of NSCs is the high transfection and transduction efficiency making it 
easy to be engineered with therapeutic gene. Unlike the use of MSCs for cancer 
therapy, which is viewed as a double-edged sword, there is no report of pro-tumor 
effects for NSCs currently. 
1.1.4 NSC-mediated cancer gene therapy 
Based on their tumor tropic and inhibitory properties, NSCs derived from 
different origins, such as somatic tissues or human pluripotent stem cells, have 
been extensively studied for their potential use in cancer gene therapy. NSCs were 
reported to be capable of delivering a therapeutic gene to a tumor distant from the 
NSC injection site (Lorico et al. 2008, Benedetti et al. 2000). The studies of 
Aboody et al. demonstrated that a host treated with NSCs that were genetically 
modified to deliver a drug-activating enzyme exhibited a decreased brain tumor 
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size and prolonged survival (Aboody et al. 2000). The ability of stem cells to 
efficiently cross the blood-brain barrier, home in on tumor cells, and subsequently 
secrete a therapeutic molecule provides a very enticing approach to treating CNS 
tumors. Furthermore, our recent research indicates that human pluripotent stem 
cells derived NSCs transduced with a baculoviral vector encoding the herpes 
simplex virus thymidine kinase (HV-tk) suicide gene were effective in inhibiting 
the growth and metastatic spread of 4T1 breast tumors, which prolonged the 
survival of the tumor-bearing mice (Yang et al. 2012b). NSCs have been widely 
investigated as chemotherapeutic (HSV-tk, 5-FC), viral (oncolytic viruses), and 
immune molecule (IL-12 and IFNγ) delivery vehicles (Kosztowski et al. 2009). 
Compared with the other experimental therapies under investigation, such as 
viral-based cancer therapy, stem cells exhibit more potential as powerful 
therapeutics; because, in addition to tumor tropism, they exhibit transcriptional, 
translational, and post-translational expression of large amounts of genetic 
information, which enables them to release therapeutic substances into the tumor 
microenvironment (Kosztowski et al. 2009, Yip et al. 2006).  
1.2 Cancer Stem Cells  
Similar to adult stem cells in humans, tumors, which are aberrant and 
heterogeneous organs, also have their own stem cells, which are referred to as 
cancer stem cells (CSCs) or tumor-initiating cells (TICs). CSCs, which comprise 
only a small population of tumors, can self-renew and differentiate into malignant 
lineages. They are postulated to be crucial for tumor initiation, maintenance, 
metastasis, and relapse (Lathia et al. 2011). CSCs were first discovered in 
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leukemia (Nagano et al. 2012) and were subsequently reported in glioma, breast 
cancer, colon cancer, ovarian cancer, pancreatic cancer, prostate cancer, 
melanoma, and multiple myeloma (Diaz & Leon 2011b). The origins of CSCs 
vary by tumor type (Nurwidya et al. 2012). CSCs may originate from transformed 
stem cells with accumulated mutations. However, some scientists have proposed 
that CSCs may also arise from the dedifferentiation of committed cancer cells. 
Moreover, several studies have demonstrated that the transformation between 
CSCs and differentiated cancer cells is in dynamic equilibrium based on the tumor 
microenvironment (Iliopoulos et al. 2011). 
1.2.1 Role of CSCs in tumor initiation and maintenance 
As stem cells, CSCs are conferred with the capability of self-renewal. CSCs are 
slowly dividing cells. During division, a CSC generates one daughter cell that is 
identical to the original CSC and another cell that is the cancer progenitor cell, 
which is rapidly dividing cell (Economopoulou et al. 2012). They can create the 
tumor bulk through continuous division and differentiation into different types of 
mature tumor cells. This is the process by which CSCs generate the tumor bulk 
and maintain tumor growth. In vivo studies have demonstrated that CSCs, but not 
non-CSCs, can reinitiate tumors that morphologically resemble the original colon 
cancer tissues when transplanted into immune-deficient mice at a low cell number, 
which suggests that these CSCs/TICs have a higher tumorigenic potential than 
non-CSCs (Inoda et al. 2011). 
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1.2.2 CSCs in cancer metastasis 
Metastasis is a complicated process and an indication of progression of solid 
malignancies. Luzzi et al. traced the fate of B16F1 melanoma cells injected 
intraportally into murine livers. Although 80% of the injected cells survived and 
extravasated on Day 3, only a small number of these cells (1 in 40) formed 
micrometastases, and only 1 in 100 micrometastases continued to grow into 
macrometastases, which suggested the inefficiency of cancer metastasis (Luzzi et 
al. 1998). In recent years, an increasing number of researchers have suggested 
that a rare population of CSCs may be responsible for cancer metastasis, which 
was suggested by Wang et al. for several reasons. First, CSCs are implicated as 
the subset within cancer tissues that have the ability to initiate and sustain cancer 
growth (Wang et al. 2013, Li et al. 2007). Second, the inherent plasticity of stem 
cells enables CSCs to be more capable of surviving in a foreign environment 
where the growth factors and cell types are different than those at the primary 
cancer site (Wang et al. 2013, Li et al. 2007). Additionally, cellular plasticity in 
CSCs may facilitate epithelial-mesenchymal transition (EMT), which is 
considered a key event during the early phase of cancer metastasis (Wang et al. 
2013, Kang & Massague 2004). A study conducted by Pang et al. indicated that 
CD26+ colon CSCs were present in both the primary and metastatic tumors in 
colorectal cancer patients with liver metastasis (Pang et al. 2010). Specifically, 
following injection into the mouse cecal wall, circulating CD26+ CSCs were 
capable of initiating metastatic growth in the liver (Pang et al. 2010). As a result, 
it has been suggested that CD26+ CSCs may be the subpopulation of cells that 
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mediate colon cancer metastasis. Using immuno-staining, Lingala et al. 
determined that CD133 and ALDH doubly positive HCC cell clusters were co-
localized within invaded vessels or in the areas adjacent to connective tissue, 
which indicated an important role of CD133+/ALDH+ hepatocellular CSCs in 
liver cancer metastasis (Lingala et al. 2010). Furthermore, the study by Kaplan et 
al. suggests that CSCs could recruit a non-neoplastic cell population and adapt 
them to create a hospitable environment for tumor cell adhesion and invasion 
(Kaplan et al. 2005). They reported that bone marrow-derived hematopoietic 
progenitor cells that express vascular endothelial growth factor receptor-1 
(VEGFR1) home to tumor-specific pre-metastatic sites and form cellular clusters 
prior to the arrival of tumor cells, which provides a permissive niche, termed a 
‘‘pre-metastatic niche’’, for incoming tumor cells (Kaplan et al. 2005, Takao et al. 
2012).  
1.2.3 CSCs in cancer relapse 
CSCs are reported to be resistant to traditional chemotherapy and radiotherapy 
(Fig. 1.2) because they have a series of self-protective mechanisms, such as an 
efficient DNA repair mechanism, high expression of multidrug-resistance-type 
membrane transporters, intrinsic expression of anti-apoptotic molecules, and slow 
cell cycle kinetics (Diaz & Leon 2011a). First, CSCs are thought to be in a 
quiescent state with low cell kinetics, enabling them to be more resistant to 
cytotoxic therapies, whereas rapidly dividing cancer progenitor cells are more 
sensitive to such therapies (Diaz & Leon 2011a). Second, it has been indicated 
that an efficient DNA repair mechanism of CSCs can reduce the injuries induced 
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by ionizing radiation. A study demonstrated that ionizing radiation induced DNA 
damage to similar degrees in CD133+ and CD133- glioma cells, but CD133+ cells 
were able to repair the DNA damage more efficiently than their CD133-
counterparts (Bao et al. 2006). CSCs can also protect themselves from 
chemotherapies and radiotherapies through the inhibition of key death effectors or 
the over-expression of anti-apoptotic factors to defend against apoptosis (Diaz & 
Leon 2011a). Ma et al. demonstrated that chemo-resistant hepatocellular CSCs 
preferentially activated Akt/PKB and Bcl-2 cell survival pathways (Ma et al. 
2008). Another important self-protection mechanism is an elevated expression of 
ATP-dependent drug efflux pumps, allowing them to pump the therapeutic drug 
out of themselves (Diaz & Leon 2011a). A subset of stem cells, referred to as 
“side population” (SP), has been identified in several tissues in mammalian 
species (Nurwidya et al. 2012). SP cells displayed resistance to multiple 
chemotherapeutic drugs, which is mediated through the increased expression of 
ATP-binding cassette (ABC) transporters. A SP is typically identified and isolated 
by Hoechst 33342 (bisbenzimide, H 33342; Ho342) staining. Hoechst 33342 is a 
specific stain for AT-rich regions of double-stranded DNA. Hoechst 33342 can be 
effluxed from a SP, thereby forming a distinct population from the main 
population in a flow cytometry profile. A SP has also been detected in breast 
cancer, lung cancer, and glioblastoma cell lines, indicating that this phenotype 
may consist of CSCs with inherently high resistance to chemotherapeutic agents 
that should be targeted during the treatment of malignant disease (Nurwidya et al. 
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2012). There is evidence for the ability of SPs to regenerate a population that 
resembles the original population (Ho et al. 2007).  
 
Fig. 1.2 CSCs in Cancer Recurrence (Cited from Wikipedia)  
 
1.2.4 Therapies targeting CSCs 
Considering the important role of CSCs in cancer initiation, metastasis, and drug 
resistance, novel therapies targeting CSCs are urgently required. The first 
possibility is to target CSC surface markers. It was reported that using antibody 
P245 to target CD44 expressed by breast cancer stem cells resulted in the growth 
inhibition of human breast cancer xenografts (Marangoni et al. 2009). Smith et al. 
demonstrated that CD133 inhibition reduced the growth rate of hepatoma Hep3B 
cells and suppressed tumor growth in a severe combined immunodeficiency 
(SCID) mouse model (Smith et al. 2008). Another potential approach, referred to 
as differentiation therapy, utilizes the stemness of CSCs. The aim of this approach 
is to force CSCs to differentiate into mature cancer cells, which are easier to 
eradicate using traditional therapies (Diaz & Leon 2011a). The first successful 
differentiation agent, reported by Ruiz-Vela A et al., was all-trans-retinoic acid 
(ATRA) and was used in the treatment of acute promyelocytic leukemia (APL) 
13 
 
(Ruiz-Vela et al. 2009). Moreover, CSCs have been demonstrated to have close 
crosstalk with extrinsic components, including growth factors, extracellular 
matrix (ECM), and stromal cells (Lathia et al. 2011). These extrinsic components 
constitute the tumor microenvironment, or tumor niche, which can be further 
classified into the hypoxic niche, perivascular niche, and invasive niche. The 
tumor microenvironment can provide the communication necessary for tumor 
growth, protect the tumor cells from stressors, and help maintain CSC stemness. 
Based on the teamwork between tumors and their microenvironments, another 
promising and attractive therapeutic approach is to interfere with the connection 
between CSCs and the tumor niche to destroy the homeostasis of CSCs (Kokuryo 
et al. 2012). 
1.2.5 Characterization of CSCs  
Based on the central roles of CSCs in cancer initiation, metastasis, and relapse, 
CSCs are characterized by several in vitro and in vivo properties. First, CSCs have 
been reported to express certain pluripotent genes, such as Oct4, Nanog, and 
SSEA4, to maintain their self-renewal capability and pluripotency (Miyoshi et al. 
2010, Lin et al. 2008, Kumar et al. 2012). Second, CSCs express cancer type-
specific CSC markers. For example, glioma stem cells have been reported to be 
CD133+ (Patru et al. 2010, Diaz & Leon 2011a), while colon cancer stem cells 
have been demonstrated to be CD24+/CD44+ (Yeung et al. 2010). Third, CSCs are 
resistant to radiotherapy and chemotherapeutic reagents because of an efficient 
DNA repair mechanism, high expression of multidrug-resistant membrane 
transporters and aldehyde dehydrogenase (ALDH), which can be characterized by 
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chemotherapeutic reagent-mediated cytotoxicity (Inoda et al. 2011), SP analysis 
(Inoda et al. 2011) or an ALDH Assay (Ginestier et al. 2007). Fourth, a 
tumorsphere assay is one strategy utilized to identify CSCs (Dontu et al. 2003). 
Free-floating spheres are a characteristic of the proliferation of solid tumors in 
vitro; they are rich in stem cells and progenitors, and they exhibit stem-like 
properties when cultured under conditions of anchorage independence and serum 
starvation (Dontu et al. 2003). Many researchers have investigated the presence of 
CSCs in glioblastoma (Stoica et al. 2009, Yuan et al. 2004), mammary tumor 
(Cocola et al. 2009, Grange et al. 2008, Penzo et al. 2009), and sarcoma cell lines 
(Fujii et al. 2009, Wilson et al. 2008) using the sphere assay. Last and most 
important, when injected into immune-deficient mice, CSCs reinitiate tumor 
formation and growth despite a low inoculation cell number.  
1.3 Cancer Immunotherapy 
Cancer immunotherapy is a new class of cancer treatment that is designed to 
provoke or boost the immune system to attack cancer cells. Cancer 
immunotherapy is based on the fact that cancer cells display subtly different 
antigens on their surfaces, which can be recognized by the immune system. 
Immunotherapy may have a greater potential to fight cancer than current 
chemotherapy or radiotherapy regimens because it is more effective and less toxic. 
In general, there are three groups of cancer immunotherapies: cell-, antibody-
, and cytokine-based therapies.  
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1.3.1 Antibody- and cytokine-based immunotherapies 
Currently, antibody therapy is the most widely used form of cancer 
immunotherapy. Monoclonal antibodies only bind to cancer cell-surface-specific 
antigens. Once bound to a cancer antigen, antibodies can induce tumor cell death 
through several mechanisms, which include the direct action of the antibody 
(through receptor blockade or agonist activity, induction of apoptosis, or delivery 
of a drug or cytotoxic agent); immune system-mediated cell killing (complement-
dependent apoptosis, antibody-dependent cellular cytotoxicity (ADCC), and 
regulation of T cell function); and effects on the tumor microenvironment 
(inhibition of tumor vasculature and stroma) (Scott et al. 2012). To date, there are 
twelve antibodies approved for the treatment of solid and hematological 
malignancies, namely, Alemtuzumab, Bevacizumab, Brentuximab vedotin, 
Cetuximab, Gemtuzumab ozogamicin, Ibritumomab tiuxetan, Ipilimumab, 
Ofatumumab, Panitumumab, Rituximab, Tositumomab, and Trastuzumab. Recent 
studies have investigated newer forms of monoclonal antibodies by combining 
parts of two antibodies together (bispecific antibody) to increase effectiveness 
(Blattman & Greenberg 2004). Moreover, in 2011, Zeng et al. proposed a new 
concept in which intracellular oncoproteins are targeted with antibody therapy and 
vaccination. Her study demonstrated that monoclonal antibodies that target PRL-1 
and PRL-3, which have been implicated in the metastasis of colorectal cancer, can 
inhibit experimental metastatic tumors that express the respective antigen (Guo et 
al. 2011). This finding extends the potential targets of antibody therapy to both 
surface and intracellular antigens. 
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Immunostimulatory cytokines are involved in the regulation and 
coordination of the communications and behaviors of the immune system. They 
have the ability to enhance the antitumor activity of the immune system and, thus, 
can be used in cancer immunotherapy. Interferons and interleukins are the most 
common groups of cytokines used for cancer immunotherapy. Interferons are 
capable of assisting the immune system in fighting cancer and may inhibit the 
growth of cancer cells. For example, interferon-α (IFN-α) enhances tumor antigen 
presentation and cytotoxicity and is used in the treatment of hairy cell 
leukemia, acquired immunodeficiency syndrome (AIDS)-related Kaposi's 
sarcoma, follicular lymphoma, chronic myeloid leukemia, and malignant 
melanoma. Interleukins are capable of assisting the immune system in generating 
cells that attack cancer. Interleukin-2 (IL-2) is the most commonly used 
interleukin and enhances NK cell and CD8+ T cell functions and increases 
vascular permeability (Dranoff 2004). IL-2 is applied in the treatment of 
melanoma and renal cell cancer (Mellman et al. 2011).  
1.3.2 Cell-based immunotherapy 
The aim of cell-based therapies is to directly inject immune cells into patients to 
activate an immune response against the cancer. The process typically includes 
the acquisition of immune cells from patients, the activation and expansion of 
immune cells specific for the tumor ex vivo, and the return of the immune cells to 
the patient. The potential immune cell candidates include dendritic cells (DCs), 
antigen-specific T-cells, and non-specific effectors (e.g., natural killer cells, γδT 
cells, and lymphokine-activated killer cells, which recognize cell surface 
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abnormalities) (Bielamowicz et al. 2013). To date, although cell-based cancer 
immunotherapy is not yet a primary type of cancer treatment, researchers have 
made substantial advancements in cancer vaccines. 
1.3.2.1 Dendritic cells as therapeutic vaccines  
Identification of DCs as the most efficient antigen-presenting cells is one of the 
significant advances in cancer immunotherapy (Palucka & Banchereau 2013). 
Exogenous antigens can be captured by DC endocytosis, released to its 
cytoplasmic compartment, and routed to the MHC-I antigen-presentation pathway. 
DC vaccination is based on this antigen cross-presentation process and can induce 
CD8+ tumor antigen-specific cytotoxic T lymphocytes (CTLs), representing a 
potentially potent therapeutic approach for cancer. DCs also play a critical role in 
bridging innate and acquired immunity by facilitating crosstalk between immune 
effector cells, such as conventional αβ T cells, γδ T cells, NK cells, and invariant 
NKT cells, directly or indirectly through cytokines derived from the effector cells 
and DCs. DCs based cancer vaccines is one type of active cancer immunotherapy, 
which have shown the most success so far in treating cancer. Sipuleucel-T 
(PROVENGE; Dendreon), a dendritic cells based cancer vaccine, is the only cell-
based therapeutic cancer vaccine approved by the U.S. Food and Drug 
Administration (FDA). It is formulated to stimulate and generate prostate acid 
phosphatase (PAP)-specific T cells for prostate cancer treatment (Cheever & 
Higano 2011).  
Previous cancer immunotherapies have involved targeting cells that 
express differentiated tumor antigens. Recent findings from animal studies, 
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cultured human tumor cells and clinical blood samples support the notion that 
DC-based CSC vaccination confers superior protective antitumor immunity by 
selectively targeting CSCs. DC-based CSC vaccines can elicit humoral and 
cellular immune responses directed towards stem cell antigens and are associated 
with the induction of efficient protective anti-CSC immunity. For example, DC-
mediated targeting of glioma CSC spheres led to greater anti-tumor immunity in 
mice compared to targeting bulk tumor cells (Pellegatta et al. 2006). These studies 
indicate that although immune tolerance to pathways shared between CSCs and 
normal adult stem cells is possible, the immune system can still recognize and 
react to the differences between the two types of stem cells, and consequently 
eradicate CSCs. Since CSCs have a recognized refractoriness to traditional 
therapies involving chemo- and radiation, immune intervention as a therapeutic 
platform to target tumor specific antigens (TSAs) and/or tumor associated 
antigens (TAAs), which is less dependent on the metabolic or proliferative state 
of cancerous cells, has become particularly attractive. The resistance of CSCs to 
conventional therapies indicates that these cancer-initiating cells may contain 
numerous mutations that encode tumor-specific neoantigens, in addition to stem 
cell antigens. Thus, using CSCs as a source of tumor antigens for DC vaccine 
preparation provides a way to stimulate immune responses directed toward 
unidentified neoantigens and tumorigenic antigens associated with CSCs, leading 
to CSC killing with possible long-lasting benefits. 
19 
 
1.3.2.2 Adoptive T-cell therapy 
While antigen-specific T cells are the primary population that mediates antitumor 
immunity, most antigen-specific T cells are present at a low frequency within the 
tumor tissues or elsewhere, and many of these cells have receptors with low 
avidity for tumor antigens (Bielamowicz et al. 2013). One strategy is to activate 
and expand the cells ex vivo and subsequently transfuse them back into the patient, 
thereby overcoming these limitations and suppressive factors present in vivo. This 
type of passive immunization is referred to as adoptive therapy (Bielamowicz et al. 
2013). Adoptive T cell therapy may result in increased antitumor immunity, 
enhanced vaccine efficacy, and limited graft-versus-host disease (GVHD). An 
example of adoptive T cell therapy is the isolation of tumor-infiltrating 
lymphocytes (TILs) from the tumor samples of patients, treatment with IL-2 ex 
vivo, and induction of TIL expansion. Following the injection of the TILs back 
into the patient, these cells act as active cancer fighters.  
Recent advances in cell and molecular biology have increased the 
feasibility of the use of genetically engineered T cells for the treatment of disease, 
which has led to an influx of new discoveries and techniques. Because CD8+ T 
cells can only exert their cytotoxic properties through the recognition of major 
histocompatibility complex (MHC)-I-presented antigens on the surface of target 
cells, it has been widely reported that many advanced cancers down-regulate 
MHC-I and exhibit defective antigen processing to escape the supervision of the 
immune system (Inoda et al. 2011). Therefore, a promising new approach has 
emerged in which T cells are modified such that they are able to fight cancer 
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without the MHC-I limitation. These cells are referred to as chimeric antigen 
receptor-expressing T (CAR-T) cells (Dotti et al. 2014). This idea and technique 
have been investigated for more than 25 years. CAR-T cell therapy combines the 
desirable targeting features of a monoclonal antibody (independent of the major 
histocompatibility complex recognition and the ability to recognize non-protein 
antigens) with the persistence, trafficking, and lytic functions of T cells (Dotti et 
al. 2014). To date, the most widely used structural pattern of CAR-T cells consists 
of an ectodomain from a single chain variable fragment (scFv), a transmembrane 
domain, and an endodomain with a signaling domain derived from CD3-ζ, with or 
without the incorporation of co-stimulatory signaling endodomains (Dotti et al. 
2014). As a result, in adoptive CAR-T cell therapy, CD8+ T cells are removed 
from the patient’s blood, genetically engineered with chimeric antigen receptors 
(CARs) and multiplied ex vivo, and then infused back into the patient’s blood, 
where they can then seek out the cancer cells and launch a precise immune attack 
against them. There have been 14 publications that have reported clinical trials of 
CAR-T cells in hematologic malignancies, and these studies have demonstrated 
very encouraging results. All but one of these studies focused on B-cell 
malignancies by targeting CD19 or CD20; the other study focused on acute 
myeloid leukemia (AML) by targeting the Lewis-Y antigen (Maus et al. 2014). 
Researchers are investigating other tumor antigens to enable CAR-T cells to 




The aim of cancer immunotherapy is to boost the immune responses involved in 
fighting cancer, and substantial progress has been made in this area in recent years. 
This study aimed to develop NSC- and DC -based cancer immunotherapy, and it 
had two main objectives: 
1. NSCs exhibit extensive tumor tropism and are emerging as a powerful vehicle 
for therapeutic gene delivery in cancer treatment, especially in the targeting of 
multi-site metastases. Adult tissues and human embryonic stem cells can be 
utilized as the sources of NSC generation; however, this approach is always 
accompanied by technical and ethical challenges. Chapter 2 discusses the research 
aimed at generating NSCs from human induced pluripotent stem cells, enhancing 
their tumor tropism via manipulation of the biological activities of proteins that 
are involved in the regulation of NSC migration toward cancer cells, and 
investigating the potential of hiPSC-derived NSCs as vehicles for cancer 
immunogene therapy. The specific aims were the following: 
(1) To investigate NSC generation from human induced pluripotent stem cells  
(2) To investigate the tumor homing properties of hiPSCs-NSCs and the cell 
trafficking regulators that mediate the tumor tropism of NSCs, thereby exploring 
the possibility of genetic manipulation to improve the tumor-targeting capacity of 
these cells 
(3) To investigate the potential of hiPSC-NSCs to deliver CD40L molecules 
expressed by baculovirus into tumor tissues for cancer immunogene therapy 
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2. DCs are the most potent antigen-presenting cells that have been studied for 
their potential use in cancer treatment vaccines world-wide. Growing evidence 
indicates that CSCs are responsible for tumorigenesis, metastasis, cancer relapse, 
and cancer treatment failure. Nevertheless, CSCs are rare in tumor samples and 
difficult to maintain in vitro. In Chapter 3, we explore the potential of monocyte-
derived dendritic cells loaded with lysates of cancer stem-like cells to activate 
immune responses that specifically target CSCs. The aims were as follows: 
(1) To explore the possibility of using OSKM transcriptional factors to induce the 
dedifferentiation of glioma cells into glioma stem-like cells. 
(2) To test the feasibility of using tumor spheres generated from OSKM-
expressing glioma cell lines as a CSC antigens source for DC-based cancer 
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2.1.1 NSCs derived from pluripotent stem cells 
Human embryonic stem cells (hESCs) are pluripotent stem cells that are capable 
of proliferating indefinitely under ideal conditions and differentiating into any cell 
type associated with the three germ layers (Gerrard et al. 2005). Over the past 
several years, many studies have demonstrated that NSCs can be successfully 
generated from hESCs using different methods that mimic the in vivo 
environment or evoke a default mechanism for NSC differentiation (Cai & Grabel 
2007). Embryoid body (EB) formation is typically utilized to imitate the embryo 
development that generates the neuroectoderm by providing appropriate cell-cell 
interactions and signals (Cai & Grabel 2007). The default pathway is induced via 
growing the ESCs at low density in serum-free medium, to starve the cells of cell-
cell interactions and signals (Cai & Grabel 2007). These methods include co-
culture method with stromal feeder cells (Perrier et al. 2004, Kawasaki et al. 
2000), EB formation method (Swistowski et al. 2009, Zhang & Zhang 2010), and 
adherent induction method in which certain supplements are added (Gerrard et al. 
2005, Nat et al. 2007, Chambers et al. 2009). Colombo et al. demonstrated a close 
similarity between somatic NSCs and ESC-derived NSCs through transcriptional 
profiling analysis (Colombo et al. 2006, Cai & Grabel 2007). Moreover, it was 
demonstrated that mouse ESC-derived NSCs proliferate more rapidly than 
somatic NSCs and favor adherent conditions over suspension conditions 
(Colombo et al. 2006, Cai & Grabel 2007). ESC-derived NSCs were able to 
differentiate into more cell types and produce neural cell types with a higher 
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efficiency than somatic NSCs, indicating a broader multi-potency (Colombo et al. 
2006, Cai & Grabel 2007). Nevertheless, the isolation of human embryonic stem 
cells is associated with ethical issues because of the destruction of human 
embryos, and the transplantation of hESC-derived cells may trigger immune 
rejection.  
  To solve these problems, human induced pluripotent stem cells (hiPSCs) 
may represent an attractive alternative because hiPSCs can be generated through 
the reprogramming of human somatic cells with certain transcription factors via 
integrated or transient expression (Yu et al. 2007, Takahashi & Yamanaka 2006, 
Kim et al. 2008, Phang et al. 2013, Stadtfeld et al. 2008). hiPSCs could be even 
more advantageous than ESCs in the generation of NSCs because they possess 
similar characteristics but circumvent the bioethical controversies associated ESC 
isolation (Nishikawa et al. 2008, Patel & Yang 2010). Moreover, somatic cells 
isolated from patients can be theoretically reprogrammed into iPSCs, which can 
be used to generate NSCs for autologous transplantation, thus minimizing the 
host-vs-graft reaction. Furthermore, human leukocyte antigen (HLA)-typed iPSCs 
could be generated to produce iPSC-derived cells that are more patient-specific 
than other cell sources (Nakatsuji 2010). Several laboratories have recently 
reported the neural conversion from hiPSCs by the generation of neural rosettes 
through an EB-based method or an adherent induction method by adding pathway 
modulation factors, such as the method of dual inhibition of SMAD signaling 
developed by Chambers et al. (Karumbayaram et al. 2009, Chambers et al. 2009, 
Hu et al. 2010). However, these methods are either time-consuming or cost a 
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substantial amount of money, which impedes large-scale clinical production. Here, 
we utilized human pluripotent stem cells as a source and developed a simple and 
cost-effective method to generate NSCs, which were characterized through the 
examination of NSC markers, tumor tropism, and differentiation capability. 
2.1.2 The mechanism of tumor tropism of NSCs 
Regardless of the source of NSCs used for cancer therapy, the migratory capacity 
of NSCs is crucial for the success in treating disseminated tumors. Cell migration 
is a highly complex process. The factors that regulate the procedure range from 
various extracellular environmental cues, cytoskeleton restructuring after sensing 
the cues, dynamic regulation of cell attachment and detachment to extracellular 
matrix to signaling coordination between all these parts to control cell movement 
(Aboody et al. 2008, Jurvansuu et al. 2008). The fact that NSCs can migrate 
towards tumors of both neural and non-neural origins suggest the existence of 
common attractants from different types of tumor cells. Although the 
understanding of the molecular mechanisms underlying NSC tumor tropism is 
limited, it has been noted that several cytokines, growth factors and receptors 
direct the migration in vitro, making it probable that NSC tumor tropism is 
meditated by multiple cell surface and secreted proteins rather than depending on 
a single specific ligand or receptor (Aboody et al. 2008, Jurvansuu et al. 2008, 
Muller et al. 2006). Those cytokines and their corresponding receptors include 
SDF-1/CXCR4, uPA/uPAR, VEGF/VEGFR2, hepatocyte growth factor/c-Met 
and SCF/c-kit signaling pathways (Zhao et al. 2008). A proper understanding of 
the basic molecular mechanisms of NSC migration towards tumors, especially 
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identification of key cellular regulators of the migration, will have important 
implications in improving the effectiveness of engineering and employing NSCs 
as tumor therapy agents. As an initial attempt to address the issue, this study used 
cDNA microarray technology to analyze gene expression patterns of NSCs 
collected from in vitro migration assays. 
2.1.2.1 Nitric oxide synthase (NOS) 
Nitric oxide (NO) is an important cellular signaling molecule that helps modulate 
vascular tone, insulin secretion, and peristalsis. NO is also actively involved in 
angiogenesis and neural development. In particular, NO may function as a 
retrograde neurotransmitter. NO is mediated in mammals by isoenzymes, such as 
nitric oxide synthase (NOS), controlled by calcium-calmodulin. NOS synthesizes 
NO through arginine oxidation. Arginine-derived NO synthesis has been 
identified in mammals, fish, birds, invertebrates, and bacteria (Liu & Gross 1996). 
In mammals, the NOS family consists of constituent isoforms, endothelial NOS 
(eNOS), neuronal NOS (nNOS), and inducible isoforms (iNOS) (Knowles & 
Moncada 1994). eNOS participates in many types of biological processes, such as 
vasodilation, insulin secretion, and regulation of cardiac function and 
angiogenesis. nNOS predominately exerts its effects in neurogenesis and 
neurotransmission. iNOS, which is synthesized by cytokine stimulation, is 
primarily involved in the immune response (Ishigami et al. 2000). 
The role of NOS in cell migration has been widely studied. However, the 
reports regarding NOS are controversial. Substantial evidence has demonstrated 
that eNOS can promote endothelial cell migration through the Akt/eNOS pathway 
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when stimulated by growth factors, such as endothelin and VEGF (Morales-Ruiz 
et al. 2000). Jadeski et al. also demonstrated a positive relationship of eNOS with 
tumor cell migration and invasiveness (Jadeski et al. 2000). Furthermore, one 
group recently reported that nNOS could stimulate human neural progenitor cell 
migration via cGMP-mediated signal transduction (Tegenge et al. 2011). 
Nevertheless, some studies have demonstrated an inverse relationship between 
NOS and cell migration. It has also been demonstrated that eNOS attenuates 
pulmonary leukocyte migration via the inhibition of endothelial adhesion 
molecule expression (Kaminski et al. 2004). Another group identified decreased 
nNOS expression and cell migration in the peri-infarction following focal cerebral 
ischemia in rats (Zhang et al. 2007). Huang et al. reported that the induction of 
inducible nitric oxide synthase (iNOS) expression inhibits macrophage-derived 
foam cell migration (Huang et al. 2014). 
2.1.3   CD40-CD40L interaction based cancer immunotherapy 
Therapy using genes encoding immunostimulatory molecules to enhance 
anticancer immunity is a promising approach toward cancer treatment. The CD40 
ligand (CD40L), also called CD154, is a 33-kDa type II membrane protein 
belonging to the TNF gene family and is mainly expressed on activated CD4+ T 
cells. It interacts with CD40 expressed on a wide range of antigen-presenting cells 
(APCs) including dendritic cells, macrophages, and B lymphocytes, as well as 
non-immune cells such as epithelial cells, endothelial cells and malignant cells 
(Loskog & Totterman 2007, Ullenhag & Loskog 2012). CD40L-CD40 interaction 
induces activation in APCs in association with T cell receptor stimulation by 
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MHC molecules on the APCs, ensuring the generation of antigen-specific 
cytotoxic T lymphocytes (CTLs). As demonstrated, CD40L promotes priming of 
tumor-specific T cells in draining lymph nodes in the presence of apoptotic tumor 
cells (Loskog & Totterman 2007, Ullenhag & Loskog 2012). Increased antigen 
presentation by APCs can lead to increased cytokine production, expression of 
other co-stimulatory molecules, and induction of cytotoxicity. CD40L can also 
exert antitumor effects by inducing tumor cell apoptosis via autocrine/paracrine 
induction of death ligands such as TNFa, FasL, and TRAIL (Loskog & Totterman 
2007). Local CD40L gene delivery to directly transduce tumor cells is often 
employed for CD40L gene therapy and can effectively inhibit tumor growth by 
mediating multiple antitumor effects including induction of T-cell responses, up-
regulation of Th1-type cytokines, and induction of apoptosis (Fernandes et al. 
2009, Gomes et al. 2009, Diaconu et al. 2012, Ullenhag & Loskog 2012). 
However, this in vivo gene therapy approach relies on high-efficiency gene 
transfer and its attractiveness could be hampered in treatments of multi-site 
cancers.  
With the increasing potential of using NSCs as cancer therapeutics, it is 
desirable to have a reliable and stable supply of human NSCs. In our previous 
studies, we have explored the feasibility of using pluripotent stem cells, such as 
hESCs and hiPSCs, to generate cellular vehicles for cancer gene therapy and 
demonstrated the effectiveness of using these in vitro generated NSCs for cancer 
suicide gene therapy in several different animal models (Zhao & Wang 2010b, 
Yang et al. 2012b, Zhao et al. 2012a). This suicide therapy approach employs the 
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herpes simplex virus thymidine kinase (HSVtk)/ganciclovir(GCV) system, in 
which HSVtk molecules phosphorylate GCV to interfere with DNA replication in 
proliferating tumor cells, therefore killing tumor cells eventually.  
However, there were some limitations with our previous studies. We 
noticed that that when NSCs were delivered intravenously into mice, the majority 
of the injected cells became stuck in the lungs, liver, and kidneys (Yang et al. 
2012b). While this distribution pattern could be useful for eliminating metastatic 
cancer cells in these organs, the potential damage to proliferating healthy cells in 
the organs caused by NSCs-delivered suicide gene products raises safety concerns. 
Such possible off-target actions should be minimized to avoid potential side 
effects that might deteriorate the situation of the patient. In an effort to overcome 
the limitation, we investigated in this study whether intravenously injected iPSCs-
NSCs can be used as a CD40L-delivery platform to treat metastatic cancer while 
minimizing injury to off-target organs. 
2.1.3.1 Baculovirus 
Insect baculovirus, as a gene delivery vector, has received substantial attention in 
recent years (Hofmann et al. 1995, Hu 2008). The most commonly utilized 
baculovirus is derived from Autographa californica multiple 
nucleopolyhedrovirus (AcMNPV) (Wang & Balasundaram 2010). Baculovirus is 
capable of accommodating and delivering large or multiple genes because of its 
high cloning capacity (Wang & Balasundaram 2010). Baculovirus mediates 
transient transgene expression in mammalian cells without replication integration 
and obvious toxicity, thus making it a safer gene delivery vehicle than most 
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mammalian viruses (Singh et al. 2009). Unlike many other viral vectors, such as 
adenovirus, there is almost no pre-existing antivirus immunity in humans, 
including baculovirus-specific T cells, because this virus is not infectious to 
humans (Strauss et al. 2007). Another important advantage of baculovirus as a 
gene therapy vehicle for cancer therapy is that baculovirus can be produced in a 
serum-free cell culture medium, avoiding the potential serum contamination 
associated with viral and prion agents (Wang & Balasundaram 2010).        
2.2 Materials and Methods 
2.2.1 hiPSCs and hESCs maintenance  
hESCs were given by Dr. Zeng Jieming from Institute of Bioengineering and 
Nanotechnology in Singapore. hESCs were maintained on Matrigel (BD 
Biosciences, San Jose, CA) in mTeSRTM1 (STEMCELL Technologies, 
Vancouver, BC, Canada) under feeder independent conditions. hiPSCs were 
generated by Dr. Yang Jing via transducing human foreskin fibroblasts (HFF, 
(Millipore, Billerica, MA) with a Cre-excisable polycistronic lentiviral vector 
containing Oct4, Klf4, Sox2, and c-Myc genes (Millipore). The hiPSCs were 
maintained on a feeder layer of Mytomycin-C (Roche Diagnostics, Basel, 
Switzerland) inactivated mouse embryonic fibroblasts (MEF, Millipore) in iPSCs 
medium consisting of DMEM/F12 (1:1 mixture) medium (Life Technologies, 
Gaithersburg, MD), 20% Knockout Serum Replacement (Life Technologies), 
2mM L-Glutamine, 0.1mM β-mercaptoethanol (β-ME, Sigma-Aldrich, St. Louis, 
Missouri, USA), 10ng/ml recombinant human basic fibroblast growth factor 
(bFGF, Peprotech, Rocky Hill, New Jersey, USA), 0.1mM NEAA (Life 
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Technologies) and penicillin/streptomycin. The hiPSCs were mechanically 
passaged every 7 days. The hiPSCs could also be cultured on Matrigel (BD 
Biosciences) in mTeSRTM1 (STEMCELL Technologies) under feeder 
independent conditions. The hiPSCs would be passaged every 5-7 days by 
digested with 1mg/ml Dispase (STEMCELL Technologies) at 37°C for 5-7 min.  
2.2.2 NSC generation and maintenance  
2.2.2.1 NSC induction by cell adhesion 
To initiate NSC differentiation, hiPSCs propagated on Matrigel were used 
because of the associated higher cell survival after dissociation (Axell et al. 2009) 
and the exclusion of contamination from MEF. hiPSCs were dissociated into 
single cells by treated with Accutase (Millipore) at 37°C for 4 min at Day 0. The 
cells were spun down and resuspended in NSC medium, composed of 
DMEM/F12, 2% B27 (Life Technologies), 2mM L-glutamine,  20ng/ml human 
epidermal growth factor (EGF, PeproTech), 20ng/ml human bFGF (PeproTech) 
and penicillin/streptomycin. Then 200,000/cm2 cells were seeded onto 0.1% 
Gelatin coated 6-well plate. A high seeding density is essential for cell survival at 
this step. A low seeding density may result in extremely low cell survival and 
attachment. Rho-associated kinase (ROCK) inhibitor, Y27632 (Peprotech) was 
added into NSC culturing medium to improve cell survival at a final concentration 
of 10µM at day 0. On Day 2, the entire medium was discarded and changed into 
fresh NSC medium. Half medium was changed every other day. After one month 
passage, adherent monolayer NSC population with characteristic bipolar or 
tripolar NSC morphology was achieved. The hiPSCs derived NSCs were split 
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every 3 - 4 days by digested with Accutase for 3-4 min and plated at a density of 
50,000/cm2 to 60,000/cm2.  
2.2.2.2 NSC induction by neural rosettes formation  
hiPSCs propagated on Matrigel (5-7 days) were dissociated with Accutase and 
resuspended in STEMdiffTM Neural induction medium (STEMCELL 
Technologies) on day 0. Then hiPSCs were seeded into AggreWellTM 800 24-well 
plates (STEMCELL Technologies) at a density of at least 1.5 million/well. ROCK 
inhibitor, Y-27632, was also added at a final concentration of 10µM. After 24 
hours of culture, uniform neural aggregates were visible inside the wells. 3/4 
medium was changed every day. On day 5, neural aggregates were harvested and 
plated onto Poly-L-Ornithine/Laminin (Sigma-Aldrich) coated 6-well plates. The 
neural rosette structure was visible 48 hours after the neural aggregates were 
plated. A full medium change was performed daily for another seven days with 
STEMdiffTM Neural induction medium. On Day 12, neural rosettes were 
selectively isolated using STEMdiffTM Neural Rosette Selection Reagent 
(STEMCELL Technologies) leaving flat cells still attached. Then the isolated 
neural rosettes were replated onto new Poly-L-Ornithine/Laminin coated 6-well 
plates in STEMdiffTM Neural induction medium and the cells could reach 80-90% 
confluence after 2-5 days culture. Further culture and expansion of NSCs could be 
performed in normal NSC medium as stated above. 
2.2.2.3 NSC induction by neural aggregates adhesion  
On day 0 single cell suspension in NSC medium was generated as described 
above and Y-27632 was also added at a final concentration of 10µM. Two million 
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cells were seeded onto non-coated 6-well plate. On Day 1, spherical cell clusters 
had formed (referred to as neural aggregates). During next five days, half medium 
was changed every day without discarding the neural aggregates. On day 5 to 7 
days, neural aggregates were picked and seeded onto 0.1% Gelatin coated 6-well 
plates at a density of 10-15 per well. After 7-10 days differentiation and growth, 
many NSC like cells will migrate out from these attached neural aggregates. Then 
these cells were dissociated and replaced at a density of 50,000/cm2. Then the 
adherent monolayer NSC population with typical bipolar or tripolar NSC 
morphology could be achieved. 
NSCs derived from the three methods could be frozen in 90% NSC 
medium supplemented with 10% Dimethyl sulfoxide (DMSO, Sigma-Aldrich) 
and remained high survival rate after thawed from liquid nitrogen storage. 
2.2.3 NSC characterization 
For neurosphere formation assay, hiPSCs derived NSCs were dissociated with 
Accutase, seeded onto Poly(2-hydroxyethyl methacrylate) (pHEMA, Sigma-
Aldrich) treated 6-well low attachment plates and cultured in suspension in NSC 
medium. 
To differentiate into neurons, hiPSCs-NSCs were plated onto poly-L-
ornithine (Sigma-Aldrich) and laminin (Sigma-Aldrich) double coated 24-well 
plate in NSC medium at 50,000 cells/cm2. Two days later, the medium was 
changed to Neurobasal medium (Life Technologies) supplemented with 2% B27, 
10ng/ml brain-derived neurotrophic factor (BDNF, Life Technologies), and 100 
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μM db-cAMP (Sigma-Aldrich) and the cells were cultured for 1 to 2 weeks. To 
initiate astrocytes differentiation, hiPSCs-NSCs were plated onto Geltrex (Life 
Technologies)-coated 24-well plate at 25,000 cells/cm2 in NSC medium, and 
changed into DMEM supplemented with 1% N2 (Life Technologies) and 1% fetal 
bovine serum (FBS, Hyclone, Waltham, Massachusetts, USA) after 2 days and 
cultured for another 2 weeks. For differentiation into oligodendrocytes, hiPSCs-
NSCs were plated onto CellStart (Life Technologies) coated 24-well plate at 
25,000 cells/cm2 in Neurobasal medium supplemented with 2%B27 and 30ng/ml 
T3 (Sigma-Aldrich) for 3 to 4 weeks.  
2.2.4 Tumor cell culture 
The mouse metastatic breast cancer cell line 4T1, mouse CT26-WT colon 
carcinoma cells, mouse Hepa1-6 hepatocellular carcinoma cells, mouse TC-1 lung 
cancer cells, human glioblastoma cells U87 and the mouse fibroblast cell line 
NIH3T3 were purchased from American Type Culture Collection (ATCC, 
Manassas, VA). 4T1 cells that stably express luciferase gene (4T1-luc) were 
purchased from Caliper Life Sciences (Hopkinton, MA). 4T1 and 4T1-luc cells 
were maintained in RPMI 1640 medium (Sigma-Aldrich) supplemented with 10% 
FBS, 2mM L-glutamine, 50U/mL penicillin and 50µg/mL streptomycin. CT26-
WT, Hepa1-6, TC-1 and U87 cells were maintained in DMEM medium (Hyclone) 




2.2.5 In vitro migration assay  
The migration capacity of hiPSCs derived NSCs towards tumor cells was 
determined by a modified Boyden chamber assay using the BD Falcon 
FluoroBlok 24-well insert with 8µm pore size (BD Biosciences) (Fig. 2.1). 50,000 
U87 human glioma cells or 4T1 mouse breast cancer cells were seeded into the 
lower receiver wells as attractants one day before. The medium in the receiver 
wells was changed into Opti-MEM (Life Technologies) the next day. 50,000 
hiPSCs derived NSCs in Opti-MEM were seeded into the upper inserted chamber. 
After 16 hours incubation at 37°C, the number of migratory NSCs attached to the 
bottom of the chamber membrane was counted.  
To assess effects of neuronal nitric oxide synthase (nNOS) inhibitors on 
cell migration, hiPSC-NSCs, U87 cells, or 4T1 cells were pre-treated with nNOS 
inhibitors S-methyl-L-thiocitrulline (SMTC, Sigma-Aldrich) at 500µM or (4S)-N-
(4-Amino-5[aminoethyl]aminopentyl)- N’-nitroguanidine (nNOS inhibitor I, 
EMD/Merck, Darmstadt, Germany) at 20 µM for one day. The next day, 50,000 
treated cells were seeded into the upper inserted chamber in Opti-MEM 
containing 500µM SMTC or 20µM nNOS inhibitor I. For hiPSCs-NSCs 
migration assays, U87 cells or 4T1 cells were seeded into the lower receiver well 
and used as attractants one day before the assay. For U87 and 4T1 tumor cell 
migration assays, 600µl Opti-MEM with 10% FBS and 20% FBS was added, 
respectively, into the lower chamber as chemical attractants. The number of 
migratory cells attached to the bottom of the chamber membrane was counted 




Fig. 2.1 In vitro migration assay 
2.2.6 Microarray 
cDNA microarray assays were preformed to compare the gene expression profiles 
between migratory and non-migratory hiPSC-NSCs. Six-well Boyden chambers 
with 8μm pore size (BD Biosciences) were utilized for cell separation. hiPSC-
NSCs were seeded at 1 million cells per insert into the upper chamber in 2ml of 
Opti-MEM, and the bottom receiver wells were filled with 3 ml of either U87 
cell- or 4T1 cell-conditioned medium as attractants. The conditioned medium was 
used as attractants instead of cancer cells in order to avoid cancer cell 
contamination when migratory hiPSC-NSCs were collected for RNA isolation.  A 
total of 24 chambers were seeded for one tumor type. After incubation at 37°C in 
5% CO2 for 16 hours, migratory cells on the bottom of the insert membrane and 
non-migratory cells on the upper side of the membrane were digested by Accutase 
and collected. Cells collected from 8 wells were combined into one sample and 
three paired replicates of migratory and non-migratory cell samples for each 
tumor attractant were used for RNA isolation.  
Total RNA was extracted from migratory and non-migratory hiPSCs 
derived NSCs using TRIzol® Reagent (Life Technologies) followed by treatment 
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with RNase-free DNase (Qiagen, Hilden, Germany) and RNeasy column 
purification (QIAGEN) according to manufacturers’ protocols. The quality of 
RNA samples was examined by electrophoresis in denaturing agarose gel 
containing formaldehyde. RNA quality was further examined using NanoDropTM 
1000 spectrophotometer (Thermo Scientific, Hudson, NH, USA). RNA 
concentrations were also determined using NanoDropTM.  
One microgram of isolated total RNA from each sample was reverse-
transcribed, T7-amplified, fragmented and labelled using Kreatech’s RNA 
ampULSe amplification and labelling kit according to the instruction manual 
provided (Kreatech Biotechnology, Amsterdam, the Netherlands). Fifteen 
microgram of the fragmented/labelled cRNA was then hybridised to GeneChip® 
Human Genome U133 Plus 2.0 Array (Affymetrix, Santa Clara, CA) containing 
more than 54000 probe sets representing all known genes in the human genome. 
Hybridization was performed for 16 hours in accordance with the user manual 
provided, followed by washing in GeneChip® Fluidics Station 450 (Affymetrix) 
and  scanning on a GeneChip® Scanner 3000 (Affymetrix) according to the 
protocol from Affymetrix. GeneChip Command Console Software (AGCC) was 
used to capture microarray images and quantify signal intensity from each feature.  
Microarray raw data was acquired using the GCOS software (Affymetrix). Data 
obtained from GCOS was transferred to GeneSpring GX software (Agilent 
Technologies, Palo Alto, CA). The data was normalized using the default setting 
of GeneSpring. To analyze the data, the genes were grouped according to 
migratory or non-migratory NSCs towards different tumor attractants. The data 
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was filtered according to their flags in such a way that 3 out of 3 sample replicates 
fulfilled the conditions of a cut-off of ≥ two-fold difference in expression level 
and a p-value of less than 0.05. Volcano plot was used to filter the data further. 
The data was then analyzed using the DAVID functional annotation clustering 
tool (DAVID, Bioinformatics Resources 6.7) with a cut-off at an enrichment 
score of 1.3 (= p < 0.05). Microarray data described in this paper have been 
deposited in NCBI Gene Expression Omnibus (http://www.ncbi.nlm.nih.gov/geo/), 
with accession number GSE40751, in a MIAME-compliant format. 
2.2.7 Gene silencing  
The knockdown of human nNOS expression was induced by transient expression 
of siRNA. Two siRNAs against human nNOS (SI02624006 and SI03028823) and 
negative control siRNA were purchased from Qiagen. Each siRNA targets a 
distinct region of target mRNA. siRNA transfections were performed in 6-well 
plates. The day before transfection, hiPSC-NSCs were seeded at a density of 
700,000 cells per well in NSC medium. The next day, the medium was changed 
into 1.8ml NSC medium without antibiotics. Lipofectamine® 2000 Reagent (Life 
Technologies) was used to transfect cells according to manufacturer’s protocol. 
Briefly, 6μl Lipofectamine® 2000 was mixed with 80pmol siRNA in 200μl Opti-
MEM medium (Life Technologies) and incubated for 20min. Then the complex 
was added directly to each well and the final concentration of siRNA was 40nM. 
Forty-eight hours after transfection, the cells were harvested for PCR, real-time 
PCR, western blot analysis or in vitro cell migration assay. Primer sequences used 
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are listed in Supplementary Table 1. Goat polyclonal anti-nNOS antibody (1:500; 
Abcam, Cambridge, UK) was used for western blot analysis. 
2.2.8 RNA extraction, cDNA synthesis and PCR 
Total RNA was extracted from cells using RNeasy Mini kit (QIAGEN), followed 
with RNase-free DNase (QIAGEN) treatment and RNeasy column purification 
(QIAGEN). One to five microgram of RNA was reverse transcribed into cDNA 
with Superscript III Reverse Transcriptase (Life Technologies).  
PCR was conducted with GeneAmp® Fast PCR Master Mix (Life 
Technologies) and the PCR reaction program was: 95°C, 10s; 94°C, 1s followed 
by 62°C, 25s, 40 cycles; 72°C, 1min. 
2.2.9 Real-time PCR 
Real-time PCR was performed with iCycler (Bio-Rad, Hercules, California, USA) 
using iQ™ SYBR® Green Supermix (Bio-Rad). The size of all amplicons ranges 
from 75bp-200bp. The reaction volume is 20µl involving 10ngcDNA, 100nM 
forward and reverse primers, 10µl 2×SYBR PCR Supermix and water. The 
amplification program is: 1 cycle, 95°C, 1min; 40 cycles, 95°C, 15s followed by 
60°C, 1min. Melting curve analysis was performed to confirm the purity and 
authenticity of PCR products. The Real-time PCR reaction is done in triplicates 
for every gene. GAPDH, ATCB and B2M were used as internal control. The data 
was presented as change fold normalized to the three internal control genes. 




Neural lineage cells were fixed with 4% paraformaldehyde (PFA, Promega, 
Madison, Wisconsin, USA) at room temperature for 15min and washed three 
times with PBS. For intracellular antigens, cells were permeabilized with 0.1% 
Triton X-100 (Bio-Rad). Then the cells were blocked in blocking buffer (0.1% 
Triton X-100, 10% goat serum (Santa Cruz Biotechnology, Santa Cruz, CA) and 
1% BSA (Life Technologies)) for 1 hour at room temperature and incubated 
overnight at 4°C with different primary antibodies in blocking buffer against β-III 
Tubulin (1:200, Promega), GFAP (1:100, Millipore), and O4 (1:100, R&D 
Systems, Minneapolis, MN). After washed with PBS for three times, the cells 
were incubated with secondary antibody conjugated with Alexa Fluor® 488 (Life 
Technologies) for two hours at room temperature. Finally, mounting medium 
mixed with 4',6-diamidino-2-phenylindole (DAPI, Vector Laboratories, 
Burlingame, CA) was used to stain the nucleus and prevent photobleaching. 
Images were acquired with a Leica DMI 6000B with LAS-AF imaging software 
and then processed with Adobe Photoshop.  
2.2.11 Western blotting     
The cells were lysed in Radioimmunoprecipitation (RIPA) Lysis Buffer (Santa 
Cruz Biotechnology) supplemented with cOmplete, Mini Protease Inhibitor 
Tablets (Roche Diagnostics). Then the samples were centrifuged at 10,000g for 
10min at 4°C. The supernatant was incubated at 95°C for 10 min with addition of 
4× NuPAGE® LDS Sample Buffer (Life Technologies). Electrophoresis was 
performed using NuPAGE® Novex 4-12% Bis-Tris Gel (Life Technologies) and 
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the proteins were transferred to PVDF membrane (Bio-Rad) by semi-dry method. 
The membranes were blocked with 5% milk (Bio-Rad) in PBST (0.1% Tween-20 
(Bio-Rad) in PBS) at room temperature for 1 hour. Then the membrane was 
incubated overnight at 4°C with goat polyclonal anti-nNOS antibody (1:500) 
(Abcam) or mouse monoclonal anti-β-actin antibody (1:500) (Santa Cruz 
Biotechnology). After washing in PBST, the membrane was incubated for 2 hours 
at room temperature with anti-goat secondary antibody (1:2000) (Santa Cruz 
Biotechnology).  
2.2.12 Baculovirus preparation, cell transduction, and detection of 
transgene expression  
The recombinant baculoviral vector expressing the eGFP reporter gene (BV-
eGFP), constructed using BAC-to-BAC baculovirus expression system (Life 
Technologies), contains the eGFP gene under the control of human 
cytomegalovirus (CMV) early promoter (Zeng et al. 2009). The recombinant 
baculoviral vector expressing CD40L (BV-CD40L) was produced by homologous 
recombination after co-transfection of Sf9 insect cells with pBacPAK9 transfer 
vector containing an expression cassette and linearized AcMNPV viral DNA 
(Clonetech, CA). The expression cassette of BV-CD40L contains the mouse 
CD40L gene (InvivoGen, San Diego, CA, USA) under the control of CMV 
promoter with the R segment and part of the U5 sequence of long terminal repeat 
from the human T-cell leukemia virus type 1 (RU5) at 5’ UTR and the 
woodchuck hepatitis virus posttranscriptional regulatory element (WPRE) at 3’ 
UTR. BV-HSVtk was generated in our lab previously (Balani et al. 2009). 
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Recombinant baculoviruses were amplified in Sf9 cells at a multiplicity of 
infection (MOI) of 0.1 plaque forming units (pfu) per cell and the virus-
containing supernatant was collected 3 days after virus infection. Viruses were 
pelleted down at 28,000g for 1 hour at 4 degree and re-suspended in PBS. 
For transduction, hiPSCs-NSCs were cultured with baculoviral vectors at 
an MOI of 100 pfu per cell overnight. A full medium change was carried out the 
next day to stop the transduction. GFP expression was detected under 
fluorescence microscope and by flow-cytometric analysis. To confirm CD40L 
gene expression, reverse transcriptase polymerase chain reaction (RT-PCR) and 
flow cytometric analysis using anti-CD40L antibody (BD biosciences) were 
performed. Primer sequences used are listed in Supplementary Table 1. PCR 
products were electrophoresised on a 1% agarose gel. 
2.2.13 Cytokine antibody array and cell viability assay 
 
To profile the cytokine production of 4T1 breast cancer cells under CD40L 
treatment, the BD Falcon HTS FluoroBlok 24-Multiwell Insert System (8 μm 
pore size) was used for co-culturing  4T1 cells with CD40L-expressing NSCs. 
4T1 cells were seeded at a density of 100,000 per well in 24-well companion 
plates. After 4T1 cells were attached, the medium was replaced with 800 μL Opti-
MEM and 24-multiwell cell-culture inserts were placed into the 24-well 
companion plates. BV-CD40L transduced NSCs and BV-eGFP transdcued NSCs, 
as vial transduction control, were seeded into multiple inserts at a density of 
50,000 per insert. After 24 hours of co-culture, the supernatants of the bottom 
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wells were harvest. The cytokine profiles in the supernatants were measured in 
triplicate using the RayBio Mouse Cytokine Antibody Array 2 (Ray Biotech, 
Norcross, GA, USA). RayBio® Analysis Tool (Raybiotech) was used to correlate 
the average signal intensities to relative expression levels of cytokines. 
Cell viability assays were performed also in the BD Falcon HTS 
FluoroBlok 24-Multiwell Insert System to evaluate the in vitro bystander 
cytotoxic effects of CD40L. 4T1 cells, which are CD40-positive, and NIH3T3 
cells, as CD40-negative control, were seeded at a density of 50,000 per well in 24-
well companion plates. After the cells were attached, 24-multiwell cell-culture 
inserts were placed into the 24-well companion plates. CD40L-expressing NSCs 
and eGFP-expressing NSCs were seeded into multiple inserts at a density of 
50,000 per insert. Cell viability was measured after 48 hours of co-culture by the 
CellTiter 96® AQueous Assay (Promega), and Caspase 3/7 activity was 
determined by the Caspase-Glo ® 3/7 Assay System (Promega). 
2.2.14 Animal studies  
2.2.14.1 In vivo migration analysis 
Female specific pathogen-free athymic nude (nu/nu) BALB/c mice (weight 20 g; 
aged 6-8 weeks) were used. Three mice were used for every experimental group. 
To generate an orthotopic glioma model, green fluorescent carbocyanine dye DiO 
(Life Technologies) labeled U87 cells (500,000 cells in 1 μl PBS) were injected 
into the right striatum of the mouse brain. On day 7 post-tumor inoculation, the 
red fluorescent dye CM-DiI (Life Technologies) labeled hiPSC-NSCs (1,000,000 
in 1 μl PBS) were injected into the same hemisphere 2 mm away from the tumor 
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inoculation site (estimation). For histological examination, mice were sacrificed 
by cardiac perfusion with PBS, followed by 4% PFA in PBS. The brains were 
harvested, suspended in 30% sucrose, and embedded in a tissue freezing medium. 
Cryostat sections were prepared and observed under fluorescent microscopy.  
To generate an orthotopic breast cancer model, 4T1 cells were inoculated 
into the mammary fat pad of anesthetized mice at a dose of 100,000 cells in 50 µl 
PBS per animal. One week later, a lipophilic, near-infrared fluorescent dye DiR 
(Caliper Life Sciences) was use to label hiPSC-NSCs. DiR has an 
excitation/emission spectrum in the near infrared (750/780 nm),  making it ideal 
for in vivo imaging due to significantly reduced auto-fluorescence from animals at 
higher wavelengths. Cells were labeled with 5 µg/ml of DiR overnight, followed 
by washing with PBS three times. The labeled cells, 1,000,000 in 200 μl PBS per 
animal, were injected into mice through the tail vein. For histological examination, 
mice were sacrificed by cardiac perfusion with PBS, followed by 4% PFA in PBS. 
The mammary fat pads were harvested for cryostat sectioning. Cryostat sections 
were labeled with DAPI and observed under a near-infrared confocal microscope.    
To examine the in vivo tumor tropism of baculovirus transduced iPSCs-
NSCs in immune-competent mice with breast cancer lung metastasis, BALB/c 
immuno-competent mice (weight: 20 g; age: 6-8 weeks) were used. Mouse 4T1-
luc breast cancer cells (20,000) were injected via the tail vein into BALB/c 
immuno-competent mice, while Dil labeled iPSCs-NSCs (1,000,000 in 200 μl 
PBS) were injected into mice through the tail vein one week post tumor 
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inoculation. Tissue distribution of Dil-labeled iPSCs-NSCs was examined under a 
fluorescent microscope.  
2.2.14.2 In vivo analysis of therapeutic effects of CD40L expression NSCs 
BALB/c immunocompetent mice (weight: 20 g; age: 6-8 weeks) were used. To 
generate an orthotopic breast cancer model, mouse 4T1-luc breast cancer cells 
were injected subcutaneously into the mammary fat pad (100,000 cells in 50 µl 
PBS). To generate a breast cancer lung metastasis model, 4T1-luc cells were 
injected intravenously via the tail vein (10,000 cells in 200 µl PBS). 
To evaluate therapeutic effects in the orthotopic breast cancer model, 
tumor-bearing mice were randomly divided into 4 groups (n = 10 per group) 3 
days post-tumor inoculation for tail vein injection: (1) PBS, 200 µl; (2) 1 million 
NSCs; (3) 1 million NSCs transduced with BV-eGFP (NSC-eGFP); and (4) 1 
million NSCs transduced with BV-CD40L (NSC-CD40L). Baculoviral 
transduction was performed 12 hours before the tail vein injection of NSCs. On 
day 28, animals received the intraperitoneal injection of D-luciferin (100 mg/kg, 
Promega) and were then euthanized. Nine organs, including the lungs, liver, 
spleens, kidneys, heart, stomach, brain, femurs and spinal cord, and mammary fat 
pad with the main tumor body, were harvested from each mouse for ex vivo 
imaging by the Xenogen IVIS-100 imaging system coupled with a cool CCD 
camera (Caliper Life Sciences). Firefly luciferase bioluminescence signals of the 
4T1-luc cancer cells were acquired with an emission filter of 560 nm.  
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To evaluate therapeutic effects in the breast cancer lung metastasis model, 
tumor-bearing mice were randomly divided into 4 groups (n = 10 per group) 7 
days post-tumor inoculation. The 2nd tail vein injection was performed with PBS, 
NSCs, NSCs expressing eGFP, NSCs expressing CD40L at 1,000,000 cells in 200 
µl per injection. Animal survival was monitored till day 42.  
Animal experiments were performed according to the guidelines for the 
Care and Use of Animals for Scientific Purposes issued by the National Advisory 
Committee for Laboratory Animal Research, Singapore. 
2.2.15 Caspase-3/7 Activity, IFNγ and TNFα secretion 
measurements 
To evaluate in vivo immune responses and apoptosis induction, the lungs were 
collected 28 days after tail vein injection of CD40L-expresssing iPSCs-NSCs and 
other control cells from the mice with breast cancer lung metastasis. Using 
ProteoJET™ Mammalian Cell Lysis Reagent (Thermo Fisher Scientific, Waltham, 
MA, USA) supplemented with pepstatin, leupeptin and aprotinin (2 ml/g tissues), 
the tissues were homogenized with pestles, VWR Pellet Mixers (VWR) and then 
sonicated on ice. The supernatants were collected after centrifugation at 13000 g 
for 20 mins at 4°C. Bio-Rad Protein Assay Dye Reagent Concentrate (Bio-Rad) 
was used to measure the protein concentration.  
The caspase activity in the lung tissues was measured using Caspase-Glo® 
3/7 Assay System (Promega). IFN-γ and TNF-α release in lung tissues were 
determined using the Mouse IFN-gamma ELISA Kit and Mouse TNF-alpha 
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ELISA Kit (BD Biosciences). For Caspase activity measurement, 30µg lung 
tissue extracts in 100µl lysis buffer was loaded into a white-walled 96-well plate. 
Then 100μl Caspase-Glo® 3/7 Reagent was added to each well with 100ul lysis 
buffer alone as blank. After 1 hour incubation at room temperature, the 
luminescence of each well was measured in a microplate luminometer.  For 
measuring IFN-γ and TNF-α release, the lung tissue extracts were diluted with 
Standard/Sample Diluent and 200µg proteins in 50ul buffer was used. ELISA was 
performed according to the manufacturer’s protocol. 
2.2.16 Statistical analysis 
All data is represented as mean ± SD. The statistical significance of differences of 
in vitro experiments was determined by unpaired Student’s t-test. The statistical 
significance of differences of animal experiments was determined by the two-
factor analysis of variance with replication followed by Fisher’s least signiﬁcant 
difference post hoc analysis. The statistical analysis of survival data was 
performed using the log rank test followed by the Holm-Sidak method for 






2.3.1 Comparison of different methods of inducing NSCs from 
hiPSCs 
2.3.1.1 Single cell adhesion method 
Because removal of cell-cell contact will initiate the default pathway of neural 
differentiation, we first attempted to culture single human iPS cells at low density 
to induce NSCs. The NSC induction process is indicated in Fig. 2.2A. The hiPSC-
derived NSCs grow at a fast rate, with a doubling time of approximately 3-4 days. 
However, the NSCs derived using this method could only be passaged 
approximately 15 times. After 10 passages, the doubling rate of the hiPSCs-NSCs 
slowed down, and the cells were subcultured every 4-5 days. After approximately 
15 passages, the cells almost stopped proliferating and approached senescence. 
Thus, we primarily used NSCs obtained from the early passages (less than 
passage 10) in the following experiments. 
RT-PCR analysis indicated that the hiPSC-derived NSCs strongly express 
NSC markers CD133, Nestin, and Sox2 and moderately express early neural 
ectodermal markers Sox1 and Pax6 (Fig. 2.2B). Immunocytochemistry confirmed 
the expression of Nestin and Musashi (Fig. 2.2C). We further successfully 
differentiated the hiPSC-derived NSCs into three downstream neural lineages, 
namely, neurons, astrocytes, and oligodendrocytes (Fig. 2.2E).  
NSCs derived from a single cell adhesion culture method exhibited strong 
tumor tropism, which was assessed by an in vitro migration assay. A modified 
Boyden chamber assay using a Falcon 24 FluroBlok 24-well insert with an 8-µm 
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pore size was utilized. NSCs were seeded into the upper chamber, while U87 
human glioma cells or 4T1 mouse breast cancer cells were seeded in the lower 
receiver wells as attractants. The results demonstrated that hiPSC-derived NSCs 
exhibit a strong migration capacity toward 4T1 (20.91%) and U87 (11.76%) 
compared with the Opti-MEM control (5.62%) (Fig. 2.2D). 
The advantage of this single cell adhesion culture method is that most cells 
derived from this method exhibit homogenous morphology and strong tumor 
tropism. However, this method has a low efficiency. Furthermore, after seeding 
dissociated the hiPSCs onto the 0.1% gelatin-coated plates, only a few single cells 



















Fig. 2.2 Induction of NSCs from hiPSCs using single cell adhesion method. (A) Representative 
images of systematic induction of NSCs from hiPSCs on day 0 (a) hiPSCs, day 1 (b) attached 
single human iPS cells, day 10 (c) NSC clusters and day 21(d) NSCs. Scale bar, 500 µm. (B) RT-
PCR to detect the NSC markers CD133, Nestin, Sox1, Sox2, and Pax6 expression of hiPSCs and 
their derived NSCs. GAPDH was used as internal control. (C) Immunocytochemistry to detect 
NSC markers Nestin (Green) and Musashi (Green) expression of hiPSCs derived NSCs. DAPI 
(Blue) was used to stain nuclei. Scale bar, 100 µm. (D) In vitro migration assay to determine the 
migration capability of hiPSCs derived NSCs towards U87 and 4T1. Opti-MEM was used as 
control. The results are expressed as the percentage of migratory cells to total cells. Values are 
mean ± SD. t-Test, ** P<0.01. (E) hiPSCs derived NSCs can be further differentiated into β-III 





2.3.1.2 Neural rosettes formation method 
Because the neural rosette is a commonly accepted structure that contains NSCs, 
various protocols have been generated based on this characteristic. Here, we 
tested the system of NSC induction from human pluripotent stem cells, which was 
developed by STEMCELL Company, using defined STEMdiffTM Neural 
Induction Medium and AggreWellTM 800 24-well plates over a 12-day culture 
period. The NSC induction process is indicated in Fig. 2.3A. These NSCs grow 
fast, and the doubling time is also approximately 3-4 days. The NSCs derived 
from this method are substantially smaller compared with those derived from the 
single cell adhesion culture method.  
RT-PCR analysis indicated that the NSCs had a high expression of CD133, 
Nestin, and Sox2, as well as a high expression of the early neural ectodermal 
markers Sox1 and Pax6 (Fig. 2.3B). However, the in vitro migration assay 
demonstrated that the migration rate of these NSCs toward U87 was 13.24%, 
while that of the cells toward 4T1 was 13.73%, which is lower than the rate 
achieved with the single cell adhesion culture method (Fig. 2.3C). Because of this 
finding, we did not passage these cells further. Because the NSCs have a strong 
expression of the early neural ectodermal markers Pax6 and Sox1 and their size is 
smaller than that of the NSCs derived from the single cell adhesion culture 
method, we infer that these NSCs may be in an earlier developmental stage than 
those from the single cell adhesion culture method. There is a possibility that 
further culturing and differentiation of these NSCs may increase their tumor 
tropism, but we did not investigate this possibility further.  
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In summary, this method developed by STEMCELL Technologies can 
consistently generate NSCs, and the time required is shorter than conventional 
methods. However, the migration capacity of these NSCs toward tumor cells is 
substantially lower compared with that of NSCs derived from the other two 
methods. Furthermore, considering the cost, this method may not be optimal for 
generating NSCs on a large scale with strong tumor tropism for cancer gene 
therapy.  
Fig. 2.3 Induction of NSCs from hiPSCs using neural rosettes formation method. (A) 
Representative images of systematic induction of NSCs from hiPSCs at day 0 (a), day 1 (b) neural 
aggregates, day7 (c) neural aggregates, day 12(d-neural rosettes, e-left flat cells) and day 17 (f) 
NSCs. Scale bar, 500 µm. (B) RT-PCR to detect the NSC markers CD133, Nestin, Sox1, Sox2 and 
Pax6 expression of hiPSCs and their derived NSCs. GAPDH is used as internal control. (C) In 
vitro migration assay to determine the migration capability of hiPSCs derived NSCs towards U87 
and 4T1. Opti-MEM was used as control. The results are expressed as the percentage of migrated 
cells to total cells. Values are mean ± SD. t-Test, ** P<0.01. 
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2.3.1.3 Neural aggregates adhesion method 
Finally, we attempted to develop a cost-effective and efficient method to induce 
NSCs with strong tumor tropism. The NSC induction process is indicated in Fig. 
2.4A. NSCs derived from hiPSCs using this method also grow fast, and the 
doubling time is still approximately 3-4 days.  
RT-PCR analysis also indicated that the hiPSC-derived NSCs exhibit a 
high expression of CD133, Nestin, Sox2, and Sox1, but they exhibit a moderate 
expression of the early neural ectodermal marker Pax6 (Fig. 2.4B). 
Immunocytochemistry also confirmed the expression of Nestin and Musashi (Fig. 
2.4C). The NSCs could be passaged approximately 15 times, which is similar to 
the case of NSCs derived using the single cell adhesion culture method. 
Furthermore, the in vitro migration assay indicated that NSCs derived from this 
method have a strong migration capacity toward U87 (13.88%) and 4T1 (23.32%), 
with Opti-MEM as the control (6.17%), which is similar to the capacity of NSCs 
derived from the single cell adhesion culture method (Fig. 2.4D). We also 
successfully utilized this method to induce NSCs from hESCs, which also exhibit 
strong tumor tropism. 
The advantage of this method is that it enables the generation of a large 
number of NSCs with strong tumor tropism. Furthermore, the principle of this 
method may resemble that of the neurosphere method. However, the disadvantage 
of this method is that it is not consistent; sometimes, the cells derived from this 
method are not NSCs. 
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In the following experiments, we primarily used Method I to induce NSCs 
with strong tumor tropism to maintain the consistency of the NSCs. 
 
Fig. 2.4 Induction of NSCs from hiPSCs using neural aggregate adhesion method. (A) 
Representative images of systematic induction of NSCs from hiPSCs at day 0 (a), day7 (b) neural 
aggregates, day 14 (c) NSCs migrating out from attached neural aggregates and day 21(d) NSCs. 
Scale bar, 500 µm. (B) RT-PCR to detect the NSC markers CD133, Nestin, Sox1, Sox2 and Pax6 
expression of hiPSCs and their derived NSCs. GAPDH was used as internal control. (C) 
Immunocytochemistry to detect NSC markers Nestin (Green) and Musashi (Green) expression of 
hiPSCs derived NSCs. DAPI (Blue) was used to stain nuclei. Scale bar, 200 µm. (D) In vitro 
migration assay to determine the migration capability of hiPSCs derived NSCs towards U87 and 
4T1. Opti-MEM was used as control. The results are expressed as the percentage of migratory 




2.3.2 Molecular mechanism underlying NSC migration toward 
tumor cells 
2.2.2.1 Tumor tropism of NSCs generated from hiPSCs 
2.2.2.1.1 In vitro migration ability of hiPSCs derived NSCs towards tumor cell 
lines  
 
To further determine whether hiPSC-derived NSCs display extensive tumor 
tropism, we examined the in vitro migration of hiPSC-derived NSCs toward 5 
different tumor cell lines (Fig. 2.5), namely, mouse breast cancer cells 4T1, 
mouse colon carcinoma cells CT26-WT, mouse hepatocellular carcinoma cells 
Hepa1-6, mouse lung cancer cells TC-1, and glioblastoma cells U87. We 
determined that hiPSC-derived NSCs have various migration capacities toward 
different types of tumor attractants, exhibiting stronger migration toward 4T1 and 
CT26-WT cells compared with U87, TC-1, and Hepa1-6 cells. 
 
Fig. 2.5 In vitro migration of hiPSCs-NSCs toward tumor cells. The mouse metastatic breast 
cancer cell line 4T1, mouse colon carcinoma cells CT26-WT, mouse hepatocellular carcinoma 
cells Hepa1-6, mouse lung cancer cells TC-1 and human glioblastoma cells U87 were used as 
attractants in Boyden chamber assays. Cell migration toward the Opti-MEM medium was included 
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as a control. (A) Images of migratory hiPSC-NSCs. Scale bar, 200 µm in DAPI images. (B) 
Quantification of hiPSC-NSCs migration. The results are expressed as the percentage of migratory 
cells to total cells. Values are mean ± SD (n = 3).  t-Test, ** P<0.01. 
 
2.2.2.1.2 In vivo migration ability of hiPSCs derived NSCs towards glioma and 
breast tumor  
 
To investigate the in vivo tumor tropism of hiPSCs-NSCs, an intracranial glioma 
model was generated by injection of green fluorescent carbocyanine dye DiO-
labeled human U87 glioma cells into the right striatum of nude mice. Seven days 
later, red fluorescent dye CM-DiI labeled hiPSC-NSCs were injected into the 
same striatum 2 mm to the left of the tumor inoculation site. Using a confocal 
microscope to examine brain sections, we observed the accumulation of hiPSC-
NSCs along the boundary of established tumor mass on day 5 after hiPSC-NSC 
injection. By day 10, extensive co-localization of hiPSC-NSCs with the tumor 
mass demonstrated deep penetration of the cells into the tumor (Fig. 2.6A). We 
further examined whether hiPSC-NSCs could migrate through the brain 
parenchyma to reach the tumor site in the opposite hemisphere. U87 glioma cells 
were pre-labeled with CM-DiI (red) and injected into the right striatum in nude 
mice. DiO-labeled hiPSC-NSCs (green) were injected into the left striatum 7 days 
later. Brain sections were collected on day 21 post-tumor inoculation for 
histological examination. We observed extensive co-localization of hiPSC-NSCs 
with the tumor mass in the collected brain sections (Fig. 2.6B). While most of 
hiPSC-NSCs infiltrated into around 50 µm, some NSCs had penetrated 100 µm 
into the tumor mass.  
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To investigate the homing capabilities of systemically injected hiPSC-
NSCs to tumors, we used the near-infrared fluorescent dye DiR to label the cells 
and injected them through tail vein into mice pre-inoculated with breast cancer 
cells in the mammary fat pad. At day 14 post-NSC injection, we examined DiR 
signals in the tissue sections of the mammary fat pad under a near-infrared 
confocal microscope and observed significantly increased DiR signals in the 
tumor inoculation site in tumor-bearing mice as compared with the signals in mice 
without tumors (Fig. 2.6C), demonstrating NSC accumulation in the tumor in this 
orthotopic breast cancer model in mice.  hiPSCs were also injected to mice to test 
their migration. However, since after dissociation into single cells, hiPSCs will 




Fig. 2.6 In vivo tumor tropism of hiPSCs-NSCs. (A) Glioma tropism. U87 cells were pre-
labeled with green fluorescent carbocyanine dye DiO and injected into the right striatum in nude 
mice. hiPSC-NSCs, prelabeled with red fluorescent dye CM-DiI, were injected into the same 
hemisphere 2 mm away from the tumor inoculation site 7 days later. Brain sections were collected 
on day 5 and day 10 after NSC injection. (B) Glioma tropism after contralateral injection of 
hiPSC-NSCs. U87 cells were pre-labeled with CM-DiI (red) and injected into the right striatum. 
DiO-labeled hiPSC-NSCs (green) were injected into the hemisphere contralateral to the tumor 
inoculation site 7 days later. Brain sections were collected on day 21 post-tumor inoculation. A 
region with a U87 tumor is shown. (C) Breast cancer tropism. Immunodeficient NSG mice were 
inoculated with 4T1 breast cancer cells in the mammary fat pad. At day 7 post-tumor inoculation, 
the near-infrared fluorescent dye DiR-labeled hiPSC-NSCs were injected through the tail vein into 
the tumor-bearing mice. The mammary fat pads were harvested from the animals at day 14 post-
NSC injection (day 21 post-tumor inoculation). Sections of the collected organs were labeled with 
DAPI and images were captured with a near-infrared confocal microscope. This animal 





2.2.2.1.3 Comparison of in vitro tumor tropism between hESCs and hiPSCs 
derived NSCs  
Next, to investigate whether a difference in tumor tropism exists between hESCs 
and hiPSC-derived NSCs, we compared the migration capacity toward U87 and 
4T1 cells between the two types of NSCs in vitro. As shown in Fig. 2.7A, the 
hESC-derived NSCs exhibited stronger migration ability toward U87 and 4T1 
cells compared with hiPSCs. Incomplete reprogramming or the heterogeneity of 
the hiPSCs may be the main reason for this result. It is suggested that a prolonged 
passaging of hiPSCs may be necessary to stabilize iPSCs in a pluripotent state.  
2.2.2.1.4 Examination of the migration capacity of hiPSCs derived NSCs with 
continuous passage  
hiPSC-derived NSCs can only be passaged 15 times. Thus, we wondered whether 
the migration capability of hiPSC-derived NSCs would be maintained at the same 
level or decline following continuous passage. In this experiment, the migration 
abilities of the NSCs derived from hiPSCs with different passages (P3 vs. P13) 
were compared. U87 and 4T1 cells were used as attractants (Fig. 2.7B). As 
expected, the migration abilities of the hiPSC-derived NSCs toward U87 or 4T1 
cells were both significantly decreased after continuous passage. We suggest that 
the differentiation of NSCs with continuous expansion may be a potential reason 





2.2.2.1.5 Comparison of tumor cells and their conditioned medium as attractants 
In the following microarray, to avoid tumor cell contamination of the RNA 
samples from migratory and non-migratory hiPSC-derived NSCs, we decided to 
use the conditioned medium from U87 and 4T1 cells as attractants. However, 
prior to this approach, we examined the potential of tumor cell conditioned 
medium as attractants using an in vitro migration assay. As shown in Fig. 2.7C, 
the conditioned medium from U87 or 4T1 cells induced similar migration of 
hiPSC-derived NSCs to the two types of tumor cells. 
 
Fig. 2.7 The migration capacity of NSCs derived from hiPSCs. The migration capacity of 
NSCs was evaluated using a modified Boyden chamber Assay. 50,000 NSCs were seeded in the 
upper chamber and the number of migratory NSC passing through the inserted chamber membrane 
was counted after 16 hours incubation. Values are mean ± SD. Scale bar, 200 µm. (A) Comparison 
of the tumor tropism between hESCs derived NSCs and hiPSCs derived NSCs. The results were 
expressed as the percentage of migratory cells to total cells. (t-Test, ** P<0.01) (B) Compare the 
tumor tropism between early passage (P3) and late passage (P13) hiPSCs derived NSCs. The 
results were expressed as migration percentage of hiPSCs-NSCs-P13 over hiPSCs-NSCs-P3. (t-
Test, * P<0.05, ** P<0.01) (C) Compare the conditioned medium from U87 or 4T1 as attractants 
with the two types of tumor cells. The results were expressed as migration percentage of 
conditioned medium over tumor cells. 
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2.2.2.2 Microarray profiling and real-time PCR to screen genes related to tumor 
tropism of NSCs 
Since hiPSCs derived NSCs still keep the property of extensive tumor tropism, 
they might become a promising gene delivery vehicle in cancer gene therapy. To 
elucidate the molecular mechanisms underlying NSC tropism for tumor, cDNA 
microarray was performed to compare gene expression profiles between 
migratory and non-migratory NSCs towards tumor cells. The modified Boyden 
chamber assay was utilized to separate migratory and non-migratory NSCs (Zhao 
& Wang 2010a). Conditioned medium from U87 and 4T1 was used as attractants 
to avoid tumor cells contamination of RNA samples. hiPSCs derived NSCs were 
seeded in the upper inserted chamber and incubated with U87 or 4T1 conditioned 
medium in the lower receiver wells for 24 hours. Then the cells migrating through 
the 8µm pores and attaching to the bottom of the membrane are the migratory 
cells, while the remaining cells left on the top of the membrane are the non- 
migratory cells. RNA was isolated from migratory and non-migratory cells, 
reverse transcribed into cDNA and converted into labeled cRNA "targets" to 
interrogate Affymetrix whole genome microarrays (Maisel et al. 2007). Twelve 
microarray chips for four different RNA sources with three experimental 
replicates per sample were used in the current study. The present gene probes on 
the 3 chips tested for the cells migrating toward the 4T1 tumor cell-conditioned 
medium were 49.1%, 50.2%, and 49.8% respectively, whereas the present gene 
probes on the 3 chips tested for non-migratory cells isolated from the same 
Boyden Chamber migration assays were 48.4%, 49.1%, and 49.0% respectively. 
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In cells collected from the migration assay toward U87 cell-conditioned medium, 
43.8%, 44.1% and 44.2% of the gene probes on the 3 chips were present in the 
migratory NSCs and 45.8%, 45.7% and 46.8% in the non-migratory cells.  
After the microarray data was filtered, there were 253 up-regulated and 
232 down-regulated probe sets in NSCs migrating toward U87-conditoned 
medium and 53 up-regulated and 101 down-regulated probe sets in NSCs 
migrating toward the 4T1-conditioned medium (Table S2). Among these were 31 
over-expressed and 35 under-expressed probe sets that overlapped between 
samples with U87- and 4T1-conditioned media as attractants (Table S3), 
indicating that there are common molecules that regulate NSC migration toward 
both U87 glioma cells and 4T1 breast cancer cells. To investigate whether the 
affected genes are associated with a specific cellular procedure or organelle that 
are crucial for NSC migration toward tumor cells, up- and down-regulated probe 
sets were subjected to DAVID functional annotation clustering analysis. A cluster 
of genes related to intracellular non-membrane-bounded organelles were detected 
to be enriched in both NSCs migrating toward 4T1-conditioned medium (19 
down-regulated genes with enrichment score of 1.46) and NSCs migrating toward 
U87-conditioned medium (37 down-regulated genes with enrichment score of 
2.13). Furthermore, there were 9 down-regulated genes overlapping between the 
two gene lists (Table 2.1). 
 Quantitative real-time PCR was then performed to verify the relative 
expression of the above 9 genes. As shown in Fig. 2.8A and B, four genes from 
the list, that is, nNOS, Hook homolog 1, Melanophilin, and APBB1IP, were 
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confirmed to exhibit lower levels of expression in migratory hiPSCs-NSCs, below 
50% of the expression levels in non-migratory cells under both testing conditions. 
nNOS, neuronal nitric oxide synthase, was the most significantly down-regulated 
gene in migratory hiPSCs-NSCs: 89% down-regulation in the assay using U87-
conditioned medium and 84% in the assay using 4T1-conditioned medium. To 
investigate the differentiation status of migratory and non-migratory hiPSCs-
NSCs, we examined the expression of NSC markers, CD133, Nestin, and Sox2, 
and glial precursor cells markers PDGFR and NG2, using RT-PCR and detected 
no difference in expression of the differentiation marker genes between migratory 
and non-migratory hiPSCs-NSCs (Fig. 2.8C). Quantitative real-time PCR 
analysis further confirmed the observation (data not shown). Our findings indicate 
that while nNOS signaling might be involved in regulating NSC migration, nNOS 










Table 2.1 Down-regulated genes related to intracellular non-membrane-bounded organelles 








Fig. 2.8 Gene expression in migratory and non-migratory hiPSCs-NSCs. (A) and (B) 
Verification of expression of down-regulated genes in migratory hiPSC-NSCs. hiPSC-NSCs 
migrating toward U87 (A) and 4T1 cells (B) and their paired non-migratory cells were collected. 
Nine down-regulated genes detected through microarray analysis were analyzed using quantitative 
PCR. The data were normalized to internal controls GAPDH, β-actin and beta-2 microglobulin 
(B2M). Values are mean ± SD (n = 3). (C) NSC marker expression in migratory and non-
migratory hiPSC-NSCs. Migrating (M) and non-migratory (N) hiPSC-NSCs toward 4T1 or U87 




2.2.2.3 Effects of nNOS inhibition on migration of NSCs toward cancer cells 
On the basis of our microarray and qPCR results, we moved forward to test 
whether inhibition of nNOS activity could promote the migration of NSCs toward 
cancer cells. Two types of nNOS inhibitors SMTC (Rakshit et al. 2009) and 
nNOS inhibitor I (Overend & Martin 2007) were used to suppress nNOS function. 
S-methyl-L-thiocitrulline (SMTC), a novel citrulline analog, has been synthesized 
and is shown to be potent inhibitors of both the constitutive brain and the 
inducible smooth muscle isoforms of nitric oxide synthase. (4S)-N-(4-Amino-
5[aminoethyl]aminopentyl)-N′-nitroguanidine TFA (nNOs inhibitor I) , a cell-
permeable, potent and highly selective inhibitor of neuronal nitric oxide synthase 
(nNOS), displays over 2500-fold and 320-fold inhibition selectivity over eNOS 
and iNOS, respectively. hiPSCs-NSCs were pre-treated with nNOS inhibitor 
SMTC or nNOS inhibitor I for 1 day and tested for their migration capacity in 
Boyden chamber assays. We observed that the pre-treatment with both nNOS 
inhibitors led to a significant increase in migration of hiPSCs-NSCs toward U87 
or 4T1 cancer cells and there was no significant difference between the effects of 
the two tested drugs. As previously reported, nNOS inhibition could promote cell 
proliferation (Maeda et al. 2000; Ciani et al. 2004). To minimize the interference 
of this effect on cell migration results, we reduced the cell migration time from 16 
h to 6 h and could still observe the increased migration of hiPSCs-NSCs, from 15% 
of migratory cells in the control group without treatment to close to 25% in the 
groups treated with the nNOS inhibitors (Fig. 2.9A). Since the doubling time of 
hiPSC-NSCs is 3–4 days, the increase in the number of migratory cells in 6 h was 
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unlikely to result from the increase in cell proliferation within such a short period. 
In a cell proliferation assay, we did not observe any significant difference in the 
change of cell number between hiPSCs-NSCs treated with the nNOS inhibitors 
and the control without treatment within 24 h (data not shown). We also examined 
whether treatment with nNOS inhibitor SMTC and nNOS inhibitor I would 
possibly increase migration of 4T1 and U87 tumor cells and observed no obvious 
differences in cell migration in Boyden chamber assays between treated and non-




Fig. 2.9 Effects of neuronal nitric oxide synthase (nNOS) inhibitors on cell migration in 
Boyden chamber. (A) Effects of nNOS on human-induced pluripotent stem cells-neural 
stem/progenitor cells (NSC) migration toward tumor cells. NSCs were cultured in the upper well 
in a Boyden chamber in the presence or absence of nNOS inhibitors (SMTC, 500 µM or nNOS 
inhibitor I, 20 µM). (B) Effects of nNOS on tumor cell migration. 4T1 or U87 cancer cells were 
cultured in the upper well in a Boyden chamber and treated with nNOS inhibitors as described 
above. DAPI images of migratory cells in (A) and (B) were taken after migration for 6 h and the 
number of migratory cancer cells was counted. Scale bar, 200 µm. Values are mean ± SD (n = 3). 




We further tested whether knock-down of nNOS expression could 
promote the migration of NSCs toward cancer cells. Two specific siRNAs 
targeting two different regions of four transcript variants of human nNOS mRNA 
were transfected into hiPSCs-NSCs. A reduction of nNOS mRNA level of about 
60% to 80% was observed 48 hours later (Fig. 2.10A & B). The knockdown 
effects on protein expression by both siRNAs were validated by Western blotting 
(Fig. 2.10C). The biological effects of nNOS knockdown were confirmed in in 
vitro Boyden chamber assays, showing a significant increase in migration of the 
siRNA-transfected hiPSCs-NSCs toward both 4T1 and U87 tumor cells (Fig. 
2.10D & E), suggesting that nNOS functions as a suppressor of tumor tropism of 
NSCs. Overall, our findings indicate that inhibition of nNOS activity may 
sensitize poorly migratory NSCs and enhance the migration of these cells toward 
tumor cells.   
The part related with nNOS has been published in Journal of 





Fig. 2.10 Effects of nNOS siRNAs on migration of hiPSCs-NSCs in Boyden chamber. (A, B, 
C) Knockdown of nNOS by two siRNAs (40 nM) validated by RT-PCR (A), quantitative real-time 
PCR (B) and Western blot (C). B2M was used as specificity control in (A) and β-actin was used as 
loading control in (C). Densitometric analysis in (C) was done by Image J software (National 
Institutes of Health, Bethesda, MD), and values were normalized to the control. (D, E) 
Knockdown of nNOS by two siRNAs promotes human induced pluripotent stem cells-NSCs 
migration toward 4T1 (D) and U87 (E) cancer cells. DAPI images of migratory NSCs were taken 
and the number of migratory NSCs was counted after 6 h. Scale bar, 200 µm. Values are mean ± 









2.3.3 NSCs engineered with CD40L mediated cancer therapy  
2.3.3.1Baculoviral transduction-mediated CD40L expression in iPSCs-NSCs 
We demonstrated the tumor tropism of NSCs derived from human iPSCs in above 
part. Successful loading of the CD40L gene into the NSCs and sustained 
transgene expression in these cells are the prerequisites for their use as a CD40L-
delivery platform for cancer therapy. Since baculoviral transduction is effective in 
mediating transgene expression in many different types of NSCs (Lee et al. 2011, 
Zeng et al. 2009, Zhao & Wang 2010b, Yang et al. 2012b), we constructed a 
recombinant baculoviral vector encoding CD40L (BV-CD40L) and examined its 
gene transfer into hiPSCs-NSCs. Two viral posttranscriptional regulatory 
elements, RU5 and WPRE, were included into the CD40L expression cassette to 
improve the transgene expression efficiency. As shown in Fig. 2.11A, baculoviral 
transduction was highly efficient in hiPSCs-NSCs. Approximately 99% of cells 
expressed high-levels of CD40L in the first two days post-transduction. Although 
the percentage of CD40L-positve cells decreased over time, possibly due to 
dilution of baculoviruses by NSC division, CD40L mRNA (Fig. 2.11B) and 
protein (Fig. 2.11A) expressions lasted for at least 14 days in hiPSCs-NSCs.  
Since the migratory capacity of NSCs towards tumors is crucial for the 
success of NSCs-based cancer gene therapy, we further tested whether CD40L 
expression mediated by baculoviral transduction would hinder the migration of 
hiPSCs-NSCs towards mouse 4T1 breast cancer cells. In vitro migration assays 
were performed using modified Boyden chambers as previously stated. We 
seeded 4T1 and 4T1-luc cells in the lower receiver wells as attractants and 
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counted the number of migratory hiPSCs-NSCs attached to the bottom of the 
inserted membrane. As shown in Fig. 2.11C, the percentages of migratory 
hiPSCs-NSCs towards tumor cells were approximately 20%, while the percentage 
of cells migrating towards plain Opti-MEM was around 5%. There is no 
difference in migration capacity observed between hiPSCs-NSCs and hiPSCs -
NSCs transduced with BV-eGFP or BV-CD40L. To examine the in vivo 
migration capacity of these transduced cells towards tumors, we generated a 
breast cancer lung metastasis model in immunocompetent BALB/c mice by 
intravenous injection of mouse 4T1 breast cancer cells via the tail vein. One week 
later, hiPSCs-NSCs transduced with BV-CD40L were labeled with the orange-red 
fluorescent dye Dil and injected intravenously into the tumor-bearing mice. At 
day 1, 3 and 7 following NSC injection, we examined DiI signals in the tissue 
sections of the lung with tumor nodules under fluorescent microscope. On day 1, 
some DiI signals could already be detected in the lungs. On day 3, DiI signals 
became stronger and obvious cell accumulation could be observed in the tumor 
nodules with high density of Hoechst-stained nuclei (Fig. 2.11D), indicating the 
migration of the hiPSCs-NSCs towards tumors in the lungs. There was no sign of 
decrease of DiI signals in the tumor regions on day 7. Thus, baculoviral 
transduction and CD40L expression did not display any noticeable effects on 





Fig. 2.11 CD40L expression in iPSCs-NSCs after baculoviral transduction. Flow cytometric 
analysis (A) and RT-PCR analysis (B) to show CD40L expression in NSCs derived from human 
iPSCs after BV transduction. iPSCs-NSCs were transduced with BV-CD40L at an MOI of 100 pfu 
per cell. The RNA and cell samples were harvested on the indicated days post-transduction. (C) In 
vitro migration as evaluated in Boyden chamber assays. Percentages of iPSCs-NSCs migrating 
towards the Opti-MEM medium or tumor cells are presented (n = 3 per group). (D) In vivo tumor 
tropism of CD40L-expressing iPSCs-NSCs in the lung. The tumor model was established by 
intravenous injection of 4T1-luc mouse breast tumor cells into Balb/c mice. The lungs were 
collected 3 days after the injection of iPSCs-NSCs pre-labeled with Dil, a red-fluorescent dye, for 
sectioning and microscope examination. Note the accumulation of Dil-positive cells within a 
tumor nodule. Panel (A), (B), and (C) were co-produced with Dr. Zhu Detu. Panel (D) was 




2.3.3.2 CD40L from BV-CD40L-transdcued hiPSCs-NSCs stimulates cytokine 
release from 4T1 cells and induces cell death in vitro and in vivo  
Given that CD40L-CD40 interaction can provide strong immunostimulatory 
effects, we investigated effects of CD40L-expressing hiPSCs-NSCs on the release 
of cytokines from CD40-positive tumor cells. The CD40 expression on the 
surface of 4T1 breast cancer cells was confirmed by flow cytometric analysis 
using an antibody against CD40. We made use of the Boyden chambers to co-
culture CD40L-expressing hiPSCs -NSCs with 4T1 cells. The two types of cells 
were physically separated, but CD40L molecules released from the hiPSCs-NSCs 
could pass through the insert membrane to interact with the 4T1 cells in the lower 
receiver wells. After 24 hours co-culture, the supernatants of 4T1 cell culture 
wells were collected, and the cytokine profiles in the supernatants were analyzed 
using an antibody array method. The array detects the expression levels of 32 
cytokines that could be classified into different groups according to hematopoietic 
functions, angiogenic properties and immune regulation. We found that CD40L 
changed the cytokine production profile of 4T1 cells broadly (Fig. 2.12A) and up-
regulated (>2-fold increase in expression) 37.5% (12 out of 32) of the cytokines 
and chemokines in the array (Table 2.2). The up-regulated cytokines were mostly 
pro-inflammatory cytokines such as IL-9, TNF-α and IFN-γ and chemokines such 
as MIP-2. The broad-acting IL-6 was the only cytokine that was significantly 
down-regulated, by nearly 4-fold (Fig. 2.12A, Table 2.2). To evaluate in vivo 
immune responses, we used ELISA kits to determine the TNF-α and IFN-γ 
concentrations in tissue homogenates of the lungs collected 28 days after tail vein 
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injection of CD40L-expresssing iPSCs-NSCs into the mice with breast cancer 
lung metastasis. We detected significantly increased levels of the two pro-

























Fig. 2.12 Release of cytokines from 4T1 breast cancer cells after co-culture with CD40L 
expresing iPSCs-NSCs. (A) Cytokine antibody arrays used the culture supernatants of the 4T1 
cells co-cultured with iPSCs-NSCs transduced with BV-eGFP or BV-CD40L. Co-culture was 
performed using Boyden chambers. The supernatants were collected 24 hours after starting the co-
cultures. Relative fold changes (average signal intensity difference) of cytokines and chemokines 
in the supernatant are shown. The density values of each test sample were normalized to the 
control spots on the same membrane graphed (n = 3 per group). (B) & (C) TNF-α (B) and INF-γ 
(C) concentrations in lung tissue homogenates. The lungs were collected 28 days after injection of 
iPSCs-NSCs into tumor-bearing mice for tissue homogenate preparation. TNF-α and INF-γ 
concentrations were measured using ELISA kits. N = 5 per group. Bar: s.d. The data are 
















In view of the broad stimulatory effects of CD40L-expressing iPSCs-
NSCs on release of multiple cytokines, including pro-apoptotic cytokines TNF-α 
and IFN-γ, we then moved on to evaluate the bystander effects of iPSCs-NSCs on 
the induction of cell death and apoptosis in 4T1 cells. To show that the effects 
originated from the CD40L-CD40 interaction between CD40L molecules released 
from iPSCs-NSCs and CD40 on 4T1 cells, instead of direct cell interaction, 
assays were performed using the Boyden chamber method as described above. 
The mouse fibroblast cell line NIH3T3, a CD40-negative cell line, was introduced 
in this assay as a negative control. After co-culture for 48 hours, cell viabilities of 
the 4T1 and NIH3T3 cell cultures in the bottom wells were measured using MTS 
assays. Caspase 3/7 activity levels were also measured using a luminogenic 
caspase 3/7 substrate. We observed the cell viability of 4T1 cells was reduced by 
more than 50% (Fig. 2.13A) and the caspase activity in 4T1 cells was 
significantly increased to 160% of control (Fig. 2.13B), demonstrating that the 
apoptosis was induced in these cells. On the contrary, the cell viability and 
caspase activity in CD40-negative NIH3T3 cell cultures were not significantly 
changed. Thus, CD40L-expressing iPS-NSCs provide a strong bystander cell 
killing effect on CD40-positive tumor cells, but not on CD40-negative cells. We 
also detected significantly increased Caspase 3/7 activities in the tissue 
homogenates of the lungs collected from the mice with breast cancer lung 
metastasis and treated with CD40L-expressing iPSCs-NSCs (Fig. 2.13C), 
indicating the induction of apoptosis after delivery of CD40L into the lungs by 















Fig. 2.13 Cell killing effects of CD40L-expressing iPSCs-NSCs on 4T1 breast cancer cells. (A) 
Cell viability assay. (B) Caspase 3/7 activity assay using cultured cells. CD40-negative NIH3T3 
cells were included as controls. Assays were performed using Boyden chambers to examine the 
bystander effects of CD40L. After 48 hours of co-culture, cell viability was assessed with the 
MTS method and caspase 3/7 activity levels were measured using a luminogenic caspase-3/7 
substrate. Abbreviations: NSC-eGFP, iPSCs-NSCs transduced with BV-eGFP; NSC-CD40L, 
iPSCs-NSCs transduced with BV-CD40L. The results are the averages of three independent 
experiments performed in triplicate. *** P < 0.001 versus the NSC-eGFP+4T1 control group by 
ANOVA. (C) Caspase 3/7 activity assay using lung tissue homogenates. The lungs were collected 
28 days after injection of iPSCs-NSCs into tumor-bearing mice for tissue homogenate preparation. 
Caspase 3/7 activity levels were measured using a luminogenic caspase-3/7 substrate. N = 5 per 
group. Bar: s.d. *** p < 0.001 vs. the group of mice injected with iPSCs-NSCs expressing eGFP 
by analysis of variance. The data are representative of two independent experiments. Panel (A) 
and (B) were co-produced with Dr. Zhu Detu. 
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2.3.3.3 Systemic delivery of hiPSCs-NSCs expressing CD40L inhibits tumor 
development  
To assess the potential of CD40L-expressing hiPSCs-NSCs as a cellular 
therapeutic for cancer treatment, we determined in vivo effects of those cells on 
tumor development in two mouse breast cancer models in immunocompetent 
BALB/c mice: an orthotopic breast cancer model generated by subcutaneous 
injection of luciferase-expressing mouse 4T1 breast cancer (4T1-luc) cells onto 
the mammary fat pad and a breast cancer lung metastasis model generated by 
intravenous injection of 4T1 cells via the tail vein.  
 We first tested the effects on tumor growth at the inoculation site and 
metastasis in the orthotopic breast cancer model (Fig. 2.14A). At day 3 post-
tumor inoculation, the tumor-bearing mice were randomly divided into 4 groups 
for tail vein injection with PBS, hiPSCs-NSCs, hiPSCs-NSCs expressing eGFP or 
hiPSCs-NSCs expressing CD40L. On day 28 post-tumor inoculation, all mice 
were sacrificed and nine organs, including the mammary fat pad with the major 
tumor body, lungs, liver, spleens, kidneys, heart, stomach, brain, femurs, and 
spinal cord were collected for ex vivo bioluminescent imaging of 4T1-luc cells. 
We observed smaller sizes of the primary tumors in the mammary fat pad in the 
NSCs-CD40L group compared with those in the control groups (Fig. 2.14B). 
Furthermore, the ex vivo organ imaging showed that there were no tumor 
metastases in the examined organs from the NSCs-CD40L group, while there 
were 5, 11 and 4 organs with metastases in the PBS, NSC and NSC-eGFP groups, 
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respectively (Fig. 2.14C). These findings suggest that NSC-CD40L not only 
inhibits primary tumor growth, but also inhibits tumor metastasis.  
 
Fig. 2.14 In vivo effects of CD40L-expressing iPSCs-NSCs on orthotopic tumor growth and 
metastasis of 4T1 breast cancer. (A) The experiment protocol. 4T1-luc cells were inoculated in 
the mouse mammary fat pad to establish an orthotopic breast cancer model in BALB/c mice. 
Three days post-tumor inoculation, PBS, iPSCs-NSCs (NSC), iPSCs-NSCs transduced with BV-
eGFP (NSC-eGFP) or iPSCs-NSCs transduced with BV-CD40L (NSC-CD40L) were injected 
through the tail vein (n = 10 mice per group). (B) Tumor diameters on day 28 post-tumor 
inoculation. Bioluminescent images show the tumor size in representative animals from each 
group. The heat map represents the tumor area, and color represents the intensity. ** P < 0.01, *** 
P < 0.001 versus the NSC-CD40L group by ANOVA. (C) 4T1 breast cancer metastasis. Nine 
organs were collected from the above mice on day 28 for ex vivo imaging. The numbers of mice 




Possible effects of CD40L-expressing hiPSCs-NSCs on tumor 
development were further investigated in the breast cancer lung metastasis model 
after tail vein injection of the cells. We observed that the survival of those treated 
mice was significantly prolonged. On day 30, despite all mice in the control 
groups had died, nearly 40% of the mice in the NSC-CD40L group remained alive. 
The median survival time increased from no more than 26 days for the three 
control groups to 30 days in the NSC-CD40L group (Zhu et al. 2014).  
The part related with CD40L has been published in Human Gene Therapy 
with Dr. Zhu Detu and me as the co-first authors. 
 
2.4 Discussion 
2.4.1 hiPSCs-derived NSCs 
The ability of malignant tumors to infiltrate the human body and the 
ineffectiveness of conventional therapies, such as surgery, radiotherapy, and 
chemotherapy, to eliminate disseminated tumors can be partially attributed to the 
poor prognosis associated with these tumors. There is an urgent need to develop 
novel treatments to overcome the limitations of current cancer therapies. NSCs 
are able to home in on not only brain tumors but also solid tumors of non-neural 
origins (Aboody et al. 2000, Brown et al. 2003, Aboody et al. 2006, Yang et al. 
2012b). Specifically, the tumor tropism of NSCs has been utilized for targeted 
delivery of anti-cancer genes to both major tumor masses and distant tumor 
outgrowths in animal tumor models. A phase 1 clinical trial of gene therapy for 
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recurrent glioblastoma multiform using a human NSC cell line to deliver a suicide 
gene is currently ongoing at the City of Hope Medical Center in Duarte, 
California. However, the large-scale production of NSCs with tumor tropism for 
clinical applications remains an issue. In the present study, utilizing human iPSCs 
as the source, we developed two methods for NSC induction and compared the 
methods with the most commonly utilized neural rosette formation method. The 
results indicate that the single cell adhesion method could generate NSCs with 
higher consistency and stronger migration capacity toward glioma and breast 
cancer cells. This method induces neural differentiation of hiPSCs through the 
dissociation of hiPSC colonies into single cells to evoke a default mechanism. It 
bypasses the stage of EB formation and avoids the difficulty associated with 
neural rosette selection. Moreover, NSCs derived from the single cell adhesion 
method are maintained in a defined serum-free medium and only require 0.1% 
gelatin, rather than laminin or Matrigel, as the coating matrix.  
If NSCs to be used are the progeny differentiated from the iPSCs that are 
generated by reprogramming of the patient’s own cells, the treatment is viewed as 
autologous cell therapy and the likelihood of immune rejection towards NSCs 
after transplantation will be significantly reduced. In the case that NSCs are 
derived from an iPSC line selected from a bank of human leukocyte antigen 
(HLA)-typed human iPSCs, they can be used as semi-allogeneic differentiated 
cells sharing some of HLA alleles with recipients. It is also possible to use iPSC-
derived NSCs as allogeneic cells for therapeutic applications that do not require 
long-term survival of transplanted cells, such as cancer therapy. Different from 
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regenerative medicine technologies using allogeneic stem cells that require long-
term immunosuppressive treatment, using iPSC-derived cells as exogenous 
cellular vehicles for cancer treatment may not need immune suppression since the 
therapy does not really require stem cell engraftment. Using a real-time PCR 
method that analyzes HLA-A short tandem repeat (STR) #54, we assessed the fate 
of intravenously injected human iPSCs-NSCs in the lung, liver and spleen of 
immune-competent BALB/c mice previously (Yang et al. 2012b). Approximately 
51% decrease of iPSCs-NSCs was detected in the 3 organs over the 4-week 
period. Thus, we would expect that allogeneic cells derived from iPSCs will 
ultimately be eliminated in patient’s body. 
Using allogeneic cells derived from iPSCs as cellular vehicles for cancer 
therapy can be justified for several reasons. Firstly, developments in genetic 
engineering methods, especially those based on targetable nucleases that are 
capable of introducing transgenes at specific sequences, have opened the 
possibility for generation of human iPSCs with therapeutic genes in safe harbor 
loci. These genetically modified iPSCs can then be used as a master cell line for 
the production of cell therapeutics. Secondly, allogeneic cell therapeutics can be 
produced in large-scale, allowing multiple-site clinical trials using the same batch 
of cells and repeated cell therapy in the same patient. Large-scale mass production 
can also simplify the logistics of cell culture operations, thus significantly 
increasing cost-effectiveness. For commercial purposes, large-scale cell 
therapeutic production is necessary to prepare “off-the-shelf” cryopreserved cells 
in a ready-to-go format. Thirdly, the allogeneic cell approach makes standardized 
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manufacture easy. This is useful in eliminating quality variability of cell 
therapeutics, thus allowing reliable comparative assessment of treatment 
outcomes in a multiple-site clinical trial.  
2.4.2 Tumor tropism of hiPSCs-NSCs 
We have previously reported that hESC-NSCs and hiPSC-NSCs can be used for 
targeted gene therapy for glioma and breast cancer (Yang et al. 2012b, Zhao et al. 
2012b). We further investigated in the present study putative molecular 
mechanisms underlying tumor tropism of hiPSC-NSCs and whether the tumor 
tropism can be enhanced by chemical drug manipulation.  
This study is the first attempt to use microarray-based gene expression 
profiling technology, a technology that allows gene expression analysis with a 
high-throughput, to map gene expression profiles in hiPSC-NSCs. Given the fact 
that limited information is available so far on the molecular mechanisms 
underlying NSC migration towards tumor, we used Affymetrix high density array 
chips for analysis of up to 45,000 transcripts (GeneChip® Human Genome U133 
Plus 2.0 Array, Affymetrix) in migratory or non-migratory NSCs collected from 
migration assays towards either human glioma tumor cell conditioned medium or 
mouse breast cancer cell conditioned medium.  
Comparing the up- and down-regulated genes in hiPSC-NSCs migrating 
towards 4T1 and U87 conditioned medium, we identified several commonly 
down-regulated genes associated with intracellular non-membrane-bounded 
organelles, suggesting that these genes may be significant in regulating the 
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migration of NSCs towards tumors. Intracellular non-membrane-bounded 
organelles are organized cellular structures with distinctive morphology and 
functions but not bounded by lipid bilayer membranes (DAVID, Bioinformatics 
Resources 6.7). These organelles include chromosomes, ribosomes, and the 
cytoskeleton. While general functions of chromosomes and ribosomes are not 
directly related to cell migration, cytoskeleton dynamics plays important roles in 
cell migration including NSC migration (Kasper et al. 2009). Of the genes 
associated with intracellular non-membrane-bounded organelles that were 
confirmed with qPCR analysis, NOS appears highly interesting, as it has been 
investigated in previous studies for its functions associated with cell migration.   
2.4.2.1 Neuronal nitric oxide synthase (nNOS) 
 NO is a radical molecule involved in various physiological and 
pathophysiological processes. It is synthesized from L-arginine by NOS, which 
exists in three isoforms based on the tissue source, inducible-NOS (iNOS), 
endothelial-NOS (eNOS) and finally neuronal-NOS (nNOS) (Moreno-Lopez et al. 
2000, Su et al. 2005, Zhang et al. 2007). These three isoforms of NOS are co-
localized with the cytoskeleton including microtubules, actin microfilaments, and 
intermediate filaments directly or indirectly. This association assists NOS in 
performing their function. Reorganization of cytoskeleton, which can be induced 
by extracellular signals, will indirectly affect NO production (Su et al. 2005). 
Thus, altered NO production by cytoskeletal reorganization might be important in 
physiological and pathophysiological conditions. In the nervous system, nNOS 
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takes part in various functions such as vascular homeostasis, neurotransmission, 
host defence and angiogenesis (Su et al. 2005). 
Several studies have demonstrated a connection between NOS expression 
and migration of neuronal cells. One such study performed on rats subject to 
cerebral ischemia indicated a decline in nNOS expression post-ischemia in 
migrating cells originated from the ependymal and sub-ventricular zone, the 
regions in the mammalian brain that retain the ability for neurogenesis in 
adulthood due to the presence of neural stem cells (Zhang et al. 2007). The study 
also noted a decreased level of nNOS expression in cerebral regions were the 
migrating cells passed through, suggesting that decreased nNOS expression in the 
migration routes could be related to the cell migration. These findings were 
consistent with an earlier study by Moreno-López et al. (Moreno-Lopez et al. 
2000), in which they found that neural precursor cells did not express nNOS 
either in proliferation or migration regions of adult mouse brains. Furthermore, 
eNOS was found to attenuate pulmonary leukocyte migration via inhibition of 
endothelial adhesion molecule expression (Kaminski et al. 2004). 
Also reported previously, there exists a positive relationship between an 
increased level of NO and NSC differentiation (Moreno-Lopez et al. 2000, Luo et 
al. 2010) and NOS inhibition enhances NSC proliferation but decreases their 
differentiation (Maeda et al. 2000, Ciani et al. 2004, Luo et al. 2010). In our study, 
older passages of NSCs, which are more differentiated and hence might have a 
higher level of NO, have a decreased migratory capacity (data not shown). The 
findings from our NSCs migration study correlate well with our microarray 
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results, supporting a hypothesis that up-regulation of nNOS increases NO 
production and thus differentiation, which in turn might reduce cytoskeletal 
dynamics, leading to reduced cell migration. Thus, down-regulation of nNOS 
would on the other hand, decrease intracellular NO level, acting as an effective 
way to enhance NSC migration toward tumors.  
However, other studies performed on rats have indicated an increased 
proliferation followed by increased migration of neural precursor cells post-
ischemia when NO donor was administrated (Zhang et al. 2001). Publications by 
Tegenge et al. (Tegenge et al. 2011) have indicated that NO stimulates migration 
of human neural progenitor cells under healthy conditions via a cGMP-mediated 
signal transduction pathway by activating the soluble enzyme, guanylyl cyclase 
using NO (Tegenge et al. 2011, Tegenge & Bicker 2009). These studies also 
showed that the migration of these cells is blocked by the use of nNOS inhibitors 
and enhanced by the use of an NO donor. The discrepancies between these studies 
and those showing increased NSC migration associated with decreased nNOS 
expression could be explained by the difference between physiological and 
pathological conditions and/or different types of pathological conditions, the 
species of biological samples used, as well as the neural precursor cell type, age 
and NO source. A previous report has indicated that regulation of neurogenesis by 
nNOS is bidirectional. This study stated that neuron derived nNOS and exogenous   
NO donors decrease neurogenesis and neuronal differentiation whereas NSCs 
derived nNOS is important for enhancing neurogenesis as indicated by decreased 
neurogenesis and neural differentiation when NSCs were treated with an nNOS 
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inhibitor (Luo et al. 2010). This suggests that altered nNOS source may result in 
altered functions. Since no previous studies have been conducted to investigate 
the effects of NO on the migration of human NSCs towards tumors, our findings 
on nNOS down-regulation in migratory NSCs deserve further scrutiny. For 
instance, investigation on whether nNOS inhibitors would increase NSCs tumor 
tropism in vivo is an interesting topic for future research. 
2.4.3 CD40L mediated cancer immunotherapy 
Approximately 90% of human malignancies arise from epithelial tissue. CD40 is 
selectively expressed in many epithelial cancers including breast, lung, ovarian, 
cervical, bladder and colon carcinomas, whereas most normal, non-proliferating 
epithelial tissues are CD40-negative (Tong & Stone 2003). Ligation of CD40 on 
these tumor cells generates direct growth-inhibitory effects without obvious side 
effects on their normal counterparts (Tong & Stone 2003). CD40/CD40L ligation 
can activate antigen-presenting cells such as dendritic cells, stimulating their 
maturation to present antigens to T cells, as well as secretion of cytokines. CD40L 
stimulation may also abrogate regulatory T-cell suppression. While being an 
immune activator, CD40L can directly induce apoptosis and/or cell cycle 
blockage in tumor cells. Hence, National Cancer Institute immunotherapy agent 
workshop held in 2007 has ranked CD40L as the No. 4 agent with high potential 
for use in cancer therapy (Cheever 2008). Given their potent anti-tumor effects in 
experimental cancer animal models, therapeutic Interventions targeting CD40L 
are currently under intense investigation in cancer therapy clinical trials (Loskog 
& Totterman 2007, Ullenhag & Loskog 2012). 
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2.4.3.1 CD40L expressing hiPSCs-NSCs mediated cancer immunotherapy 
The current study presented a new approach of CD40L-based cancer therapy and 
demonstrated the feasibility of delivering CD40L into tumors by systemically 
injected tumor tropic stem cells to inhibit tumor development. Different from the 
strategy of local CD40L gene transduction of tumor cells, our approach makes use 
of a cellular vehicle pre-loaded by baculoviral CD40L transduction and the tumor 
tropism property of the cells following systemic delivery to activate the local 
CD40L-CD40 interaction within tumors. Since the systemic delivery of CD40L-
loaded NSCs can target multiple metastases in different sites through circulation, 
our approach is attractive in enabling efficient therapy for metastatic cancer. As 
suggested by our in vitro study, the tumor growth inhibition could be through a 
bystander mechanism of the CD40L protein from donor iPSCs-NSCs to nearby 
tumor cells and associated with the cell killing effects mediated by Th1-type 
cytokines. It has been demonstrated previously that CD40L protein transfer to 
tumor cells occurs in transduced fibroblasts, epithelial cells and bone marrow 
stromal cells (Biagi et al. 2003). Our in vivo experiments further demonstrated the 
increase in the TNF-α and INF-γ concentrations and Caspase 3/7 activity in the 
lungs collected from tumor bearing animals treated with CD40L-expressing 
iPSCs-NSCs. In an ongoing study, we have tested human iPSCs cell-derived 
endothelial progenitor cells that genetically modified to express CD40L to treat 
4T1 metastasis in immunocompromised Balb/c nude mice and again observed the 
anticancer effects of CD40L (unpublished observation). Balb/c nude mice lack T 
cells but still acquire B cells and innate immune cells, such as NK cells and 
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complement immune system. Thus, up-regulation of Th1 cytokines and induction 
of apoptosis, but not induction of T-cell responses, might play more important 
roles in the observed antitumor action in the current study. 
We observed in this study the accumulation of iPSCs-NSCs in the lungs, 
liver, and kidneys after intravenous administration in mice. While such an 
accumulation can be valuable for cancer therapy in these organs, CD40 ligation-
based therapy there could potentially damage CD40-positve healthy cells. One 
example is apoptosis in CD40-positive hepatocytes after CD40 activation by anti-
CD40 agonist monoclonal antibodies (Afford et al. 1999). CD40 ligation on 
endothelial cells also triggers complex stimulating effects on the secretion of 
cytokines, chemokines, coagulation factors, and adhesion molecules (Karmann et 
al. 1995, Thienel et al. 1999). As the advantages of using a cellular vehicle to 
deliver gene therapeutics, several genetic engineering strategies can be adopted to 
minimize such off-target side effects and enhance the tumor-specific treatment. 
For example, tumor-specific promoters, such as the hypoxia response elements, 
the proendothelin-1 promoter, and the survivin promoter, can be used to restrict 
therapeutic gene expression in tumor environment (Dong & Nor 2009, Keung et 
al. 2013). Given the fact that the vesicular stomatitis virus glycoprotein (VSV-G) 
can act in a pH-dependent manner to kill cells through syncytium formation, we 
have genetically engineered VSV-G to generate a mutant that is capable of 
stimulating the formation of multinucleated syncytia specifically at the tumor 
extracellular pH. Injection of iPSCs-NSCs expressing the VSV-G mutant through 
tail vein can selectively kill tumors in the mice with metastatic breast cancers in 
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the lungs, without detectable hepato- and nephro-toxicities in off-target organs 
(Zhu et al. 2013a).  
2.4.3.2 Safety of baculovirus  
To employ NSCs as donor cells to carry the CD40L gene or other therapeutic 
genes for cancer therapy, the cells need to be manipulated genetically in a safe 
and effective way to express transgenes long enough to achieve therapeutic goals. 
Our previous studies demonstrated that insect baculoviral vectors are effective in 
transducing human NSCs for transgene expression. Advantages associated with 
baculoviral transduction include large gene cloning capacity, ease of virus 
generation, low cytotoxicity to transduced cells, and the absence of the risks of 
virus replication and infection in human cells (Airenne et al. 2013). Commonly 
used replication-defective gene therapy vectors are derived from human viruses 
such as adenovirus, retrovirus and adeno-associated virus. Some of them may 
carry the risk of recombination with wild-type viruses resulting in replication-
competent infectious viruses. Also, pre-existing immune responses in the host 
against adenovirus raise the concern that the use of adenovirus-based vectors will 
be restricted or compromised (Jooss & Chirmule 2003, Bessis et al. 2004). Using 
human blood samples, it has been demonstrated that baculovirus is not targeted by 
pre-existing immunity in humans (Strauss et al. 2007). However, the non-
integrating nature of baculovirus only permits transient transgene expression, 
which will limit efficacy in applications that need long-term expression of a 
transgene. To overcome the limitation, we have developed several baculoviral 
transduction-based approaches using either recombinase-mediated cassette 
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exchange (RMCE), zinc finger nuclease (ZFN) technology or transcription 
activator-like effector nuclease (TALEN) technology for site-specific integration 
of a transgene in human pluripotent cells without random integration 
(Ramachandra et al. 2011, Tay et al. 2013, Phang et al. 2013, Zhu et al. 2013b). 
We are in the midst of establishing iPSC lines to achieve stable expression of 
transgenes in the differentiated progeny of the iPSCs, including NSCs.  
Baculoviruses are commonly found in nature. As insect-specific pathogens, 
baculoviruses have been used as biopesticides to protect forest and crop against 
injurious insects. Clinical evaluation of volunteer human subjects in feeding tests 
using occluded Heliothis zea baculovirus reveals no signs of inflammation, 
allergy, or side effects, demonstrating the safety of the viruses (Heimpel & 
Buchanan 1967). Recombinant baculoviruses are currently widely applied in the 
biotech industry for protein production in insect cells. The US Food and Drug 
Administration (FDA) has so far approved two protein therapeutics manufactured 
using baculovirus/insect cells. Cervarix®, a vaccine for the prevention of human 
papillomavirus (HPV)-associated cervical cancer, is produced in a 
baculovirus/insect cell system expressing the L1 major capsid protein of HPV. 
Provenge® is a therapeutic cancer vaccine for advanced prostate cancer, which 
uses patients’ dendritic cells pulsed with a recombinant protein containing 
prostatic acid phosphatase fused with granulocyte-macrophage colony-stimulating 
factor (Lesch et al. 2011). The fused protein is produced with a baculovirus/insect 
cell system. European Medicines Agency (EMA) has also approved human use of 
Cervarix®. The approvals of these two products that make use of proteins 
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manufactured in baculovirus/insect cell systems set important precedents for 
future baculovirus therapies to gain regulatory endorsement (Airenne et al. 2013). 
In conclusion, cancer gene therapy using CD40L-expressing stem cell 
vehicles provides a promising means to stimulate the immune system to combat 
cancer. When iPSC derivatives are used, this approach provides the possibility of 
ex vivo gene therapy to use the progeny of iPSCs generated by re-programming 
of the patient’s own cells, thus holding potential for translation to clinical 
application. 
This part of data has been published in Human Gene Therapy with Dr. 
Zhu Detu and me as the co-first authors. 
 
2.4.4 Future direction 
2.4.4.1 Improving NSCs generation efficiency from hiPSCs 
In this chapter, we discuss the development of a simple and cost-effective method 
to generate NSCs from hiPSCs with extensive tumor homing properties; however, 
the method is not quite consistent and efficient. Very recently, both Life 
Technologies and STEMCELL Technologies developed efficient and rapid 
methods for NSC generation adapted to human pluripotent stem cells with similar 
steps. Small clumps or single cells derived from hiPSCs were plated onto Geltrex 
or poly-Ornithine/Laminin- or Matrigel™-coated plates with or without the 
addition of Y-27632. After 6 to 9 days in culture, NSCs were acquired. However, 
the cost of the methods from these two companies is quite high, and the 
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components of their medium are unpublicized, which indicates that the methods 
are not applicable for large-scale clinical production of NSCs for cancer gene 
therapy. However, based on their methods, we incorporated some modifications 
to our method. The main reason for the low efficiency of the single cell adhesion 
method was that only a few cells attached to the 0.1% gelatin after the hiPSC 
colonies were dissociated, despite the addition of Y27632. To improve single cell 
attachment, the single hiPSCs could first be seeded onto Matrigel with the 
addition of Y-27632 for several days. Our previous data demonstrated that 
dissociated hiPSCs could attach and survive well on Matrigel in the presence of 
Y-27632. Then, the partially neurally differentiated hiPSCs could be transferred 
to 0.1% gelatin for further differentiation. 
2.4.4.2 Validation of nNOS function in vivo 
In this study, we demonstrated that the inhibition of nNOS activity promotes the 
migration of hiPSC-derived NSCs toward cancer cells through nNOS inhibitors or 
nNOS siRNA. However, our work is restricted in in vitro studies. To further 
confirm our findings, in vivo validations should be conducted. An orthotopic 
breast cancer model can be used for this purpose. Mouse 4T1-luc breast cancer 
cells were subcutaneously injected into the mammary fat pad. Seven days post-
tumor cell inoculation, hiPSC-derived NSCs pre-treated with or without nNOS 
inhibitors or nNOS siRNA were injected into the mice to observe their migration 
toward breast cancer cells.  
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2.4.4.3 Validation of the potential of hiPSCs-NSCs delivered CD40L in 
immunocomprised mice model 
In this study, we demonstrated that intravenously injected iPSCs-NSCs can be 
used as a CD40L delivery platform to treat metastatic cancer, while minimizing 
injury to off-target organs. However, the in vivo experiments were performed 
using immunocompetent mice, which makes investigation of the mechanism of 
inhibiting tumor growth and metastasis by CD40L-delivered hiPSCs-NSCs 
difficult. According to the CD40-CD40L interaction mechanism, tumor mass 
inhibition can be mediated through CD40L ligation to tumor cells, which causes 
their growth inhibition directly, or immune cells, which results in the activation of 
immune responses. Using an immunocompromised mouse model, we could 
exclude the effects associated with the activation of the immune responses. 
Subsequently, we repeated our in vivo experiment but replaced the 

































Glioma is the most common type of brain tumor, comprising one-third of all brain 
and CNS tumors (Goodenberger & Jenkins 2012). Gliomas primarily consist of 
astrocytomas, ependymomas, and oligodendrogliomas. Glioblastoma multiforme 
(GBM) and anaplastic astrocytoma are the most common and lethal types of high-
grade malignant astrocytomas (Wu et al. 2013). The average survival time of 
patients with advanced glioma is less than one year. Glioma treatments 
predominately include conventional surgery, radiotherapy, and chemotherapy, 
while stem cell-mediated suicide gene therapy represents more advanced 
treatment (Kosztowski et al. 2009). Nevertheless, the diagnosis and prognosis 
remain poor, and recurrence rates are high. The scientific evidence that has 
accumulated during the previous decade indicates that in various human 
malignancies, including gliomas, there are small subpopulations of highly 
tumorigenic cells, CSCs, or TICs (Bao et al. 2006). CSCs hold stem cell abilities 
to self-renew and give rise to phenotypically diverse tumor cell populations. 
These tumorigenic cells are crucial in sustaining tumor growth and initiating 
distant metastases. Gliomas often penetrate into adjacent normal tissues, thereby 
forming tumor microsatellites (Nakamura et al. 2004), which have been proposed 
to be mediated by CSCs (Lee et al. 2011). Clinically, CSCs are responsible for 
tumor resistance to major conventional therapies, including chemotherapy and 
radiotherapy (Medema 2013). Despite primary tumor removal by surgery and 
tumor bulk shrinkage in response to initial chemotherapy and radiotherapy, tumor 
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relapse and metastasis after therapy often occur. This finding is likely a result of 
the failure to eradicate CSCs, which can subsequently reproduce the entire 
malignant phenotype. As a result, effective therapies that target glioma stem cells 
are needed to improve the prognosis of glioma patients. 
3.1.2 OSKM gene expression in cancer stem cells 
Since 2006, somatic fibroblast cells were demonstrated to be reprogrammed into 
pluripotent stem cells (iPSCs) using defined four transcriptional factors which are 
Oct4, Sox2, Klf4 and c-Myc (OSKM) or Oct4, Sox2, Lin28 and Nanog (Yu et al. 
2007, Takahashi & Yamanaka 2006). Several other cell types such as T cells 
(Vizcardo et al. 2013), neural progenitor cells (Kim et al. 2008) were also 
successfully reprogrammed into iPSCs. Oct4 and Sox2, together with Nanog, are 
the three genes encoding the core elements of the regulatory circuitry responsible 
for maintaining the pluripotency of embryonic stem (ES) cells. Klf4 plays 
important roles in both carcinogenesis and normal development, especially in the 
transcription regulatory network important for self-renewal and pluripotency in 
ES cells and iPS cells. Myc is a well-studied classical oncogene and one of the 
most highly amplified oncogenes in many different human cancers. 
High similarities between iPS cells derivation through reprogramming and 
oncogenic transformation have been noted: both can be induced by a series of 
genetic and epigenetic modifications and utilize similar transcriptional networks. 
During the process of changing from somatic differentiated cells to iPSCs cells, 
the cells acquire unlimited proliferation properties and self-renewing activities, 
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the two characteristics that are most important for cancer cells. Indeed, studies 
have shown that the iPSCs genes are expressed in various types of tumors and 
involved in their tumorigenic development, supporting the notion that cell 
reprogramming and tumor transformation utilize common mechanisms. Ectopic 
expression of Oct4 can dose-dependently increase the malignant potential of 
embryonic stem cells and is sufficient to induce tumors in mice (Gidekel et al. 
2003). Sox2 was identified as an amplified lineage-survival oncogene in lung and 
esophageal squamous cell carcinomas (Bass et al. 2009). An increased expression 
of pluripotency-related factors is frequently detectable in poorly differentiated 
solid tumor, suggesting that these malignant cells have gained undifferentiated, 
stem cell properties (Ben-Porath et al. 2008). Clinically, the increased expression 
of Oct4 and Sox2 in subtypes of cancers is associated with aggressive disease 
courses, such as undifferentiated histology, resistance to therapy, metastases, 
relapse, and shorter patient survival rates (Dhodapkar et al. 2010, Samardzija et al. 
2012, Liu et al. 2013a). Because of the correlations, the two proteins have been 
proposed as novel predictors of distant recurrence and poor prognosis in cancer 
patients.  
Recently, direct evidence linking the Oct4 and Sox2 genes to CSCs has 
emerged. The two proteins are found to be enriched in CSCs of several cancers as 
compared to relatively differentiated cancer cells with same origin (Wright et al. 
2008, Nishii et al. 2009, Dhodapkar et al. 2010, Samardzija et al. 2012, Liu et al. 
2013a). In lung cancer-derived CD133-positive cells, Oct4 expression is needed 
to maintain cancer stem-like properties of the cells (Chen et al. 2008). In 
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glioblastoma, knockdown of Sox2 leads to the inhibition of proliferation and loss 
of tumorigenicity of glioma CSCs (Gangemi et al. 2009). In ostersarcoma, a 
subpopulation of tumor cells have been identified that are capable of activating an 
exogenous Oct4 reporter and are more tumorigenic than their counterparts in 
reconstituting heterogenous tumors with both Oct4-positive and Oct4-negative 
cells (Levings et al. 2009). In breast cancer, ectopic expression of Oct4 in normal 
breast cells lead to the generation of cells with tumor-initiating and colonization 
abilities and development of high-grade, poorly differentiated breast carcinomas 
in nude mice (Beltran et al. 2011). In epithelial ovarian cancer, CSCs isolated 
from ovarian primary tumors have an enhanced expression of Oct4 (Samardzija et 
al. 2012). In colorectal cancer (CRCs), the ectopic expression of the iPSCs genes 
promotes sphere-formation, proliferation, colony formation and migration of 
human CRC cells, and the signature for iPSCs gene expression in CRCs can be 
used to predict the survival of cancer patients (Liu et al. 2013b). These findings 
suggest that some of the iPSCs genes might function as the master regulators of 
CSC induction and the key factors in the maintenance of CSC identity. Being the 
proteins that are over-expressed on CSCs, or highly active in these tumorigenic 
cells, but have limited expression in normal tissue, the Oct4 and Sox2 products 
are potential targets for immune intervention. 
At present, a few studies have shown the successful reprogramming of 
tumor cell lines into immature or pluripotent states through certain transcription 
factors or even miRNAs (Corominas-Faja et al. 2013, Utikal et al. 2009, Kumar 
et al. 2012, Su et al. 2011, Miyoshi et al. 2010, Lin et al. 2008), which has opened 
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up a new perspective for cancer stem cells study and novel targeting therapies 
development. Since it is still unknown that whether these reprogrammed cancer 
cells are the same with in vivo CSCs, here cancer stem-like cells is used to 
describe these reprogrammed cancer cells with certain cancer stem cells 
properties. Those results indicated that certain cancer cell lines such as breast 
cancer, melanoma, colon cancer, and gastrointestinal cancer cell lines could be 
reprogrammed into cancer stem-like cells through defined factors. Different 
transcriptional factors combinations or miRNA were used, such as OSKM factors 
with or without Sox2, Oct4, CD44, and miRNA-302. Here we tested the 
possibility of utilizing OSKM to reprogram glioma cell lines into glioma cancer 
stem-like cells. 
3.1.3 Dendritic cells  
Dendritic cells (DCs) are the most potent antigen-presenting cells that play a 
pivotal role in T cell activation and in the initiation of antigen-specific immune 
responses (Tan & O'Neill 2005). There are different subsets of DCs based on their 
lineages in human immune systems, although the most widely used DCs are the 
myeloid DCs derived from monocytes (Chiang et al. 2011). Dendritic cells 
process and present endogenous or exogenous antigens through MHC-I or MHC-
II. Specifically, DCs can also uptake exogenous antigens from apoptotic, necrotic, 
or even live cancer cells and present them to CD8+ T cells through MHC-I via the 
cross-presentation that is very important for antitumor immunity (Melief 2008). 
DC differentiation can be divided into two stages, namely, the immature and 
mature stages. Immature DCs are present in and traffic through non-lymphoid 
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peripheral tissues, thereby monitoring the environment for pathogen infection 
(Granucci et al. 2004). Immature DCs are capable of internalizing different forms 
of antigens with high efficiency through specialized receptors (Tarte et al. 2000). 
These antigens include whole cell lysates, RNA, exosomes, and apoptotic bodies 
(Tarte et al. 2000). During the immature state, DCs express low levels of co-
stimulatory molecules. Upon exposure to microbial agents or inflammatory 
mediators in the periphery, immature DCs differentiate into a mature state, which 
is characterized by a high expression of MHC and co-stimulatory molecules but 
lower phagocytic and endocytic capabilities (Frankenberger & Schendel 2012). 
Exposure to microbial products also modifies DC expression of chemokine 
receptors (switch from CCR1 and CCR5 to CCR7) and adhesion molecules, 
which causes in vivo traffic from the periphery to lymph nodes with T cell 
accumulation (Tan & O'Neill 2005, Tarte et al. 2000). Activated DCs present 
pathogen-encoded antigens to naïve antigen-specific T cells to initiate primary T 
cell immune responses (Tan & O'Neill 2005).  
3.1.4 Cytotoxic T cells  
CD8+ T cells, also known as cytotoxic T cells, play a crucial role in antitumor 
immunity. CD8+ T cells recognize unique tumor-specific antigens (TSAs), which 
develop from mutations or viral oncogenesis, and tumor-associated antigens 
(TAAs), which are derived from the aberrant expression of antigens that are 
normally developmentally or tissue-restricted through a MHC-I-restricted manner 
(Blattman & Greenberg 2004). A T cell that has differentiated in the bone marrow 
and successfully undergone the positive and negative processes of central 
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selection in the thymus, but has not encountered its cognate antigen within the 
periphery, is referred to as a naïve T cell. Prior to exerting antitumor effects, naïve 
CD8+ T cells must be activated by antigen-presenting cells (APCs) and 
differentiate into functional effector T cells. After encountering the specific 
antigen on target cells, activated CD8+ T cells produce cytokines, such as IFNγ 
and TNFα which can interfere with the proliferation of malignant cells, and 
perforin and/or Fas that lead to tumor cell lysis. Inoda et al. demonstrated that 
chemotherapy-resistant colon cancer stem cells are sensitive to cytotoxic T cell-
mediated cell death (Inoda et al. 2011), which indicates the potential of cytotoxic 
T cells in targeting and attacking CSCs. 
3.1.5 Gene editing 
Previously, genetic engineering has primarily been mediated though a randomly 
integrated lentivirus or retrovirus, which preferentially integrates into coding or 
regulatory regions of genes with active transcription within the host genomes; this 
approach increases the likelihood of oncogene activation, gene silencing, and 
insertional mutagenesis. Recently, with the great advancement of genetic 
engineering technology, such as zinc finger nuclease (ZFN) technology, 
transcription activator-like effector nuclease (TALEN) technology, and the RNA-
guided Genome Modification (CRISPR) technique, site-specific integration of a 
transgene in cells has become substantially easier and more efficient 
(Ramachandra et al. 2011, Tay et al. 2013, Phang et al. 2013, Zhu et al. 2013b). In 
this study, we utilized baculovirus-mediated ZFN technology to integrate OSKM 
genes specifically in AAVS1. 
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3.1.5.1 Zinc finger nuclease 
Zinc finger nucleases (ZFN) are engineered with zinc finger DNA binding 
domain fused to a non-specific nuclease domain consisting of FokI restriction 
enzyme (Xiao et al. 2011). They can recognize and bind to specific DNA 
sequence depending on the design to make a specific cutting and then induce 
homologous recombination in the region with high efficiency through triggering 
homologous DNA repair mechanism. The homologous DNA repair mechanism 
makes use of another copy of the DNA which is a donor plasmid containing the 
gene of interest flanked by sequence homologous to the target site.  
 
3.1.5.2 Adeno-associated virus integration site 1 
The adeno-associated virus integration site 1 (AAVS1) is located on chromosome 
19 of the human genome with the length of 4067bp. The AAVS1 locus carries the 
PPP1R12C gene, encoding a protein phosphatase, regulatory subunit 12C, which 
is ubiquitously expressed in human cells. It has been shown that the disruption of 
this gene at the AAVS1 locus has no negative effects on human cells (Owens et al. 
2008). AAVS1 site was demonstrated to be an ideal choice for site-specific 




3.2 Materials and Methods 
3.2.1 Cell culture 
Human glioblastoma cell lines U87, U251, U118, A172, T98G, and human T2 
cell line were purchased from American Type Culture Collection (ATCC). Those 
cell lines were maintained in DMEM medium supplemented with 10% FBS, 2mM 
L-glutamine, 50U/mL penicillin and 50µg/mL streptomycin. The engineered 
glioma cells with OSKM expression were cultured in DMEM/F12, 2% B27, 2mM 
L-glutamine, 20ng/ml human EGF and penicillin/streptomycin. 1% FBS was 
supplemented to the medium to allow adherent culture. T2 cell were maintained 
in IMDM (Life Technologies) supplemented with 20% FBS. 
3.2.2 Baculovirus preparation and cell transduction 
pFastBac1 (Life Technologies) was utilized for baculovirus generation, which 
allows the gene of interest to be transferred into a baculovirus shuttle vector 
(bacmid) via transposition. pFB-ZFN, pFB-eGFP-AAVS1 and pFB-OKSM-
AAVS1 were constructed in the laboratory previously. For pFB-ZFN, the 
engineered ZFNs contain the right and left homologous arms belonging to the 
AAVS1 locus fused with an obligate heterodimer form of the FokI endonuclease, 
whose expression was controlled under human elongation factor 1α (EF1α) 
promoter. The right and left ZFNs, 993-bp each, were separated by a 0.6-kb 
internal ribosome entry site (IRES) (Fig. 3.1A). The region that we used pFB-




For the donor pasmid pFB-eGFP-AAVS1, an 810-bp left homologous arm 
and an 837-bp right homologous arm pertaining to the AAVS1 locus inserted into 
pFB-eGFP, a pFastBac1 vector constructed in the laboratory previously. For 
constructing the donor plasmid pFB-OKSM-AAVS1 (Oct4, Klf4, Sox2, and c-
myc), a polycistronic cassette from pHAGE-EF1α-STEMCCA (Millipore) was 
utilized. The cassette contains the EF1α promoter; human Oct4, Klf4, Sox2, and 
c-myc genes joined with self-cleaving 2A sequence and IRES as a fusion gene 
(OSKM); and the woodchuck hepatitis virus posttranscriptional regulatory 
element (WPRE)( Fig. 3.1B). Another cassette EF1α-eGFP was inserted in 
another direction in order to monitor the baculovirus transduction and integration. 
Recombinant BVs, including BV-ZFN, BV-eGFP-AAVS1 and BV-OKSM-
AAVS1 were generated using pFB-ZFN, pFB-eGFP-AAVS1 and pFB-OKSM- 
AAVS1 respectively, and propagated in Sf9 insect cells according to the protocol 
of the Bac-to-Bac Baculovirus Expression System from Life Technologies. 
Recombinant DNA research in this study followed the National Institutes of 
Health guidelines. 
For transduction, glioma cells were cultured with baculovirus in 
DMEM/F12 at an MOI of 100 pfu per cell for BV-ZNF or BV-eGFP-AAVS1 and 
50 pfu per cell for BV-OSKM-AAVS1 overnight. A full medium change was 
carried out the next day to stop the transduction. GFP expression was detected 




Fig. 3.1 Schematic representation of related baculovirus construction. (A) Schematics for BV-
ZFN construct and the DNA binding sites for the AAVS1-ZFN pairs.  (B) Schematics for BV-
OSKM-AAVS1 construction. (C) Schematic representation of AAVS1 within the PPP1R12C gene, 
the BV-OKSM-AAVS1 donor construct, the cutting site of BV-ZFN, and the modified AAVS1 
following homologous recombination. 
 
3.2.3 Genomic DNA isolation and PCR 
Genomic DNA was extracted from tumor cells using DNeasy Blood & Tissue Kit 
(QIAGEN) according to the recommended protocol. Genomic PCR was 
conducted with Platinum® PCR SuperMix High Fidelity (Life Technologies). The 
reaction involved 200ng gDNA product, 200nM forward and reverses primers, 
20µl Platinum® PCR SuperMix High Fidelity. The PCR reaction program was: 
94°C, 5min; 94°C, 25s followed by 65°C, 45s; 72°C, 2min 30s; 35 cycles; 72°C, 
10min. PCR products were electrophoresised on a 1% agarose gel. Primer 
sequences used are listed in Supplementary Table 1. 
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3.2.4 Real-time PCR 
Real-time PCR was conducted as previously reported. The Real-time PCR 
reaction is done in triplicates for every gene. B2M was used as the internal control. 
Data was normalized to the internal control gene and presented as change fold 
compared to wild-type cells. Primer sequences used are listed in Supplementary 
Table 1. 
3.2.5 Western blotting     
Western blotting was performed as above descriptions. Mouse monoclonal anti-
Oct4 antibody (1:500), mouse monoclonal anti-β-actin antibody (1:500) and anti-
rabbit secondary antibody (1:2000) were purchased from Santa Cruz 
Biotechnology. Rabbit monoclonal anti-Sox2 (1:500) was purchased from Novas 
Biologicals.  
3.2.6 Primary and secondary Tumor sphere Assay 
U87-EGFP, U87-#5 and U87-#20 were dissociated into single cells and 
resuspended in CSC medium consisting with DMEM/F12, 2% B27, 2mM L-
glutamine, 20ng/ml human EGF and penicillin/streptomycin. 200 cells in 200µl 
CSC medium per well was seeded in to pHEMA treated low attachment 96-well 
plates. 20 wells were analyzed for every cancer stem like cell clone. The 
experiment was repeated independently three times. The primary sphere 




For secondary sphere assay, spheres from primary sphere assay (U87-
EGFP and U87-#20) were dissociated with Tripsin, seeded into low attachment 
96-well plates with one cell/well in 200ul CSC medium and cultured for one week. 
60 wells were analyzed for every cancer stem-like cells clone. The results were 
expressed as number of secondary spheres per 60 cells. The size of secondary 
spheres was also measured. 
3.2.7 Survival studies for etoposide and dexorubicin  
U87-EGFP, U87-#5, and U87-#20 were dissociated and seeded in 96 well plates 
at 10,000 cells per well in 200ul CSC medium supplemented with 1% FBS. The 
three groups of cells were treated with Etoposide (0.5µg/ml and 5µg/ml) (Sigma-
Aldrich) or Dexorubicin (1µg/ml and 5µg/ml) (Sigma-Aldrich). After 48 hours 
treatment, the viability was measured through MTT assay. The results were 
expressed as % viability over the cells without treatment. 
3.2.8 DC differentiation and maturation 
Frozen human peripheral blood mononucleated cells (PBMCs) (100 million per 
vial) were purchased from STEMCELL Technologies. PBMCs were thawed with 
CellGro® DC Medium (CellGenix) supplemented with 5% human AB serum 
(Valley Biomedical, Winchester, VA) followed by treated with DNAse I (Sigma-
Aldrich) in serum-free CellGro® DC Medium for 15min at 37 degree. Monocytes 
were isolated through overnight plastic attachment. The floating PBMCs were 
harvested for naïve CD8+ T cells sorting. Monocytes were cultured in serum-free 
CellGro® DC Medium supplemented with 200ng/ml GM-CSF (Peprotech) and 
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1000U/ml IL-4 (Peprotech) for 36 hours to obtain fast immature DCs. 
Alternatively, monocytes were cultured in CellGro® DC Medium supplemented 
with 5% human AB serum, 50ng/ml GM-CSF (Peprotech) and 100ng/ml IL4 
(Peprotech) for 4 days to obtain Day 4 immature DCs. Immature DCs were frozen 
in 90% CellGro® DC Medium supplemented with 5% human AB serum, 50ng/ml 
GM-CSF, 100ng/ml IL4, and 10% DMSO (Sigma-Aldrich) and remained about 
80% survival rate after thawed from liquid nitrogen storage. 
Maturation was elicited by 18 hours incubation of gold standard (100 
ng/ml TNF-α + 5 ng/ml IL-1β + 5 U/ml IL-6 + 1mM prostaglandin E2 (PGE2)), 
alternative 1 (4 mg/ml monophosphoryl lipid A (MPLA) + 500 U/ml IFN-γ) or 
alternative 2 (60 EU/ml LPS + 2000 IU/ml IFN-γ). TNF-α and IFN- γ were 
purchased from Miltenyi Biotec (Bergisch Gladbach, Germany), IL-1β and IL-6 
from Biosource International (BioSource International, Inc., Camarillo, CA), 
PGE2 and MPLA from InvivoGen. 
3.2.9 Measurement of IL-10 and IL-12p70 through ELISA 
Supernatants from mature DC culture were harvested and centrifuged at 12,000g 
for 15min at 4 °C to remove cell debris. The supernatants were then subjected to 
IL-10 and IL-12p70 ELISA analysis according to manufacturer’s 
recommendations to evaluate the IL-10 and IL-12p70 release from mature DCs. 
The Human IL-10 and IL-12p70 ELISA Kit were purchased from BioLegend 
(Biolegend, CA, USA).  
112 
 
3.2.10 Tumor lysates preparation and DC pulsing 
For whole tumor lysates preparation, tumor cells were detached with Accutase, 
resuspended in PBS and subjected to six times freeze-thaw cycles in liquid 
nitrogen and room temperature. For heat-shocked tumor lysates supernatants 
preparation, the cells were heat-shocked at 42℃ for one hour and then recovered 
at 37℃ for 2 hours. The cells were washed, resuspended in PBS and subjected to 
6 times freeze-thaw cycles. The large particles and cell debris were removed from 
the cell lysate by centrifugation at 400g for 10 min, 10,000g for 30min at 4 °C 
followed by filtering through a 0.2-µm filter.  
Pulsing of DCs was performed before induction of maturation. Collect all 
the floating and loosely attached immature DCs through Gentle Cell Dissociation 
Reagent (STEMCELL Technologies) or Accutase. Then DCs were mixed with 
tumor lysates at 1:1 cell ratio overnight in serum-free CellGro® DC Medium.  
3.2.11 Naïve CD8+ T cell isolation, maintenance and priming 
PBMCs were subjected to naïve CD8+ T cells isolation through EasySep™ 
Human Naïve CD8+ T Cell Enrichment Kit (STEMCELL Technologies) 
according to the manufacturer’s recommendations. The isolated naïve CD8+ T 
cells were maintained in CellGro® DC Medium supplemented with 5% human 
AB serum and 20ng/ml IL-7.  
Based on classical CD8+ T Cells priming protocol, after DCs maturation 
were induced, mature DCs were washed twice and mixed together with naïve 
CD8+ T cells as 1:10 DC:T ratio in CellGro® DC Medium supplemented with 5% 
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human AB serum. IL-2 (50IU/ml) and IL-7 (20ng/ml) were added on day 3 and 
day 5 after first priming. For second priming, autologous immature DCs were 
thawed two days before for pulsing and maturation. On day 7, primed T cells 
were mixed together with mature DCs again as 10 T: 1 DC ratio for second 
priming in half the fresh and half the conditioned CellGro® DC Medium 
supplemented with 5% human AB serum. IL-2 (50 IU/ml) and IL-7 (20 ng/ml) 
were added on day 3 and day 5 after second priming. On day 7 after second 
priming, activated T cells were collected for further analysis. 
For the one priming dose protocol (Wolfl et al. 2011), mature DCs were 
added at a 1:4 DC: T cell ratio with 30ng/ml IL-21 (Peprotech). 72 h after 
initiation of the culture, IL-7 and IL-15 (Peprotech) was added at a final 
concentration of 5ng/ml. The cells were subsequently fed every 2–3 days. 
Evaluation was done at day 10 or 11 as indicated. 
3.2.12 Elispot  
Human IFN-γ ELISpotPLUS kit (HPR), pre-coated, strips from Mabtech 
(Stockholm, Sweden) was utilized to analyze IFN-γ secretion of CD8+ T cells. 
Briefly, Elispot plate was washed with filtered PBS for 4 times, then blocked with 
CellGro® DC Medium supplemented with 10% FBS for one hour at room 
temperature. One million T2 cells were incubated with 10 µg/ml peptides in 2ml 
serum-free IMDM alone at 37 °C for 3 hours. After that, 50,000 activated CD8+ T 
cells were mixed together with 5,000 T2 cells pulsed with peptides as 10:1 T:T2 
ratio. After overnight incubation at 37 °C, the cell culture mixture was removed, 
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followed by five times wash by filtered PBS. Detect antigen-specific T cells by 
the sequential addition of biotinylated mouse anti-human IFN-γ (2 hours at room 
temperature), 5 times wash with filtered PBS, alkaline phosphatase-conjugated 
streptavidin (1 hour at room temperature), five times further wash with filtered 
PBS, and substrates for streptavidin. CTL ImmunoSpot Entry Analyzer was 
utilized to scan the plate and count the spots corresponding to IFN-γ producing 
cells. Data was expressed as number of spots per 1 million T cells. 
3.2.13 Peptides and antibodies 
All peptides were purchased from GenScript (Scotch Plains, NJ). The peptides 
used were CEA: YLSGANLNL; Oct4: GLEKDVVRV; Sox2: TLMKKDKYTL; 
hTERT: ELTLGEFLKL. The following antibodies were used for flow cytometric 
analysis: CD8-PE, CD57-APC, CD44-APC, A2B5-APC, CD15-APC, CD49f-
APC, CD133-APC (Miltenyi Biotech), CD45RO-FITC, CD62L-APC, CD45RA-
FITC, CCR7-PE, CD27-PE, CD28-APC, CD3-APC, CD40-PE, CD54-FITC, 
CD80-FITC, CD83-APC, CD86-PE, CD127-APC, CD69-APC (BioLegend). 
Cells were analyzed using Accuri-C6 (BD Pharmingen).  
3.2.14 Statistical analysis 
All data is represented as mean ± SD. The statistical significance of differences of 
in vitro experiments was determined by unpaired Student’s t-test. A p-value < 





3.3.1 Reprogramming glioma cells into glioma cancer stem-like 
cells via pluripotent Yamanaka four factors 
3.3.1.1 Characterization of spheres derived from glioma cell lines  
The human glioma cell lines U87, U251, A172, T98G and U118 (Table 3.1) were 
first analyzed to determine the percentage of each that was composed of glioma 
stem cells. To accomplish this, flow cytometry was performed with the most 
commonly used glioma stem cell marker, CD133. Fig. 3.2F indicates that 
CD133+ glioma stem cells were a rare subpopulation (less than 1%) of every 
glioma cell line. Cancer stem cells are characterized by their capacity to survive 
anoikis under non-adherent conditions and to form floating colonies known as 
tumorspheres (Singh et al. 2013). Thus, the sphere-forming assay is utilized as a 
routine method for enriching cancer stem cells. Here, we also tested the utility of 
the sphere-forming assay as a tool for enriching glioma stem cells. Small numbers 
of cells from different glioma cell lines were separately cultured in CSC medium 
in low-binding plates to allow them to form spheres. As shown in Fig. 3.2A-E, all 
of these glioma cell lines were capable of forming spheres after 7 to 14 days of 
culture in suspension; however, the spheres differed in size and quantity. 
Expression of the glioma stem cell marker CD133 was also examined in these 
tumorspheres and compared with that in the original adherent glioma cell lines 
(Yuan et al. 2004). However, the flow cytometry results suggested that the 
sphere-forming assay was not useful for enriching these glioma cell lines for 
CD133+ glioma stem cells (Fig. 3.2F).  
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Fig. 3.2 Tumorsphere formation of different glioma cell lines. (A-E) Sphere formation of U87, 
U118, A172, T98G, and U251. A small number of glioma cells were cultured in CSC medium for 
7 days. Scale bar, 500 µm. (F) Flow cytometric analyses of CD133 expression percentage in 
original adherent glioma cell lines and their derived spheres. Unstained cells were used as negative 





3.3.1.2 Selection of OSKM-EGFP specifically integrated U87 clones  
Firstly, baculovirus transduction efficiency was evaluated in these glioma cell 
lines and their derived spheres through flow-cytometry using baculovirus 
encoding EGFP (Table 3.2). Glioma cell lines without baculovirus transduction 
was used as the negative control. EF1α-EGFP-AAVS1-encoding baculovirus 
transduction was most efficient in the U87 and U251 cell lines (90%), and a 
similar transduction efficiency was observed in single cells dissociated from the 
spheres. Baculovirus transduction efficiency was extremely low in A172 cells 
(<1%); however, through sphere formation and suspension transduction, the 
transduction efficiency of the EF1α-EGFP-AAVS1-encoding baculovirus was 
improved to 18.9%. Baculovirus transduction remained very inefficient in the 
other two glioma cell lines, U118 and T98G, despite sphere formation and 
suspension transduction. U251 and U87 cells had the greatest baculovirus 
transduction efficiency; however, U251 cells were resistant to G418. Therefore, 
U87 was selected to test the possibility of using the four OSKM for 
reprogramming cancer cells into cancer stem-like cells. 







Secondly, we determined whether ZFN could mediate AAVS1 site-
specific integration in U87 cells. The ZFN ORF encoding sequences are cloned 
under the control of an EF1α promoter with an internal ribosome entry site (IRES) 
that separates the two domains of ZFN. EF1α-eGFP-AAVS1 was used as the ZFN 
donor due to its small size, which contributes to a higher integration efficiency. 
After co-transduction with ZFN and the ZFN donor EF1α-eGFP-AAVS1 for one 
week, the cells were subjected to gDNA isolation and genomic DNA PCR. The 
primers were designed as shown in Fig. 3.3A; one primer was located at the 
AAVS1 site within the genome, while the other primer was located at the WPRE 
site within the donor fragment. If the donor fragment is successfully integrated 
into the gDNA, a 3-kb PCR fragment results. Fig. 3.3B demonstrates the 
successful insertion of the ZFN donor EF1α-eGFP-AAVS1 into the AAVS1 site 
within the genome of U87 cells.  
 
Fig. 3.3 Characterization of U87 cells with specific integration in AAVS1. (A) Schematic 
representation of primer set designed to characterize specific integration into AAVS1. A primer 
specific for WPRE and a primer specific for chromosome 19 downstream of the 3’-end of the right 
AAVS1 homologous arm were used. The size of amplification product is expected to be 3kb. (B) 
PCR analyses of genomic DNA to check the availability of AAVS1 in U87. The amplification of a 
3-kb fragment demonstrates the successful integration at AAVS1 through BV-ZNF and BV-eGFP 
donor. (C) PCR analysis of genomic DNA to confirm AAVS1 integration of the OSKM cassette. 
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The amplification of a 3-kb fragment demonstrates the successful integration at AAVS1 through 
BV-ZNF and BV-OSKM donor. C8, a previously established cell line with AAVS1 integration, 
was used a positive control. 
 
After confirming the availability of AAVS1 of U87 cells and the 
feasibility of baculovirus-delivered ZFN, another ZFN donor, EF1α-OSKM-
eGFP-AAVS1, was utilized to introduce pluripotent OSKM for cancer stem cell 
reprogramming. This four-factor sequence was acquired from Addgene, with 
EF1α as a promoter. HOct4 and hKlf4 were separated by a self-cleaving F2A 
peptide sequence, while hSox2 and hMyc were separated by a self-cleaving P2A 
peptide. The two parts were connected through IRES. The viral 
posttranscriptional regulatory element, WPRE, was included in the cassette to 
improve the transgene expression efficiency as previously described. An EF1α-
eGFP was cloned in another transcription direction to enable monitoring of the 
integration. Furthermore, neomycin was also included for G418 selection of U87 
cells with integration. Following co-transduction of the ZFN and ZFN donor 
EF1α-OSKM-eGFP-AAVS1 for three days, U87 cells with AAVS1 site-specific 
integration of four factors were selected using 300µg/ml G418 for about 14 days. 
After acquiring the clones with neomycin and eGFP expression, genomic PCR 
was conducted to examine the specificity of OSKM integration. Nine of the 21 
clones exhibited specific integration in AAVS1 (Fig. 3.3C). C8, a HCT8 cell line 
with OSKM integration in AAVS1 that was previously generated in our lab, was 
used as a positive control. 
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 After confirming the OSKM site-specific insertion, real-time PCR was 
performed to examine OSKM expression. Primers were designed to discriminate 
between endogenous, exogenous, and overall OSKM expression. To detect 
endogenous OSKM expression, primers were designed to amplify part of the UTR 
region of the four genes; to examine overall OSKM expression, the primers were 
located within the ORF region of the four genes. To detect the exogenous four-
factor expression, one of the primers was located within the connection parts of 
the four factors, such as P2A, F2A, or IRES, while the other primer was located 
within the ORF region of the four factors. B2M was used as an internal control. 
The pluripotent gene Nanog was also examined. Nevertheless, only 2 of the 9 
site-specific integrated U87 clones exhibited significant OSKM over-expression. 
Fig. 3.4A only shows the overall OSKM expression of the two U87 clones. 
Because the wild-type U87 cell line exhibits endogenous Klf4 and c-Myc 
expression, after exogenous OSKM over-expression, the overall Klf4 and c-Myc 
mRNA expression remained preserved at the same level. The endogenous Oct4 
and Sox2 expression was not induced, possibly because of the sustained 
exogenous Oct4 and Sox2 expression in AAVS1. There was an approximately 
450- and 15.69-fold increase in Nanog expression in the two clones. The overall 
OSKM expression of the two U87 clones was further confirmed through RT-PCR 
at the mRNA level (Fig. 3.4B) and Western blotting at the protein level (Fig. 
3.4C). Both results demonstrated that wild-type U87 cells do not exhibit Oct4 and 
Sox2 expression but do exhibit Klf4 and c-Myc expression. After successfully 
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integrating the exogenous OSKM into AAVS1, there was robust overall Oct4, 
Sox2, Klf4, and c-Myc expression.  
   
Fig. 3.4 Characterization of OSKM expression in U87 clones. U87-WT: wild-type U87 cells. 
U87-#5 and U87-#20: U87 clones with OSKM integration. (A) Real-time PCR analyses of overall 
Oct4, Sox2, Klf4, c-Myc, and Nanog expression in U87 clones. B2M was used as an internal 
control. The expression was normalized to wild-type U87. (B) RT-PCR analysis of overall Oct4, 
Sox2, Klf4 and c-Myc expression in wild-type U87 cells and two U87 clones with OSKM 
integration. B2M was used as an internal control. (C) Western blotting to confirm the expression 
of OSKM. Expression of Oct4, Sox2, Klf4 and c-Myc was detected in U87 #5, but not in wild-
type U87 and HFF. β-actin was included as a loading control. U87-WT and HFF were used as 







3.3.1.3 In vitro characterization of the cancer stem cells properties of U87 
clones with OSKM expression 
Although it is known that glioma cells exhibit pluripotent four-factor expression, 
whether they have CSC-associated properties is unknown. A series of in vitro 
functional assays were performed to characterize the U87 cells with OSKM 
expression. First, the most popular glioma cancer stem cell marker CD133 and 
three recently reported markers, A2B5, CD15, and Integrin α6 (CD49f), were 
assessed in the cells and derived spheres through flow-cytometry analysis 
(Tchoghandjian et al. 2010, Pollard et al. 2009, Brescia et al. 2012, Ogden et al. 
2008, Read et al. 2009). U87-EGFP was used as the negative control to exclude 
the effects of gene insertion in AAVS1 and G418 selection (Table 3.3). For the 
adherent cells, compared with U87-EGFP control, there was only a two-fold 
increase in CD133 expression in U87-#5 (4-10%). There was a significant 
increase in CD49f expression in both U87 clones (U87-EGFP: 6.4%; U87-#5: 
99.6%; U87-#20: 78.4%). A2B5 expression was increased in U87-#5 cells 
(70.5%), but it was decreased in U87-#20 cells (10.9%). CD15 expression was not 
changed in U87-EGFP (8.9%) or U87-#5 (9.5%) cells, but it was decreased in 
U87-#20 cells (2.9%). Moreover, compared with U87-EGFP derived spheres, 
there was an overall increase in the spheres derived from the four glioma cancer 
stem cell markers, with the exception of CD49f in U87-#20 and A2B5 in U87-#5. 
Thus, with regard to CSC marker expression, CD133 and CD15 expression 
remained low and did not change significantly, but A2B5 and CD49f expression 
exhibited a significant increase in U87 cells with OSKM. 
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Table 3.3 Flow-cytometry analysis of CSC markers expression  
in U87-OSKM clones and their derived spheres 
 
 
 Despite CSC surface marker expression, the most potent characteristics of 
CSCs are their self-renewal capability and drug resistance, which are responsible 
for tumor initiation and relapse. Because CSCs can survive anoikis under non-
adherent conditions and form floating colonies known as tumorspheres, primary 
and secondary sphere formation assays were conducted to investigate the sphere 
formation capability of the U87 cells with OSKM expression. For the primary 
sphere assay, EGFP or OSKM-integrated U87 cells were seeded into low-binding 
96-well plates at a density of 200cells/well in CSC medium and cultured for 7 
days. The results are represented as the ratio of the total number of primary 
spheres to the total number of seeded cells (Fig. 3.5A). The result is controversial 
for U87-#5 exhibited lower, while U87-#20 cells higher primary sphere formation 
compared with U87-EGFP cells. Some sphere clusters were formed, which made 
it difficult to determine the number of spheres. A secondary sphere formation 
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assay was conducted based on the primary spheres (Fig. 3.5B). The primary 
spheres were dissociated into single cells and seeded again into low-binding 96-
well plates to form spheres at a density of one cell per well. Because clone 5 of 
U87 cells has a low sphere formation capacity, it was not included in the 
secondary sphere assay. Consistent with the primary sphere assay, U87-#20 cells 
exhibited higher secondary sphere formation capability compared with U87-
EGFP cells. Moreover, the average size of the secondary spheres derived from the 
U87 cells with OSKM expression was larger than that of the spheres derived from 
the U87-EGFP cells. Therefore, the primary and secondary sphere formation 




Fig. 3.5 Ectopic expression of OSKM leads to increased sphere formation capability in 
human glioma cells. (A) Primary sphere assay efficiency. The cells were seeded with a density of 
200 cells per well in 96 well low binding plates and cultured in CSC medium for 7 days. Since the 
primary sphere is derived from single cells, the efficiencies of primary sphere formation were 
expressed as number of primary spheres over total seeding cell number. Data was represented as 
the mean ± SD (n=2) (t-Test, ** P<0.01). (B) Secondary sphere assay efficiency. The cells derived 
from dissociated primary spheres were seeded with a density of one cell per well in 96 well low 
binding plates and cultured in CSC medium for 7 days. The efficiencies of secondary spheres 
formation were expressed as number of secondary spheres over total seeding number. The 







As discussed in the introduction section, multidrug resistance appears to 
be inherent in putative CSCs (Diaz & Leon 2011b), and the glioma cells were 
further subjected to an assessment of drug resistance. Two drugs, etoposide and 
doxorubicin, were used. Etoposide is a cytotoxic anti-cancer drug and belongs to 
the topoisomerase inhibitor drug class. Doxorubicin is an anthracycline antibiotic, 
and it exerts its effects by intercalating DNA. These two types of drugs have been 
utilized to treat gliomas in both clinical and pre-clinical studies (Leonard & Wolff 
2013, Yang et al. 2012a). The survival of U87 cells was assessed through a MTT 
assay at concentrations of 0.5 and 5µg/ml for etoposide and 1 and 5µg/ml for 
doxorubicin. Fig. 3.6A&B shows that both U87-#5 and U87-#20 cells displayed 
higher survival and stronger drug resistance to etoposide and doxorubicin at both 
concentrations. Unexpectedly, 1 µg/ml doxorubicin promoted the proliferation of 
all U87 groups. The higher survival of these clones indicates their cancer stem 








Fig. 3.6 Ectopic expression of OSKM leads to increased resistance to chemotherapeutic 
agents in human glioma cells. Two OSKM and one GFP expressing clones from U87 cells were 
incubated in the presence of etoposide (A) or dexorubicin (B) for 2 days. After incubation, the cell 
viabilities were measured by MTT assay. Data are reported as means ± SD (n=3). Differences 
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between U87-EGFP and OSKM expressing cells were examined for statistical significance using 
the Student's t-test (t-Test, * P<0.05, ** P<0.01). 
 
3.3.2 Examination of activation and expansion of CD8+ T cells 
reactive against cancer stem cell antigens 
After inserting OSKM genes into the AAVS1 site and inducing the 
reprogramming of U87 into the glioma stem-like cells, the modified cell lines 
should provide an unlimited source for CSC antigens preparation. To assess 
whether the Day 4 DCs loaded with lysates of cancer stem-like cells were able to 
activate the CD8+ cytotoxic T cells that recognize CSC antigens, such as Oct4, 
Sox2, and CD133, in vitro priming of CD8+ T cells was performed, and the 
antigen recognition ability of primed CD8+ T cells was analyzed by Elispot assays.  
3.3.2.1 DC generation, pulsing and maturation 
DCs possess various characteristics that are essential for adaptive immunity 
activation, including antigen capture, processing, and presentation. The quality of 
DCs critically influences CD8+ T cell priming. In this study, DC differentiation, 
maturation, and antigen loading methods were investigated. Two well-established 
protocols were utilized to derive DCs from monocytes (Chiang et al. 2011, Massa 
& Seliger 2013). Monocytes were isolated through overnight plastic attachment 
from PBMCs. Frozen PBMCs were purchased from STEMCELL Technologies. 
The first protocol consisted of a serum-free DC induction protocol, which only 
requires approximately 36 hours. The other protocol is a 4-day DC induction 
protocol with 5% human AB serum addition. First, from the perspective of timing 
and yield, although the differentiation time of 36-hour DCs is less than half that of 
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the Day 4 DCs, the yield is approximately 4-5% of the PBMCs, compared with 7-
10% for the Day 4 DCs. Second, based on the morphology and DC marker 
expression, as shown in Fig. 3.7A&B, the size of 36-hour immature DCs is 
smaller than that of the Day 4 immature DCs. Most 36-hour immature DCs are 
loosely attached and exhibit bipolar or tripolar morphology, while most Day 4 
immature DCs are floating and display a rounded morphology. There are more 
branched projections (as arrow shows in Fig. 3.7B) in Day 4 immature DCs 
compared with 36-hour mature DCs. Following maturation with LPS + IFNγ, DC 
expressions of CD40, CD80, CD83, and CD86 were examined by flow cytometry. 
The expressions in 36-hour mature DCs were generally lower than those in Day 4 
mature DCs (Fig. 3.7C). The potential reasons for the low induction efficiency of 
36-hour DCs be that some of the monocytes still have not fully differentiated into 
immature DCs, and the serum-free culture condition decreases monocyte viability. 
However, the 5% human AB serum addition on Day 4 of DC differentiation is not 
a well-defined and reproducible culture condition. Human serum contains 
numerous proteins that modify the antigen capture and processing of DCs (Tarte 
et al. 2000). Given the number and quality of DCs required for CD8+ T cell 




Fig. 3.7 Comparison of 36 h DCs and 4 days DCs derived from monocytes. (A, B) Images of 
immature DCs. (A): images of 36 h immature DCs, (B): image of 4-day immature DC. Arrows 
show the branched projections from 4-day imDC, (C) Flow cytometric analyses of expression of 
DCs co-stimulatory markers CD40, CD80, CD83 and CD86 in 36 h mature DCs and 4-day mature 
DCs. Unstained cells were used as negative control. It is the result of representative experiment. 
 
 
The DC differentiation process can be divided into two major stages, 
namely, immature and mature stages (Tarte et al. 2000). The immature DCs are 
able to uptake antigens with high efficiency, but they express low levels of co-
stimulatory molecules, which are necessary for T cell activation (Tarte et al. 
2000). Following exposure to certain maturation signals, such as inflammatory 
cytokines and bacterial products, DCs decrease or even lose their capacity to 
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uptake antigens but increase the expression of CD80, CD86, and MHC-II, thereby 
becoming potent antigen-presenting cells (APCs). Optimal maturation signals 
result in sufficient T cell activation. Thus, different maturation stimuli were 
compared, including the gold standard stimulus (TNF-α + IL-1β + IL-6 + PGE2) 
and two other maturation cocktails, namely, alternative 1 (MPLA + IFN-γ) and 
alternative 2 (LPS+ IFN- γ), selected from previously published papers (Massa & 
Seliger 2013, Wolfl et al. 2011). As shown in Fig. 3.8A-C, if matured with 
alternative 1 or 2, most mature DCs attached tightly and displayed an elongated 
morphology; if matured with the gold standard, most mature DCs floated or were 
loosely attached. Co-stimulatory molecules CD40, CD80, and CD86 and mature 
DC marker CD83 were examined by flow cytometry. CD40 expression was high 
and similar between these three maturation cocktails matured DCs (Fig. 3.8E). 
The CD86 expression percentage was also high and similar between these three 
groups, but the expression intensity was higher in the gold standard group. For 
CD80 and CD83, the gold standard matured DCs exhibited the highest expression 
percentage and intensity (CD80: 96.5%, CD83:99.1%), while MPLA + IFN-γ 
matured DCs exhibited the lowest expression (CD80: 82.9%, CD83: 88.2%) (Fig. 
3.8E). IL-12p70 and IL-10 secretion of the three maturation combinations in 
activated DCs was measured by an enzyme-linked immunosorbent assay (ELISA). 
LPS+ IFN-γ or MPLA + IFN-γ matured DCs displayed the highest secretion of 
IL-12p70 (LPS+ IFN-γ: 697.7 pg/ml, MPLA + IFN-γ: 672.1 pg/ml), whereas the 
gold standard induced low or even no levels of IL-12p70 secretion (13.3 pg/ml), 
which is possibly due to the lack of Toll-like receptors (TLRs) stimulation 
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(Zobywalski et al. 2007). Moreover, MPLA + IFN-γ elicited the lowest secretion 
of IL-10 (8.7 pg/ml), whereas the gold standard or LPS+ IFN-γ induced higher 
IL-10 secretion (gold standard: 17.3 pg/ml, LPS+ IFN-γ: 14.2 pg/ml) (Fig. 3.8D). 
Based on the co-stimulatory molecule expression and IL-12-p70/IL-10 secretion, 
LPS+ IFN-γ and MPLA + IFN-γ maturation cocktails may be the best options. In 






Fig. 3.8 Comparison of different maturation combinations. (A-C) Images of mature DC 
activated by different stimuli. (A):  LPS IFN-γ, (B): TNF-α + IL-1β + IL-6 + PGE2, (C): MPLA + 
IFN-γ. Scale bar: 200µm. (D) Supernatants obtained at the end of maturation were analyzed for 
IL-10 and Il-12p70 content by ELISA. Data was represented as the mean ± SD (n=3). Differences 
between the groups were examined for statistical significance using the Student's t-test (t-Test, * 
P<0.05, ** P<0.01) (E) Mature DCs were assessed for costimulatory molecules expression by 
flow cytometry. Unstained cells were used as negative control. It is the result of representative 
experiment. 
 
 After maturation with LPS + IFN-γ, DCs firmly attach to the plate, but 
they do not float or loosely attach, similar to the characteristics of gold standard 
matured DCs. Thus, we optimized the detachment methods for mature DCs. 
Researchers typically use EDTA or low temperature incubation (4 degree) for 15-
20 min to detach DCs. However, 4-degree treated DCs exhibit more severe cell 
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death. Although EDTA works better than 4-degree treatment, the harvest 
efficiency is as low as approximately 50%. Certain published articles used 
Accutase to detach DCs for T cell activation, which is a substantially simpler 
method of detachment and can achieve 80% recovery. However, Accutase is 
enzyme-containing, which potentially destroys the surface antigens presented by 
DCs. Thus, we further tested the capability of Accutase-treated DCs to present 
antigens and prime CD8+ T cells. After first priming by Accutase-treated DCs, the 
CD8+ T cells grew and survived well during the first three days (Fig. 3.9A). 
However, after the second priming by Accutase-treated DCs, the CD8+ T cells 
exhibited severe apoptosis (Fig. 3.9C). This result may have been due to the 
destruction of DC surface antigens; CD8+ naïve T cells are not sufficiently 
activated, which finally resulted in CD8+ T cell death. We subsequently tested 
another enzyme-free gentle cell dissociation reagent from STEMCELL 
Technologies. Excitingly, this type of solution efficiently detached the tightly 
attached mature DCs, yielding a recovery similar to that afforded by Accutase. 
Furthermore, this solution detached DCs sufficiently activated CD8+ naïve T cells 
without eliciting T cell apoptosis (Fig. 3.9B). Seven days after the second priming 
by gentle cell dissociation reagent-treated DCs, the CD8+ T cells still maintained 





Fig. 3.9 Images of CD8+ T cells activated by mature DCs detached via different methods. (A): 
CD8+ T cells primed by Accutased detached DCs at day 3, (B): CD8+ T cells primed by gentle 
cell dissociation reagent detached DCs at day 3, (C): CD8+ T cells primed by Accutased detached 
DCs at day 14, (D): CD8+ T cells primed by gentle cell dissociation reagent detached DCs at day 
14. Scale bar: 200µm.  
 
After determining the optimal DC differentiation, maturation, and 
detachment methods, the next step was to select a method to prepare cancer stem-
like cell antigens to pulse DCs without disturbing DC functions. It has been 
reported that tumor lysates produce a suppressive effect on DC maturation and 
functions. CSC-like cell lysates were utilized to prepare tumor antigens. Different 
types of CSC-like cells derived antigen mixtures were tested, which involved 
whole tumor lysates and tumor lysate supernatants. Since it is reported that 
imDCs could uptake and express exogenous RNA to present the antigens on their 
surface, RNA was also included for testing. It is reported PBS-pulsed DCs were 
used as a positive control. Immature DCs were used for pulsing because of their 
strong phagocytic and endocytic capabilities (Tarte et al. 2000). The pulsed DCs 
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were further exposed to the maturation stimuli LPS+ IFN-γ. CD40, CD83, and 
CD86 expressions were examined by flow cytometry. As shown in Table 3.4, 
tumor lysate supernatant-pulsed DCs exhibited a higher expression of CD40, 
CD83, and CD86 compared with whole tumor lysates and total tumor RNA-
pulsed DCs. The DC marker expression of the tumor antigen mixture-pulsed DCs 
was lower than that of unpulsed DCs, which demonstrates the reported 
suppression of DC maturation by tumor lysates. Thus, tumor lysate supernatants 
were selected as the tumor antigen preparation method for DC antigen pulsing. 
 







3.3.2.2 CD8+ T cells priming and Elispot 
The immune response toward tumors depends on the way in which the tumor cells 
die (Hatfield et al. 2008). As previously reported, necrotic and stress-related death 
can be associated with the activation of antitumor immunity (Hatfield et al. 2008). 
These death pathways cause the release of signals, including "eat-me signals", 
such as calreticulin (CRT); damage-associated molecular patterns (DAMPs), such 
as heat-shock (HS) proteins; cellular nucleic acids; and the high-mobility group 
box 1 (HMGB1), recognized by TLRs, integrins, and scavenger receptors 
(Aguilera et al. 2011). Heat is one type of danger signal that stresses cells, 
resulting in the expression of HS protein. HS proteins provide a natural link 
between innate and adaptive immune responses by combining the ideal properties 
of the antigen carriage (chaperoning), which targets and activates the antigen-
presenting cells (APCs), including DCs (McNulty et al. 2013). Here, we further 
investigated whether heat-shocked tumor cell lysate supernatant (HS-TLS)-loaded 
DCs could elicit stronger CD8+ T cell antigen-specific responses than whole 
tumor lysates (TLs).   
 Four-day DCs generated from monocytes were pulsed with CRC-3.11-
derived HS-TLS or TL, matured with LPS + IFN-γ, and then used to prime 
autologous naïve CD8+ T cells twice for two weeks (Chiang et al. 2011). Naïve 
CD8+ T cells were utilized as responder cells. Memory T cells were excluded to 
avoid the non-specific, cytokine-driven expansion of the memory T cells because 
of the lower activation threshold of memory T cells (Wolfl et al. 2011). 
Furthermore, memory cells keeps conditions more consistent within different 
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individuals, as the percentage of naïve T cells varies significantly from donor to 
donor and decreases with age (Wolfl et al. 2011). Naïve T cells were prepared by 
initial negative selection for CD8+ T cells, followed by the depletion of CD45RO+ 
and CD57+ cells, with a purity of over 90% CD8+CD45RO-CD57- T cells (Fig. 
3.10A). However, because of the importance of cell-cell interactions, naïve CD8+ 
T cells alone cannot be maintained for a long time. The typical survival rate after 
6 days of culture with IL-7 is approximately 50-80%. However, for some donors, 
the survival rate is less than 10%. Thus, we tried another method of culturing 
PBMCs with IL-2 and IL-7 after removing the attached monocytes until one day 
prior to naïve CD8+ T cell priming. The rationale for this method is that the naïve 
CD8+ T cells are within the PBMC environment, where cell-cell interactions still 
exist. Then, after 6 days of culture, we performed naïve CD8+ T cell sorting. The 
total cell number of PBMCs cultured for 6 days was decreased by half, and the 
final number of naïve CD8+ T cells was similar to that associated with a 
previously developed method after culturing naïve CD8+ T cells for 6 days with 
IL-7. Moreover, the naïve CD8+ T cells derived from the two methods exhibited 
similar expression of, for example, CD45RA, CD27, CD28, and CD62L (Fig. 
3.10B). Naïve CD8+ T cells sorted from culturing PBMC without monocytes 
performed more consistently; however, the cost of the cytokines is more than the 
cost of the previous method because of the large starting number of PBMCs. In 





Fig. 3.10 Isolation of naïve CD8+ T cells. (A) Characterization of naïve CD8+ T cells by flow 
cytometry analysis before and after sorting. CD8, CD45RO, and CD57 were analyzed. (B) 
Characterization of naïve CD8+ T cells markers expression sorted on day 0 or after 6 days culture 
in T cells medium through flow cytometry. CD8, CD45RO, CD45RA, and CD57 were analyzed. 
Unstained cells were used as negative control. It is the result of representative experiment. 
 
After two consecutive weeks of stimulation and expansion, as shown in 
Fig. 3.11A, the CD8+ T cells primed with HS-TLS-pulsed DCs and TL-pulsed 
DCs were successfully expanded approximately 8.97 and 8.46 times, respectively, 
which are slightly higher expansion rates than those derived from unpulsed DCs 
(6.6×). The number of naïve CD8+ T cells maintained with IL-2 + IL-7 was the 
same as the starting number. The activated CD8+ T cells were harvested and 
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subjected to a human IFN-γ Elispot assay to evaluate their colon cancer stem cell 
antigen-specific response. The PBMCs tested here were HLA-A2+ cells. In the 
Elispot assay, T2 cells (HLA-A2+) pulsed with different HLA-A2-restricted 
peptides derived from colon cancer stem cell antigens were used as stimulator 
cells. The T2 cell line is transporter-associated with antigen processing (TAP)-
deficient, which results in inefficient loading of human leukocyte antigen class 1 
molecules with endogenous peptides (Amrolia et al. 2003). As a consequence, the 
HLA-A2 molecules of T2 cells can be efficiently loaded with exogenous peptides. 
The human IFN-γ Elispot results suggest that HS-TLS-pulsed DCs stimulated a 
greater number of IFN-γ-secreting CD8+ T cells, which specifically recognized 
different peptides of colon cancer stem cell antigens presented on the T2 cells 
(Oct4: 800 spots, Sox2: 840 spots, hTERT: 820 spots, EpCAM: 860 spots, CEA: 
800 spots), compared with the CD8+ T cells primed with TL-pulsed DCs (Oct4: 
740 spots, Sox2: 700 spots, hTERT: 740 spots, EpCAM: 520 spots, CEA: 540 
spots), with unpulsed T2 used as an antigen specificity control (HS-TLS: 460 
spots, TL: 600 spots) (Fig. 3.11C). The number of activated CD8+ T cells that 
spontaneously released IFN-γ was very low, which further indicates their antigen 
recognition specificity. Moreover, there was a low number of IFN-γ-secreting T 
cells within naïve CD8+ T cell populations, and unpulsed DC-primed CD8+ T 
cells stimulated with both unpulsed or peptide-pulsed T2 cells in the Elispot assay. 
However, because of the haploidentical match between T2 cells and donor 
PBMCs, after adding unpulsed T2 cells, CD8+ T cells primed by TL and HS-TLS-
pulsed DCs generated a specific allogenic reaction background that was 
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substantially stronger resulting from TL-pulsed DC-primed T cells. Thus, HS-
treated tumor lysate supernatant-pulsed DCs were able to better prime CD8+ T 
cells that recognize colon cancer stem cell antigens and generated a more antigen-
specific response compared with the TL-pulsed DCs. 
 Furthermore, the markers that characterize different CD8+ T cell 
populations (naïve T cells, effector T cells, and memory T cells) were also 
analyzed by flow cytometry (Fig. 3.11B). The CD3+CD8+ T cells within the 
expanded T cell population still maintained over 95%. The increase in CD44 
expression intensity and CD45RO expression percentage and the decrease in 
CD45RA intensity indicate that naïve CD8+ T cells were activated and 
differentiated into effector and memory T cells. The expression of CD62L and 
CD69 further demonstrates that both CD8+ effector T cells and memory T cells 
existed among the activated T cells. However, there was no difference in the 





Fig. 3.11 DCs pulsed with heat-shocked 3.11 lysates supernatants in the presence of IL-2 and 
IL-7 stimulated potent and specific autologous colon cancer stem cells antigens reactive T 
cells response in vitro. Donor’s naïve CD8+ T cells were cocultured with autologous unpulsed DC 
or DCs pulsed with 3.11 derived whole lysates or heat-shocked 3.11 lysates supernatants for 
consecutive two weeks with IL-2 and IL-7 addition. (A) CD8+ T cells expansion after primed by 
DCs. (B) Assessment of effector and memory markers expression of activated CD8+ T cells 
through flow cytometry. Unstained cells were used as negative control. The mean of fluorescence 
intensity (MFI) obtained with each MoAb was indicated in the parentheses. Unstained cells were 
used as negative control. It is the result of representative experiment. (C) The stimulated T cells 
were evaluated for reactivity against tumor antigens through human IFNγ Elispot. The T cells 
(HLA-A2+) were tested against HLA-A2+ T2 pulsed with HLA-A2+ restricted hTERT, Oct4, Sox2 
and CEA peptides, unpulsed T2 or medium. The results are the means of the number of IFN-γ 
spots per 106 T cells. 
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 Next, we tested the ability of lysate-pulsed DCs to prime autologous HLA-
A2- donor PBMCs. Tumor lysate-pulsed DCs were used as stimulator cells in the 
Elispot assay to evaluate the specific response toward the whole tumor antigen 
mixtures, which also eliminated the allogeneic effects. Reprogrammed glioma 
cancer stem-like cells (U87-#5) were used to prepare the tumor lysates. As Fig. 
3.12 indicates, there was large number of IFN-γ-secreting CD8+ T cells previously 
primed with lysate-pulsed DCs that reacted to whole tumor antigens presented by 
autologous DCs. Few IFN-γ spots were detected when the T cells previously 
primed with lysate-pulsed DCs were incubated alone or stimulated with unpulsed 
DCs in the Elispot assay. The antigen specificity was further demonstrated by a 
lower number of spots within the unpulsed DC-primed CD8+ T cells when 







Fig. 3.12 DCs pulsed with heat shocked glioma lysates supernatants stimulated potent and 
specific glioma antigens reactive T cells response in the presence of IL-2 and IL-7 in vitro 
with naïve CD8+ T cells as responders. CD8+ naïve T cells were cocultured with autologous 
unpulsed DC or DCs pulsed with glioma U87 lysates for two weeks with IL-2 and Il-7 addition 
and assessed for reactivity against glioma whole antigens through human IFN-γ Elispot. The 
activated T cells were tested in the presence of autologous DCs pulsed with U87 lysates, unpulsed 
DCs or media only. The results are the means of the number of IFN-γ spots per 106 T cells. Data 
was represented as the mean ± SD (n=3) (t-Test, ** P<0.01). 
 
 We also tried replacing IL-2 with other cytokines, such as IL-15 and IL-21, 
to enhance the antitumor immune response. However, although the CD8+ T cells 
were expanded 4-6 times after stimulation by HS-TLS-pulsed DCs, this type of 
method yielded CD8+ T cells with much stronger allogeneic reactions toward T2, 
which may have caused the smaller difference between CD8+ T cells stimulated 
by T2 alone and pulsed with peptides derived from tumor antigens (Fig. 3.13). 
This finding may have occurred because of the increased sensitivity to allogeneic 




Fig. 3.13 DCs pulsed with heat shock treated 3.11 lysates supernatants failed to stimulate 
potent and specific autologous colon cancer stem cells antigens reactive T cells response in 
the presence of IL-7, IL-15 and IL-21 in vitro with naïve CD8+ T cells as responders.  Donor’s 
CD8+ naïve T cells were cocultured with autologous unpulsed DC or DCs pulsed with 3.11 
derived heat shock treated 3.11 lysates supernatants for 10 days in the presence of IL-7, IL-15 and 
IL-21. The stimulated T cells were evaluated for reactivity against colon cancer stem cells 
antigens through human IFN-γ Elispot. The T cells (HLA-A2+) were tested against HLA-A2+ T2 
pulsed with hTERT, Oct4 and Sox2 peptides, unpulsed T2 or medium. The results are the means 
of the number of IFN-γ spots per 106 T cells. 
 
 Finally, due to the cost and labor needed for naïve CD8+ T cells sorting, 
we also gave peripheral blood lymphocytes (PBL) as responder cells a try. The 
PBL were primed twice by HS-TLS (derived from CRC-3.11) pulsed DCs for two 
weeks. After 14 days expansion with IL-2 and IL-7, the total expansion of PBL is 
as high as 20 times (Fig. 3.14A). The CD3+CD8+ T cells percentage within PBL 
was checked through flow-cytometry. There are more CD3+CD8+ T cells in HS-
TLS pulsed DCs primed PBL (70.2%) than unpulsed DC primed PBL (60.5%) 
and PBL alone (59.7%) (Fig. 3.14B). Then those expanded PBL were also 
subjected to human IFN-γ Elispot (Fig. 3.14C). However, possibly because of the 
other components existing within PBL, there displayed much stronger allogeneic 
reactions towards T2. As a result, for PBL primed with lysates pulsed DC, the 
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IFN-γ spots number are almost similar of PBL stimulated with both unpulsed T2 
or peptides pulsed T2. Furthermore, unpulsed DC primed PBL even show higher 
number of IFN-γ spots towards unpulsed T2 or peptides pulsed T2. 
 
 
Fig. 3.14 DCs pulsed with heat shock treated 3.11 lysates supernatants failed to stimulate 
potent and specific autologous colon cancer stem cells antigens reactive T cells response in 
the presence of IL-2 and IL-7 in vitro with PBL as responder cells. Donor’s PBL were 
cocultured with autologous unpulsed DC or DCs pulsed with heat shock treated 3.11 lysates 
supernatants for consecutive two weeks with IL-2 and IL-7 addition. (A) Total cells expansion 
after primed by DCs. (B) Assessment of percentage of CD8+ T cells through flow cytometry. 
Unstained cells were used as negative control. It is the result of representative experiment. (C) The 
stimulated T cells were evaluated for reactivity against tumor antigens through human IFN-γ 
Elispot. The T cells (HLA-A2+) were tested against HLA-A2+ T2 pulsed with hTERT and CEA 




3.4 Discussion  
3.4.1 OSKM-expressing CSC-like cells as a generic source of 
tumor antigens 
CSCs are rare tumor cells; hence, obtaining adequate sources and quantities of 
specific CSC antigens are difficult. CSCs isolated from primary tumors will 
rapidly differentiate into the non-CSCs that represent the majority of cells in 
tumors in vitro. These are the major limiting factors that have slowed down the 
discovery of drugs targeting CSCs and a technical barrier preventing large-scale 
production of CSCs for clinical cancer immunotherapy.  
To overcome the problems, in this project we used cancer cells ectopically 
expressing OSKM genes to derive cancer stem-like cells. Similar to normal 
somatic cells, cancer cells can also be reprogrammed by the OSKM genes into 
iPS cell-like states to generate induced pluripotent cancer (iPC) cells (Miyoshi et 
al. 2010, Ramos-Mejia et al. 2012, Semi et al. 2013). The clinical relevance of 
this approach is highlighted by pathological findings of OSKM gene expression in 
CSCs discussed above. Our study showed that glioma cells with ectopic 
expression of the OSKM genes displayed augmented CSC-like properties such as 
up-regulation of certain CSC surface markers, enhanced tumor sphere formation, 
and drug resistance.  
We therefore envision that OSKM-expressing glioma cell lines can be 
used as a readily accessible source to provide CSC-related antigens for DC 
immunotherapy. These cells will have OSKM gene products as over-expressed 
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“tumor-associated” antigens, which are expressed at high densities on cell surface. 
Pluripotency-associated antigens are attractive as cancer immunotherapy targets, 
since this class of antigens may be less susceptible to immune tolerance 
mechanisms that may limit the repertoire of reactive T cells, especially the high-
avidity T cells, present in vivo. Clinically, vaccines targeting pluripotency-
associated genes on CSCs could be useful against diverse cancers with poorly 
differentiated characteristics, instead of targeting a defined subset of cancer. Thus, 
these vaccines may serve as a universal cancer immunotherapeutic platform, 
particularly in the setting of maintenance therapy to prevent or delay cancer from 
returning. The ability of the human immune system to mediate T cell responses 
against pluripotency-associated genes has been investigated (Dhodapkar & 
Dhodapkar 2011). When human leucocyte antigen (HLA)-A*0201-restricted 
Sox2-derived peptides are tested for the activation of glioma-reactive CD8+ CTLs, 
specific CTLs against the peptide can be raised and are capable of lysing glioma 
cells, confirming Sox2 as a target antigen for CTLs (Schmitz et al. 2007). While 
Oct4-specific memory CD4+ T cells are readily detectable in peripheral blood of 
healthy humans, immunity to Oct4 was detected in only 35% of patients with 
newly diagnosed germ-cell tumors (Dhodapkar et al. 2010). However, 
chemotherapy of germ-cell tumors leads to the induction of anti-Oct4 immunity in 
vivo in these patients, demonstrating the lack of immune tolerance to Oct4 in 
humans (Dhodapkar et al. 2010). OSKM reprogramming resets the epigenetic 
signature of cancer cells while leaving their genetic mutations untouched. Such 
epigenetic changes will facilitate dedifferentiation of non-tumorigenic cancer cells 
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toward a less differentiated state, a reverse process of CSC differentiation into 
tumor cells that can result in cells with tumor-initiating capacity. Thus, besides 
pluripotency-associated genes, OSKM-engineered glioma cells express many 
CSC-associated tumorigenic antigens. Furthermore, these cells also carry original 
TAAs associated with somatic mutation, internal deletions, chromosome 
translocation in the parent cancer cells and many unidentified neoantigens. 
Overall, the OSKM-expressing glioma cells will provide a broad spectrum of 
tumor antigens. 
The use of a stable cancer cell line as a generic TAA source provides 
many advantages for vaccine preparation and application. Firstly, the use of an 
established cell line helps to circumvent a time-consuming and cost-intensive 
patient-individualized GMP production and eliminates the need for the continuous 
production of tailor-made individual vaccines. Secondly, the use of an established 
cell line simplifies the logistics, reduces the laboriousness of the vaccine 
production and delivery process, and increases its cost-effectiveness. Thirdly, the 
use of an established cell line allows for the highly standardized and large-scale 
production of allogeneic vaccines, so called “off-the-shelf” products suitable for 
all patients with a particular tumor type. Lastly, the use of a single batch of allo-
vaccines for all vaccines, independent of HLA haplotype, eliminates variability in 
the quality and composition of the vaccines, facilitating reliable comparative 
analysis of clinical outcome. In the current project, we tested the capability of DC 
pulsed with lysates derived from OSKM-expressing glioma spheres to active 
CD8+T cells reactive to cancer stem cells antigens. 
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As a classical way, chemotherapy is performed with a pre-defined number 
of cycles (3–6 months), followed by complete break or maintenance with less 
toxic drugs. The current study has the potential to lead to the development of an 
autologous immune cell-based treatment regimen, namely DC-based 
immunotherapy targeting CSCs, with the hope that the regimen can be used as an 
option for glioma maintenance therapy. While quite a few laboratories have tested 
DC cancer immunotherapy for glioma or even glioma stem cells (Olin et al. 2014, 
Ji et al. 2013, Xu et al. 2014, Everson et al. 2014), an effort of using DCs loaded 
with whole lysates of engineered cancer stem-like cells to target glioma CSCs 
would still be a pioneering work that we believe needs to be explored. The work 
is innovative because it capitalizes on a genetic engineering approach to enhance 
CSC properties of glioma cells before using them for DC pulsing. At the 
completion of this project, we expect that the information collected will be helpful 
for us to determine whether or not the new therapeutic regimen can be advanced 
to a clinical trial stage.  
Moreover, the programming process of cancer stem-like cells has opened 
a window for us to investigate intrinsic processes of tumorigenesis(Corominas-
Faja et al. 2013). On the other hand, we are also provided an opportunity to 
examine the self-renewing mechanism of CSCs, which will promote novel cancer 
therapies developments.  
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3.4.2 DC-based therapeutic cancer vaccines targeting CSC-like 
cells 
3.4.2.1 DC generation 
Clinical trial protocols for the production of DC vaccines commonly employ a 
two-step process, in which monocytes are first differentiated toward immature DC 
by a 7-day culture in the presence of GM-CSF and IL-4, followed by a maturation 
step stimulated with LPS and INF-γ. The past several years have seen the 
development of the third generation of DC vaccines (Frankenberger & Schendel 
2012), in which young DCs are prepared within 3 or 4 days of GM-CSF and IL-4 
stimulation and then the DCs are matured with the help of Toll-like receptor 
agonist, the TLR-4 ligand monophosphoryl lipid A (MPLA), together with INF-γ. 
Published studies have demonstrated that such DCs display much higher 
stimulatory capacity for naïve T cells, resulting in polyfunctional and long-lasting 
activation of innate and adaptive effector cells with potent antitumor cytolytic 
activity (Frankenberger & Schendel 2012, Wolfl et al. 2011, Chiang et al. 2011). 
The third generation of DCs also results in a high yield of robust cells that better 
withstood the stress of cell lysate loading during DC pulsing and subsequent 
cryopreservation for later applications. Furthermore, this DC protocol reduces the 
costs of vaccine generation by reducing the amounts of cytokines needed for DC 
cultivation and the occupancy time needed in a GMP clean room facility for large 
scale vaccine production. Other studies are investigating the properties of fast 
DCs (within 48 hours) (Dauer et al. 2005, Massa & Seliger 2013), however, there 
are not reported ongoing clinical trials at this time employing these cells. Here, 
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we demonstrated that 4-day DCs exhibit higher expression of co-stimulatory 
molecules and might be more potent to activate CD8+ T cells.  
Activation and maturation of DCs is critical for the induction of an 
immune response. Activated innate lymphocytes (NK cells, NKT cells, or γδ T 
cells) have been known to induce the most effective maturation signals in DCs by 
cytokines (TNF-a, IFN-γ) and by cell-cell contact-dependent signals (CD40-C40 
L interaction) (Munz et al. 2005). In addition, microbial products recognized as 
pathogen-associated molecular patterns (PAMPs; e.g., LPS, viral dsRNA, 
bacterial CPG-OGN) can also directly contribute to DC activation (Munz et al. 
2005), which is the widely utilized method of activating immature DCs. TNF-α + 
IL-1β + IL-6 + PGE2 is the most often used maturation stimulus, which is known 
as the gold standard (Massa & Seliger 2013). However, this method has been 
shown to induce extremely low levels of IL-12p70 and high levels of IL-10. Our 
study indicates that MPLA + IFN-γ (Massa & Seliger 2013) and LPS+ IFN-γ 
(Chiang et al. 2011), which have recently been reported as DC activation 
alternatives, can induce fully matured DCs, characterized by higher secretion of 
Il-12p70 and lower secretion of IL-10. 
If activated by LPS or MPLA and IFN-γ, mature DCs attach firmly to the 
plate and are very difficult to harvest. Thus, an effective method of detaching DCs 
is necessary. Several studies have used Accutase to detach DCs for downstream 
applications (Alfaro et al. 2011, Brandt et al. 2003). However, our results show 
that Accutase is not recommended for DC detachment because Accutase-treated 
152 
 
DCs could lead to T cell apoptosis rather than activation, which may be caused by 
partial destruction of surface antigen or co-stimulatory molecules.  
3.4.2.2 Lysates generated from heat-shocked OSKM-expressing tumor cells 
Since dying tumor cells provide both a source of tumor antigens and endogenous 
danger signals triggering antigen presenting cell activation, heat stress has been 
used to induce tumor cell death before using their lysates for DC pulsing. Heat 
stress strongly increases the levels of heat shock proteins, a superfamily of 
distinct proteins that are expressed constitutively at low levels and significantly 
induced under conditions of cellular stress. In the immune system, these proteins 
can both induce the maturation of DCs and provide chaperoned polypeptides for 
specific triggering of the acquired immune response (Colaco et al. 2013). Thus, 
stressed dying tumor cells are proposed to be a superior antigen source for DC 
pulsing and uptake of apoptotic bodies of these cells or necrotic cells has been 
used to generate mature DCs that are more adept at eliciting tumor antigen 
specific CTLs. In the current study, DCs were co-pulsed with the heat-shocked 
tumor lysates. This modified protocol takes advantages offered by HSP 
expression induced by heat stress, yielding a more immunogenic DC vaccine that 
is able to effectively elicit CSC antigen-specific CD8+ CTLs.  
3.4.2.3 Generation of Sox2, Oct4, and CSC antigen-specific CTLs in vitro 
Our current study demonstrated that human DCs pulsed with OSKM-expressing 
colon cancer cells can induce colon CSC antigen-specific CTLs, including Sox2 
and Oct4-CTLs. The frequency at which specific T cells recognize individual 
antigens after immunizations is typically very low. Elispot technology, a method 
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that can detect individual cytokine-secreting cells, is highly sensitive in measuring 
T cell immunity, possibly enabling the detection of antigen-specific T cells in a 
frequency range of 1:10,000-1:1,000,000. Although many studies have 
demonstrated a specific immune response toward certain antigens that utilize 
PBMCs as responder cells, our study failed to detect antigen-specific CTLs when 
peripheral blood lymphocytes (PBLs) were used as the initial responding cells. 
Memory T cells are known to have a lower activation threshold and can be 
expanded nonspecifically by cytokines; the depletion of memory cells and the use 
of highly purified naïve CD8+ T cells aid in the detection of antigen-specific 
CTLs and may facilitate the maintenance of more comparable conditions between 
donors (Wolfl et al. 2011).  
IL-2 and IL-7 are the most widely used cytokines for the expansion of 
antigen-specific T cells. Initial protocols of adoptive T cell transfer in humans 
were dependent on widely ranging doses of supplemental IL-2 (Wolfl et al. 2011). 
However, IL2 is known to be capable of inducing regulatory T cells. Recent 
studies have demonstrated the advantages of using IL-7, IL-15, and IL-21 for the 
expansion of antigen-specific T cells. Wo¨lfl et al. demonstrated the successful 
induction of Melan-A-specific cytotoxic T cells using these cytokines and only 
one priming dose, which avoids the prolonged culture times and repetitive 
stimulation that result in the exhaustion of T cells. Unfortunately, this protocol did 




3.4.3 Future Directions 
3.3.3.1 Reprogramming of glioma into cancer stem cells  
In this chapter, we discuss the possibility of using OSKM to reprogram a glioma 
cell line, U87, into cancer stem-like cells. U87 cells with OSKM expression only 
exhibited a slight increase in their tumor formation capability and therapeutic 
drug resistance. However, U87 cells with OSKM did not exhibit significant 
changes in glioma stem cell surface marker expression or SP. These results 
indicate that U87 cells are not fully reprogrammed into cancer stem-like cells. 
Very recently, by comparing the epigenetic landscapes of stem-like glioblastoma 
cells against their differentiated counterparts, Suva et al. identified four core 
transcriptional factors, namely, POU3F2 (BRN2), SOX2, SALL2, and OLIG2, 
whose expression is sufficient to reprogram differentiated glioblastoma cells into 
stem-like cells capable of in vivo tumor propagation (Suva et al. 2014). They also 
used these transcriptional factors to identify candidate tumor-propagating cells 
(TPCs) in primary glioblastoma tumors. Thus, in our future research, we may also 
test these transcriptional factors for their ability to facilitate glioma 
reprogramming. Concurrently, our lab is also cloning three transcriptional factors, 
namely, Oct4, Sox3, and Nanog, because Nanog also plays an essential role in the 
maintenance of stem cell pluripotency and is typically expressed in immature or 
undifferentiated cancer cells. These three transcriptional factors may be more 
universal than other transcriptional factors in reprogramming cancer cells. 
Additionally, in this study, we only tested one glioma cell line. In future work, we 
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may investigate the reprogramming possibility in other glioma cell lines or 
primary glioma cells. 
 
3.3.3.2 DC-based cancer immunotherapy  
In this study, although out results indicate the activation and expansion of colon 
cancer stem cell antigen-specific cytotoxic cells, the increase in this activation and 
expansion is not very significant. In future work, we will perform a DC uptake 
assay to examine and monitor DC uptake of CFSE-labeled tumor lysates. Because 
pulsing is performed with the addition of 5% human AB serum, we want to 
investigate whether pulsing cells under a serum-free condition can increase DC 
uptake. Nevertheless, whether the serum-free condition will decrease the viability 
of DCs and affect DC maturation remains to be determined. Furthermore, in the 
current study, we only performed the stimulations two times. It is not understood 
whether increasing the stimulation times can increase the expansion of antigen-
specific cytotoxic T cells without causing T cell exhaustion. We will increase the 
priming dose to three to four times to determine whether antigen-specific 
cytotoxic T cells could be more specifically expanded. Moreover, in this study, 
we only utilized the Elispot assay to examine the presence of antigen-specific 
cytotoxic T cells. We will conduct a cytotoxicity assay to determine whether 
CD8+ T cells stimulated by U87-OSKM lysate-pulsed DCs can attack more 
glioma cells compared with wild-type U87 lysate-pulsed DCs. At the completion 
of this project, we expect that the information collected will aid in determining 
whether the new therapeutic regimen can be advanced to a clinical trial stage. If 
the results fully support our hypothesis, we will prepare and submit an 
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Investigational New Drug (IND) Application for the initiation of a human clinical 
trial in Singapore, which will provide benefits to taxpayers by enabling early 




































In this PhD dissertation, I aimed to develop neural stem and dendritic cell-based 
cancer immunotherapies. As discussed in Chapter 2, I generated neural stem cells 
from human induced pluripotent stem cells through a single cell adhesion method 
and demonstrated that hiPSC-derived NSCs still display extensive tumor homing 
properties in vitro and in vivo. We further investigated the mechanism underlying 
their tumor tropism and identified the nNOS protein through microarray analysis, 
the inhibition of which increased the migration capability of hiPSCs-NSCs toward 
the tumor in vitro. Thus, nNOS may represent a candidate protein involved in the 
regulation of NSC migration toward cancer cells that can be manipulated to 
enhance tumor tropism. 
Next, I engineered hiPSCs-NSCs with CD40L delivered via baculovirus. 
Through in vitro and in vivo experiments, we determined that the engineered 
hiPSC-derived NSCs could inhibit tumor growth and metastasis through direct 
CD40-CD40L interactions on tumors or by activation of immune responses. 
Moreover, NSC-based CD40L cancer immunotherapy caused fewer side effects in 
the liver and kidney in the treated mice compared with NSC-based suicide gene 
cancer therapy.  
To more specifically target CSCs that may be the source of cancer 
initiation and relapse through cancer immunotherapy, we generated DCs from 
human monocytes. DCs, the most potent antigen-presenting cells, could activate 
cytotoxic T cells to facilitate antitumor immunity. We specifically inserted and 
over-expressed OSKM transcriptional factors in the AAVS1 of glioma cells to 
reprogram them into cancer stem-like cells through a baculovirus-delivered ZFN. 
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The modified cancer cells could be utilized as cancer stem cell antigen sources. 
Using the Elispot assay, we demonstrated that DCs pulsed with the antigens from 
cancer stem-like cells could effectively expand cytotoxic T cells and activate 
them against CSC antigens, such as Oct4 and Sox2. 
This study is the first to investigate the potential of hiPSC-derived NSCs 
engineered with CD40L and DCs loaded with antigens from artificially 
reprogrammed cancer stem-like cells for cancer immunotherapy. Utilizing NSCs 
and DCs to target micro-satellite metastasis and CSCs, which represent the 
greatest challenge in cancer treatment, our research demonstrated the preliminary 
effectiveness of this approach, which will aid in future cancer immunotherapy 
design. Furthermore, hiPSC-derived NSCs provide an excellent solution for 
immune rejection because hiPSCs can be produced from a specific patient. 
However, the reprogrammed cancer stem-like cells provide an unlimited source of 
CSC antigens, thereby avoiding the problem of working with a small number of 
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nNOS-2_R 5'- TGTAGCGGGAGTTGTCACAG-3' 
NG2_F 5'- CACGGCTCTGACCGACATAG-3'                      
NG2_F 5'- CCCAGCCCTCTACGACAGT-3'    
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Supplementary Table 2 Up- and down-regulated genes in microarray 
Up‐regulated genes in NSCs migrating towards U87 conditioned medium 













Ensembl Gene Title 
200865_at up 3.58 EIF3F  eukaryotic translation initiation factor 3, subunit F 
201858_s_at up 10.15 SRGN ENSG00000
122862 
serglycin 
201981_at up 2.26 PAPPA ENSG00000
182752 
pregnancy-associated plasma protein A, 
pappalysin 1 





growth arrest-specific 6 /// similar to growth arrest-
specific 6 
203434_s_at up 2.06 MME ENSG00000
196549 
membrane metallo-endopeptidase 
203435_s_at up 2.21 MME ENSG00000
196549 
membrane metallo-endopeptidase 
203498_at up 2.48 RCAN2 ENSG00000
172348 
regulator of calcineurin 2 
203766_s_at up 2.06 LMOD1 ENSG00000
163431 
leiomodin 1 (smooth muscle) 
204072_s_at up 2.59 FRY ENSG00000
073910 
furry homolog (Drosophila) 
204610_s_at up 2.09 CCDC85B ENSG00000
175602 
coiled-coil domain containing 85B 
204748_at up 2.09 PTGS2 ENSG00000
073756 
prostaglandin-endoperoxide synthase 2 
(prostaglandin G/H synthase and cyclooxygenase) 
204955_at up 2.09 SRPX ENSG00000
101955 
sushi-repeat-containing protein, X-linked 
205200_at up 2.69 CLEC3B ENSG00000
163815 
C-type lectin domain family 3, member B 
205518_s_at up 2.19 CMAH ENSG00000
168405 
cytidine monophosphate-N-acetylneuraminic acid 
hydroxylase (CMP-N-acetylneuraminate 
monooxygenase) pseudogene 
205525_at up 2.10 CALD1  caldesmon 1 
205624_at up 2.68 CPA3 ENSG00000
163751 
carboxypeptidase A3 (mast cell) 
206548_at up 2.71    
206702_at up 2.25 TEK  TEK tyrosine kinase, endothelial 
206707_x_at up 2.11 FAM65B ENSG00000
111913 
family with sequence similarity 65, member B 
206806_at up 2.05 DGKI ENSG00000
157680 
diacylglycerol kinase, iota 
207717_s_at up 2.00 PKP2 ENSG00000
057294 
plakophilin 2 
208109_s_at up 2.42 C15orf5  chromosome 15 open reading frame 5 
209167_at up 2.63 GPM6B ENSG00000
046653 
glycoprotein M6B 
209291_at up 4.28 ID4 ENSG00000
172201 
inhibitor of DNA binding 4, dominant negative 
helix-loop-helix protein 
209292_at up 5.41 ID4  Inhibitor of DNA binding 4, dominant negative 
helix-loop-helix protein 
209293_x_at up 3.43 ID4 ENSG00000
172201 
inhibitor of DNA binding 4, dominant negative 
helix-loop-helix protein 
209946_at up 2.30 VEGFC ENSG00000
150630 
vascular endothelial growth factor C 
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210109_at up 2.60 C7orf54  chromosome 7 open reading frame 54 
210121_at up 2.21 B3GALT2 ENSG00000
162630 
UDP-Gal:betaGlcNAc beta 1,3-
galactosyltransferase, polypeptide 2 
210230_at up 2.86    
210299_s_at up 2.09 FHL1 ENSG00000
022267 
four and a half LIM domains 1 




phosphodiesterase 4D interacting protein 
210571_s_at up 2.38 CMAH ENSG00000
168405 
cytidine monophosphate-N-acetylneuraminic acid 
hydroxylase (CMP-N-acetylneuraminate 
monooxygenase) pseudogene 
210605_s_at up 2.03 MFGE8 ENSG00000
140545 
milk fat globule-EGF factor 8 protein 
211029_x_at up 2.19 FGF18 ENSG00000
156427 
fibroblast growth factor 18 
212279_at up 2.13 TMEM97 ENSG00000
109084 
transmembrane protein 97 
212912_at up 2.01 RPS6KA2 ENSG00000
071242 
ribosomal protein S6 kinase, 90kDa, polypeptide 2 
213089_at up 2.11 LOC10027
2216 
 hypothetical LOC100272216 
213605_s_at up 2.58 LOC100134401 /// 
LOC100272216 
hypothetical protein LOC100134401 /// 
hypothetical LOC100272216 
213652_at up 2.07 PCSK5  Proprotein convertase subtilisin/kexin type 5 
213808_at up 2.02    
213904_at up 2.20    
213906_at up 2.56 MYBL1 ENSG00000
185697 
v-myb myeloblastosis viral oncogene homolog 
(avian)-like 1 




inhibitor of DNA binding 2, dominant negative 
helix-loop-helix protein /// inhibitor of DNA binding 
2B, dominant negative helix-loop-helix protein 
(pseudogene) 
214130_s_at up 2.34 PDE4DIP ENSG00000
178104 
phosphodiesterase 4D interacting protein 
214283_at up 2.41 TMEM97 ENSG00000
109084 
transmembrane protein 97 
214722_at up 2.18 NOTCH2N
L 
 Notch homolog 2 (Drosophila) N-terminal like 
214927_at up 2.06 ITGBL1  integrin, beta-like 1 (with EGF-like repeat domains) 
214967_at up 2.04    
214981_at up 2.51 POSTN  periostin, osteoblast specific factor 
215058_at up 2.54 DENND5B ENSG00000
170456 
DENN/MADD domain containing 5B 
215074_at up 2.71 MYO1B  myosin IB 
215199_at up 2.29 CALD1  caldesmon 1 
215204_at up 2.12    
215268_at up 3.00 KIAA0754  hypothetical LOC643314 
215296_at up 2.14 CDC42BP
A 
 CDC42 binding protein kinase alpha (DMPK-like) 
215318_at up 2.01 CG012  hypothetical gene CG012 
215571_at up 2.34    
216007_at up 3.86    
216147_at up 2.30    
218469_at up 2.38 GREM1 ENSG00000
166923 
gremlin 1, cysteine knot superfamily, homolog 
(Xenopus laevis) 
218723_s_at up 2.29 C13orf15 ENSG00000
102760 
chromosome 13 open reading frame 15 
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219054_at up 2.29 C5orf23 ENSG00000
181495 
chromosome 5 open reading frame 23 
219789_at up 2.35 NPR3 ENSG00000
113389 
natriuretic peptide receptor C/guanylate cyclase C 
(atrionatriuretic peptide receptor C) 
219790_s_at up 2.06 NPR3 ENSG00000
113389 
natriuretic peptide receptor C/guanylate cyclase C 
(atrionatriuretic peptide receptor C) 
219973_at up 2.54 ARSJ  arylsulfatase family, member J 
220097_s_at up 2.01 TMEM104  transmembrane protein 104 
220161_s_at up 2.11 EPB41L4B ENSG00000
095203 
erythrocyte membrane protein band 4.1 like 4B 
220327_at up 2.12 VGLL3 ENSG00000
206538 
vestigial like 3 (Drosophila) 
220518_at up 2.14 ABI3BP  ABI family, member 3 (NESH) binding protein 
220786_s_at up 2.07 SLC38A4 ENSG00000
139209 
solute carrier family 38, member 4 
221118_at up 2.21 PKD2L2 ENSG00000
078795 
polycystic kidney disease 2-like 2 
221172_at up 2.41 C7orf69  chromosome 7 open reading frame 69 
221211_s_at up 2.08 C21orf7 ENSG00000
156265 
chromosome 21 open reading frame 7 
222371_at up 2.03    
223672_at up 2.20 SGIP1 ENSG00000
118473 
SH3-domain GRB2-like (endophilin) interacting 
protein 1 
224397_s_at up 3.49 TMTC1 ENSG00000
133687 
transmembrane and tetratricopeptide repeat 
containing 1 
225016_at up 2.53 APCDD1 ENSG00000
154856 
adenomatosis polyposis coli down-regulated 1 
225239_at up 2.20    
225241_at up 2.37 CCDC80 ENSG00000
091986 
coiled-coil domain containing 80 
225762_x_at up 2.40 LOC28480
1 
 hypothetical protein LOC284801 
225767_at up 2.89 LOC28480
1 
 hypothetical protein LOC284801 
226302_at up 2.04 ATP8B1 ENSG00000
081923 
ATPase, class I, type 8B, member 1 
226322_at up 6.39 TMTC1 ENSG00000
133687 
transmembrane and tetratricopeptide repeat 
containing 1 
226492_at up 2.45 SEMA6D ENSG00000
137872 
sema domain, transmembrane domain (TM), and 
cytoplasmic domain, (semaphorin) 6D 
226497_s_at up 2.55    
226498_at up 3.73    




Rho guanine nucleotide exchange factor (GEF) 19 
226893_at up 2.35 ABL2 ENSG00000
143322 
v-abl Abelson murine leukemia viral oncogene 
homolog 2 (arg, Abelson-related gene) 
226931_at up 2.73 TMTC1 ENSG00000
133687 
transmembrane and tetratricopeptide repeat 
containing 1 
226933_s_at up 3.81 ID4  Inhibitor of DNA binding 4, dominant negative 
helix-loop-helix protein 
227061_at up 2.82    
227168_at up 2.07 MIAT  myocardial infarction associated transcript (non-
protein coding) 
227486_at up 2.29 NT5E ENSG00000
135318 
5'-nucleotidase, ecto (CD73) 
227609_at up 2.43 EPSTI1 ENSG00000
133106 
epithelial stromal interaction 1 (breast) 
228153_at up 2.93 RNF144B ENSG00000
137393 
ring finger protein 144B 
228367_at up 2.02 ALPK2 ENSG00000
198796 
alpha-kinase 2 
228481_at up 2.75    
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228551_at up 2.55 DENND5B ENSG00000
170456 
DENN/MADD domain containing 5B 
228635_at up 2.06 PCDH10 ENSG00000
138650 
protocadherin 10 
228697_at up 8.16 HINT3 ENSG00000
111911 
histidine triad nucleotide binding protein 3 
228731_at up 2.81    
228732_at up 2.73    
228885_at up 2.34 MAMDC2 ENSG00000
165072 
MAM domain containing 2 
229057_at up 2.04 SCN2A ENSG00000
136531 
sodium channel, voltage-gated, type II, alpha 
subunit 





229339_at up 4.30    





229765_at up 2.43 ZNF207 ENSG00000
010244 
zinc finger protein 207 
230051_at up 2.08 C10orf47 ENSG00000
148426 
chromosome 10 open reading frame 47 
230503_at up 2.15    
230560_at up 2.54 STXBP6 ENSG00000
168952 
syntaxin binding protein 6 (amisyn) 
231382_at up 2.00 FGF18  Fibroblast growth factor 18 
231504_at up 2.54 CCDC148 ENSG00000
153237 
coiled-coil domain containing 148 
231867_at up 2.95 ODZ2 ENSG00000
145934 
odz, odd Oz/ten-m homolog 2 (Drosophila) 
231883_at up 2.47 FBXW8 ENSG00000
174989 
F-box and WD repeat domain containing 8 
231993_at up 2.02 ITGBL1  Integrin, beta-like 1 (with EGF-like repeat 
domains) 
232174_at up 2.09    
232268_at up 3.27    
232286_at up 2.28    
232333_at up 4.21    
232372_at up 2.26    
232395_x_at up 2.96 AGBL3  ATP/GTP binding protein-like 3 
232424_at up 2.29 PRDM16 ENSG00000
142611 
PR domain containing 16 
232442_at up 6.35 LOC10013
1601 
 similar to hCG1980470 
232453_at up 2.37    
232472_at up 2.22    
232544_at up 2.00    
232656_at up 2.04    
232726_at up 2.04    
232748_at up 2.38 PAPPA  pregnancy-associated plasma protein A, 
pappalysin 1 
232835_at up 5.08    
233073_at up 2.32    
233090_at up 2.27    
233109_at up 2.15 COL12A1  Collagen, type XII, alpha 1 
233112_at up 2.46    
233114_at up 2.32    
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233241_at up 2.06 NCRNA00
153 
 non-protein coding RNA 153 
233365_at up 2.44    
233386_at up 2.04    
233438_at up 4.49 C6orf162  Chromosome 6 open reading frame 162 
233499_at up 2.23 LRRC7 ENSG00000
033122 
leucine rich repeat containing 7 
233720_at up 2.14 SORBS2  Sorbin and SH3 domain containing 2 
233907_s_at up 2.24 SERTAD4  SERTA domain containing 4 
234032_at up 2.09    
234137_s_at up 2.98    
234151_at up 3.08    
234389_x_at up 2.03    
234989_at up 2.23 NCRNA00
084 
 non-protein coding RNA 84 
235276_at up 4.18 EPSTI1  Epithelial stromal interaction 1 (breast) 
235421_at up 2.53 MAP3K8  Mitogen-activated protein kinase kinase kinase 8 
235879_at up 2.05 MBNL1  Muscleblind-like (Drosophila) 
235969_at up 2.01 FLJ33996  hypothetical protein FLJ33996 
236029_at up 2.06 FAT3 ENSG00000
165323 
FAT tumor suppressor homolog 3 (Drosophila) 
236038_at up 2.77    
236114_at up 2.22    
236168_at up 2.03    
236329_at up 2.08 FLJ33996 /// 
LOC100127971 
hypothetical protein FLJ33996 /// hypothetical 
protein LOC100127971 
236335_at up 2.84    
236561_at up 2.24 TGFBR1  Transforming growth factor, beta receptor 1 
237206_at up 4.13 MYOCD  myocardin 
237290_at up 3.48    
237310_at up 2.49    
237426_at up 2.44 SP100 ENSG00000
067066 
SP100 nuclear antigen 
237491_at up 3.17    
237768_x_at up 2.16    
237839_at up 8.45    
238067_at up 2.09 TBC1D8B ENSG00000
133138 
TBC1 domain family, member 8B (with GRAM 
domain) 
238451_at up 2.81 MPP7 ENSG00000
150054 
membrane protein, palmitoylated 7 (MAGUK p55 
subfamily member 7) 











ArfGAP with GTPase domain, ankyrin repeat and 
PH domain 10 /// ArfGAP with GTPase domain, 
ankyrin repeat and PH domain 4 /// ArfGAP with 
GTPase domain, ankyrin repeat and PH domain 9 
/// BMS1 pseudogene 5 /// hypothetical 
LOC399753 
238558_at up 2.17    
238621_at up 2.22 FMN1  formin 1 
239162_at up 2.05    
239201_at up 2.37 PFTK2 ENSG00000
138395 
PFTAIRE protein kinase 2 
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239227_at up 2.58    
239604_at up 2.18    
239758_at up 2.01    
239787_at up 2.88 KCTD4 ENSG00000
180332 
potassium channel tetramerisation domain 
containing 4 
239948_at up 2.03 NUP153 ENSG00000
124789 
nucleoporin 153kDa 
239957_at up 2.54    
240120_at up 2.56    
240145_at up 2.35    
240259_at up 2.41 FLRT2  Fibronectin leucine rich transmembrane protein 2 
240450_at up 2.54    
240458_at up 2.14    
240512_x_at up 2.28 KCTD4 ENSG00000
180332 
potassium channel tetramerisation domain 
containing 4 
240542_at up 3.33    
240593_x_at up 2.24    
240665_at up 2.04    
240866_at up 2.92    
240990_at up 2.05 RAB5A  RAB5A, member RAS oncogene family 
241457_at up 2.59    
241679_at up 2.08    
241681_at up 2.31    
241692_at up 2.04    
242126_at up 2.28    
242172_at up 2.04 MEIS1  Meis homeobox 1 
242324_x_at up 3.54 CCBE1 ENSG00000
183287 
collagen and calcium binding EGF domains 1 
242405_at up 2.54    
242722_at up 3.13 LMO7 ENSG00000
136153 
LIM domain 7 
242726_at up 2.32    
242849_at up 2.83    
242853_at up 2.04    
243184_at up 2.56    
243470_at up 2.14    
243711_at up 2.92 DDAH1  dimethylarginine dimethylaminohydrolase 1 
243813_at up 5.93    
243864_at up 2.49 CCDC80 ENSG00000
091986 
coiled-coil domain containing 80 
243874_at up 2.36 LPP  LIM domain containing preferred translocation 
partner in lipoma 
243933_at up 2.59    
244304_at up 2.87 LOC73148
4 
 hypothetical LOC731484 
244340_x_at up 2.37    
244414_at up 2.61    
244447_at up 2.28    
244476_at up 2.09    
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244511_at up 2.24    
244592_at up 7.15    
244859_at up 2.28    
244885_at up 2.00    
1553275_s_at up 2.79    
1554769_at up 2.14 ZNF785 ENSG00000
197162 
zinc finger protein 785 
1554997_a_at up 2.24 PTGS2 ENSG00000
073756 
prostaglandin-endoperoxide synthase 2 
(prostaglandin G/H synthase and cyclooxygenase) 
1555392_at up 2.53 LOC10012
8868 
 testin-related protein TRG 
1555471_a_at up 2.15 FMN2 ENSG00000
155816 
formin 2 
1556323_at up 3.08 CUGBP2  CUG triplet repeat, RNA binding protein 2 
1556583_a_at up 2.50 SLC8A1  solute carrier family 8 (sodium/calcium 
exchanger), member 1 
1556641_at up 3.90 SLC7A14  solute carrier family 7 (cationic amino acid 
transporter, y+ system), member 14 
1556658_a_at up 2.44    
1556935_at up 2.30    
1557079_at up 2.82 ITGBL1  Integrin, beta-like 1 (with EGF-like repeat 
domains) 
1557238_s_at up 2.03    
1557685_at up 2.62 C4orf38  Chromosome 4 open reading frame 38 
1557765_at up 2.18 LOC64340
1 
 hypothetical protein LOC643401 
1558836_at up 2.63    
1558854_a_at up 2.17    
1558964_at up 2.24 FAT3 ENSG00000
165323 
FAT tumor suppressor homolog 3 (Drosophila) 
1559156_at up 2.46    
1559391_s_at up 2.45    
1559393_at up 3.34 ALDH1L2  aldehyde dehydrogenase 1 family, member L2 
1559394_a_at up 2.50    
1559410_at up 3.93    
1559529_at up 2.11 PTK2  PTK2 protein tyrosine kinase 2 
1560199_x_at up 2.24 LOC72815
3 
 similar to FAM133B protein 
1562420_at up 4.41    
1562528_at up 2.31    
1562529_s_at up 2.26    
1564733_at up 2.09    
1566163_at up 3.10    
1566482_at up 2.23    
1568736_s_at up 3.43    
1569477_at up 3.90    
1569577_x_at up 2.79    





Down‐regulated genes in NSCs migrating towards U87 conditioned medium 















down -2.13 STAT1  signal transducer and 
activator of transcription 1, 
91kDa 












acidic (leucine-rich) nuclear 
phosphoprotein 32 family, 
member A /// hypothetical 
protein LOC100128146 
201101_s_at down -2.02 BCLAF1 ENSG00000
029363 
BCL2-associated 
transcription factor 1 
201565_s_at down -2.17 ID2 ENSG00000
115738 
inhibitor of DNA binding 2, 
dominant negative helix-loop-
helix protein 
201566_x_at down -2.37 ID2  inhibitor of DNA binding 2, 
dominant negative helix-loop-
helix protein 








202761_s_at down -2.22 SYNE2 ENSG00000
054654 
spectrin repeat containing, 
nuclear envelope 2 
202880_s_at down -2.36 CYTH1 ENSG00000
108669 
cytohesin 1 
202950_at down -2.03 CRYZ ENSG00000
116791 
crystallin, zeta (quinone 
reductase) 
203015_s_at down -2.16 SSX2IP ENSG00000
117155 
synovial sarcoma, X 
breakpoint 2 interacting 
protein 
203158_s_at down -2.23 GLS ENSG00000
115419 
glutaminase 
203234_at down -2.29 UPP1 ENSG00000
183696 
uridine phosphorylase 1 
203835_at down -2.08 LRRC32 ENSG00000
137507 
leucine rich repeat containing 
32 
204092_s_at down -2.08 AURKA ENSG00000
087586 
aurora kinase A 
204337_at down -2.32 RGS4 ENSG00000
117152 
regulator of G-protein 
signaling 4 
204338_s_at down -2.56 RGS4 ENSG00000
117152 
regulator of G-protein 
signaling 4 
204339_s_at down -2.65 RGS4 ENSG00000
117152 
regulator of G-protein 
signaling 4 








204867_at down -2.25 GCHFR ENSG00000
137880 
GTP cyclohydrolase I 
feedback regulator 
204988_at down -4.19 FGB ENSG00000
171564 
fibrinogen beta chain 




Rho GTPase activating 
protein 26 





205289_at down -2.18 BMP2 ENSG00000
125845 




205304_s_at down -2.20 KCNJ8 ENSG00000
121361 
potassium inwardly-rectifying 
channel, subfamily J, 
member 8 





cytosolic, 1C, member 2 
205552_s_at down -2.62 OAS1 ENSG00000
089127 
2',5'-oligoadenylate 
synthetase 1, 40/46kDa 
205767_at down -2.54 EREG ENSG00000
124882 
epiregulin 
205923_at down -2.05 RELN ENSG00000
189056 
reelin 
206010_at down -2.16 HABP2 ENSG00000
148702 
hyaluronan binding protein 2 
206070_s_at down -4.08 EPHA3 ENSG00000
044524 
EPH receptor A3 
206306_at down -4.52 RYR3 ENSG00000
198838 
ryanodine receptor 3 




chromosome 14 open 
reading frame 106 
206852_at down -2.05 EPHA7 ENSG00000
135333 
EPH receptor A7 
206872_at down -2.23 SLC17A1 ENSG00000
124568 
solute carrier family 17 
(sodium phosphate), member 
1 
207298_at down -3.15 SLC17A3 ENSG00000
124564 
solute carrier family 17 
(sodium phosphate), member 
3 





e, isozyme C (putative) 
207542_s_at down -3.10 AQP1 ENSG00000
106125 
aquaporin 1 (Colton blood 
group) 
207655_s_at down -5.08 BLNK ENSG00000
095585 
B-cell linker 
208121_s_at down -2.66 PTPRO ENSG00000
151490 
protein tyrosine 
phosphatase, receptor type, 
O 
208323_s_at down -5.23 ANXA13 ENSG00000
104537 
annexin A13 




208621_s_at down -2.42 EZR ENSG00000
092820 
ezrin 
208930_s_at down -2.44 ILF3 ENSG00000
129351 
interleukin enhancer binding 
factor 3, 90kDa 
209047_at down -2.73 AQP1 ENSG00000
106125 
aquaporin 1 (Colton blood 
group) 
209070_s_at down -2.65 RGS5 ENSG00000
143248 
regulator of G-protein 
signaling 5 
209071_s_at down -2.22 RGS5 ENSG00000
143248 
regulator of G-protein 
signaling 5 
209160_at down -4.05 AKR1C3 ENSG00000
196139 
aldo-keto reductase family 1, 
member C3 (3-alpha 
hydroxysteroid 
dehydrogenase, type II) 
209189_at down -2.09 FOS ENSG00000
170345 
v-fos FBJ murine 
osteosarcoma viral oncogene 
homolog 
209257_s_at down -2.04 SMC3 ENSG00000
108055 
structural maintenance of 
chromosomes 3 
209631_s_at down -2.19 GPR37 ENSG00000
170775 
G protein-coupled receptor 
37 (endothelin receptor type 
B-like) 




209763_at down -2.03 CHRDL1 ENSG00000
101938 
chordin-like 1 




210119_at down -3.80 KCNJ15 ENSG00000
157551 
potassium inwardly-rectifying 
channel, subfamily J, 
member 15 





210689_at down -2.74 CLDN14 ENSG00000
159261 
claudin 14 





dunce homolog, Drosophila) 




linked (RAD54 homolog, S. 
cerevisiae) 
211080_s_at down -2.02 NEK2 ENSG00000
117650 
NIMA (never in mitosis gene 
a)-related kinase 2 
211081_s_at down -2.32 MAP4K5 ENSG00000
012983 
mitogen-activated protein 
kinase kinase kinase kinase 
5 
211445_x_at down -2.47 NACAP1  nascent-polypeptide-
associated complex alpha 
polypeptide pseudogene 1 
211806_s_at down -2.10 KCNJ15 ENSG00000
157551 
potassium inwardly-rectifying 
channel, subfamily J, 
member 15 
212070_at down -2.42 GPR56 ENSG00000
205336 
G protein-coupled receptor 
56 
212092_at down -2.08 PEG10 ENSG00000
217473 
paternally expressed 10 




212105_s_at down -2.23 DHX9 ENSG00000
135829 
DEAH (Asp-Glu-Ala-His) box 
polypeptide 9 
212468_at down -2.11 SPAG9  sperm associated antigen 9 









213446_s_at down -2.12 IQGAP1 ENSG00000
140575 
IQ motif containing GTPase 
activating protein 1 
213763_at down -2.46 HIPK2  homeodomain interacting 
protein kinase 2 
214438_at down -2.14 HLX ENSG00000
136630 
H2.0-like homeobox 




histone cluster 1, H2bc 
214519_s_at down -2.24 RLN2 ENSG00000
107014 
relaxin 2 
214774_x_at down -2.71 TOX3 ENSG00000
103460 
TOX high mobility group box 
family member 3 
215046_at down -2.52 C2orf67 ENSG00000
144445 
chromosome 2 open reading 
frame 67 
215108_x_at down -2.84 TOX3 ENSG00000
103460 
TOX high mobility group box 
family member 3 
215465_at down -2.34 ABCA12 ENSG00000
144452 
ATP-binding cassette, sub-
family A (ABC1), member 12 
216205_s_at down -2.01 MFN2 ENSG00000
116688 
mitofusin 2 
216238_s_at down -5.62 FGB ENSG00000
171564 
fibrinogen beta chain 
216282_x_at down -2.08 POLR2C ENSG00000
102978 
polymerase (RNA) II (DNA 
directed) polypeptide C, 
33kDa 
216488_s_at down -2.76 ATP11A ENSG00000
068650 
ATPase, class VI, type 11A 
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216623_x_at down -2.82 TOX3 ENSG00000
103460 
TOX high mobility group box 
family member 3 
217234_s_at down -2.31 EZR ENSG00000
092820 
ezrin 
217790_s_at down -2.31 SSR3 ENSG00000
114850 
signal sequence receptor, 
gamma (translocon-
associated protein gamma) 
217878_s_at down -2.92 CDC27 ENSG00000
004897 
cell division cycle 27 
homolog (S. cerevisiae) 
218002_s_at down -3.16 CXCL14 ENSG00000
145824 
chemokine (C-X-C motif) 
ligand 14 
218211_s_at down -2.71 MLPH ENSG00000
115648 
melanophilin 
218353_at down -2.36 RGS5 ENSG00000
143248 
regulator of G-protein 
signaling 5 
218751_s_at down -2.13 FBXW7 ENSG00000
109670 
F-box and WD repeat 
domain containing 7 
219010_at down -2.12 C1orf106 ENSG00000
163362 
chromosome 1 open reading 
frame 106 
219012_s_at down -2.42 C11orf30 ENSG00000
158636 
chromosome 11 open 
reading frame 30 
















coiled-coil domain containing 
88A 
219508_at down -2.29 GCNT3 ENSG00000
140297 
glucosaminyl (N-acetyl) 
transferase 3, mucin type 
219773_at down -2.52 NOX4 ENSG00000
086991 
NADPH oxidase 4 
219976_at down -3.43 HOOK1 ENSG00000
134709 
hook homolog 1 (Drosophila) 




chromosome 14 open 
reading frame 105 
220117_at down -2.49 ZNF385D ENSG00000
151789 
zinc finger protein 385D 
220122_at down -2.53 MCTP1  multiple C2 domains, 
transmembrane 1 
220977_x_at down -2.38 EPB41L5 ENSG00000
115109 
erythrocyte membrane 
protein band 4.1 like 5 





221107_at down -2.07 CHRNA9 ENSG00000
174343 
cholinergic receptor, 
nicotinic, alpha 9 
221238_at down -2.08 NSBP1 ENSG00000
198157 
nucleosomal binding protein 
1 
221745_at down -2.74 WDR68 ENSG00000
136485 
WD repeat domain 68 
823_at down -2.35 CX3CL1 ENSG00000
006210 
chemokine (C-X3-C motif) 
ligand 1 
222484_s_at down -3.32 CXCL14 ENSG00000
145824 
chemokine (C-X-C motif) 
ligand 14 
222729_at down -2.22 FBXW7 ENSG00000
109670 
F-box and WD repeat 
domain containing 7 
222816_s_at down -2.01 ZCCHC2 ENSG00000
141664 
zinc finger, CCHC domain 
containing 2 




family with sequence 
similarity 60, member A 
223233_s_at down -2.01 CGN ENSG00000
143375 
cingulin 
223578_x_at down -2.53 MALAT1  metastasis associated lung 
adenocarcinoma transcript 1 
(non-protein coding) 





223704_s_at down -2.06 DMRT2 ENSG00000
173253 
doublesex and mab-3 related 
transcription factor 2 
223784_at down -2.12 TMEM27 ENSG00000
147003 
transmembrane protein 27 
223939_at down -4.87 SUCNR1 ENSG00000
198829 
succinate receptor 1 
223940_x_at down -2.76 MALAT1  metastasis associated lung 
adenocarcinoma transcript 1 
(non-protein coding) 
224559_at down -2.06 MALAT1  metastasis associated lung 
adenocarcinoma transcript 1 
(non-protein coding) 
224568_x_at down -2.63 MALAT1  metastasis associated lung 
adenocarcinoma transcript 1 
(non-protein coding) 
224828_at down -2.40 CPEB4 ENSG00000
113742 
cytoplasmic polyadenylation 
element binding protein 4 
225119_at down -2.06 CHMP4B ENSG00000
101421 
chromatin modifying protein 
4B 




(TM), and cytoplasmic 
domain, (semaphorin) 6A 





225792_at down -2.77 HOOK1 ENSG00000
134709 
hook homolog 1 (Drosophila) 
225996_at down -2.57 LONRF2 ENSG00000
170500 
LON peptidase N-terminal 
domain and ring finger 2 
226281_at down -2.91 DNER ENSG00000
187957 
delta/notch-like EGF repeat 
containing 
226530_at down -2.09 BMF ENSG00000
104081 
Bcl2 modifying factor 




Rho GTPase activating 
protein 26 





conjugating enzyme E2 
FLJ25076 
226615_at down -2.03 XPR1  xenotropic and polytropic 
retrovirus receptor 





conjugating enzyme E2 
FLJ25076 
226856_at down -2.43 MUSTN1  musculoskeletal, embryonic 
nuclear protein 1 
227314_at down -2.34 ITGA2 ENSG00000
164171 
integrin, alpha 2 (CD49B, 
alpha 2 subunit of VLA-2 
receptor) 
227404_s_at down -2.25 EGR1  Early growth response 1 




227452_at down -2.06    
227467_at down -2.32 RDH10  retinol dehydrogenase 10 
(all-trans) 




227758_at down -2.54 RERG ENSG00000
134533 
RAS-like, estrogen-
regulated, growth inhibitor 
227918_s_at down -2.12 ZYG11B ENSG00000
162378 
zyg-11 homolog B (C. 
elegans) 
228017_s_at down -2.15 NKAIN4 ENSG00000
101198 
Na+/K+ transporting ATPase 
interacting 4 








228582_x_at down -2.33    
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228716_at down -2.06 THRB ENSG00000
151090 
thyroid hormone receptor, 
beta (erythroblastic leukemia 
viral (v-erb-a) oncogene 
homolog 2, avian) 
228754_at down -2.23 SLC6A6 ENSG00000
131389 
solute carrier family 6 
(neurotransmitter transporter, 
taurine), member 6 





dunce homolog, Drosophila) 
229019_at down -3.77 ZNF385B ENSG00000
144331 
zinc finger protein 385B 
229419_at down -2.21 FBXW7 ENSG00000
109670 
F-box and WD repeat 
domain containing 7 
229975_at down -2.12 BMPR1B  bone morphogenetic protein 
receptor, type IB 
230551_at down -2.98 KSR2  kinase suppressor of ras 2 
230561_s_at down -2.06 C2orf67 ENSG00000
144445 
chromosome 2 open reading 
frame 67 
230585_at down -3.97    
230846_at down -2.32 AKAP5  A kinase (PRKA) anchor 
protein 5 
230923_at down -3.96 FAM19A
1 
 family with sequence 
similarity 19 (chemokine (C-
C motif)-like), member A1 
230925_at down -6.30 APBB1IP ENSG00000
077420 
amyloid beta (A4) precursor 
protein-binding, family B, 
member 1 interacting protein 
230964_at down -2.79 FREM2 ENSG00000
150893 
FRAS1 related extracellular 
matrix protein 2 
231213_at down -2.89 PDE1A  phosphodiesterase 1A, 
calmodulin-dependent 
231576_at down -2.45    
231723_at down -2.21 SNX12 ENSG00000
147164 
sorting nexin 12 
231819_at down -2.71  ENSG00000
218739 
 
231875_at down -2.26 KIF21A ENSG00000
139116 
kinesin family member 21A 
231916_at down -3.08 EXOSC6  exosome component 6 
232318_s_at down -3.09 LOC1218
38 
 hypothetical LOC121838 




235018_at down -2.07    
235122_at down -3.69 HIVEP3 ENSG00000
127124 
human immunodeficiency 
virus type I enhancer binding 
protein 3 
235165_at down -3.13 PARD6B ENSG00000
124171 
par-6 partitioning defective 6 
homolog beta (C. elegans) 
235183_at down -2.96    
235645_at down -2.04 ESCO1 ENSG00000
141446 
establishment of cohesion 1 
homolog 1 (S. cerevisiae) 
235722_at down -2.34 SYNJ2B
P 
 synaptojanin 2 binding 
protein 
235740_at down -4.31    
235831_at down -3.36    
236234_at down -5.14 PDE1A  phosphodiesterase 1A, 
calmodulin-dependent 
236843_at down -2.26 NOX4  NADPH oxidase 4 
236977_at down -2.42 LOC6465
88 




237328_at down -2.02    




pleckstrin homology domain 
containing, family A 
(phosphoinositide binding 
specific) member 2 
238378_at down -2.05    
238623_at down -2.45    
238755_at down -5.38    
238835_at down -4.00    
239002_at down -2.08 ASPM ENSG00000
066279 
asp (abnormal spindle) 
homolog, microcephaly 
associated (Drosophila) 
239132_at down -3.86 NOS1  Nitric oxide synthase 1 
(neuronal) 
239164_at down -2.32    
239262_at down -2.20    
239486_at down -2.49    
240484_at down -2.31    
241820_at down -2.10 RIF1 ENSG00000
080345 
RAP1 interacting factor 
homolog (yeast) 
241955_at down -3.29 HECTD1 ENSG00000
092148 
HECT domain containing 1 
242321_at down -2.59    




242536_at down -3.29    
242579_at down -2.04 BMPR1B  bone morphogenetic protein 
receptor, type IB 
242680_at down -3.70    
242691_at down -2.06    




243946_at down -2.18 SMOC2 ENSG00000
112562 
SPARC related modular 
calcium binding 2 
244043_at down -2.17    
244171_at down -2.67 MKLN1 ENSG00000
128585 
muskelin 1, intracellular 
mediator containing kelch 
motifs 
244485_at down -2.21    
244567_at down -2.24    
244745_at down -2.99 RERG ENSG00000
134533 
RAS-like, estrogen-
regulated, growth inhibitor 
244864_at down -2.21    
1560477_a_at down -2.18 SAMD11 ENSG00000
187634 
sterile alpha motif domain 
containing 11 
1552378_s_at down -2.77 RDH10 ENSG00000
121039 
retinol dehydrogenase 10 
(all-trans) 









1554199_at down -2.95 PTPRO  protein tyrosine 
phosphatase, receptor type, 
O 
1554285_at down -4.57 HAVCR2 ENSG00000
135077 
hepatitis A virus cellular 
receptor 2 




ADAM metallopeptidase with 









dunce homolog, Drosophila) 
1555039_a_at down -2.03 ABCC4 ENSG00000
125257 
ATP-binding cassette, sub-
family C (CFTR/MRP), 
member 4 
1555175_a_at down -2.43 PBLD ENSG00000
108187 
phenazine biosynthesis-like 
protein domain containing 
1555555_at down -2.36 BBS9  Bardet-Biedl syndrome 9 
1555725_a_at down -2.97 RGS5 ENSG00000
143248 
regulator of G-protein 
signaling 5 
1555800_at down -19.70 ZNF385B ENSG00000
144331 
zinc finger protein 385B 
1555801_s_at down -3.78 ZNF385B ENSG00000
144331 
zinc finger protein 385B 
1558143_a_at down -2.51 BCL2L11 ENSG00000
153094 
BCL2-like 11 (apoptosis 
facilitator) 
1558404_at down -2.18 LOC6442
42 
 Hypothetical protein 
LOC644242 




1558905_at down -3.28    
1560100_at down -2.61 DLX1 ENSG00000
144355 
distal-less homeobox 1 
1560884_at down -3.68 SLC17A1  Solute carrier family 17 
(sodium phosphate), member 
1 
1562828_at down -2.29    
1566032_at down -2.61    
1566605_at down -2.37 TEX9  Testis expressed 9 


















Up‐regulated genes in NSCs migrating towards 4T1 conditioned medium 











Ensembl Gene Title 
202218_s_at up 2.26 FADS2 ENSG000001
34824 
fatty acid desaturase 2 
203027_s_at up 2.77 MVD ENSG000001
67508 
mevalonate (diphospho) decarboxylase 




B cell RAG associated protein 
204221_x_at up 2.37 GLIPR1  GLI pathogenesis-related 1 
204694_at up 2.02 AFP ENSG000000
81051 
alpha-fetoprotein 
204748_at up 2.87 PTGS2 ENSG000000
73756 
prostaglandin-endoperoxide synthase 2 
(prostaglandin G/H synthase and 
cyclooxygenase) 
205738_s_at up 2.68 FABP3 ENSG000001
21769 
fatty acid binding protein 3, muscle and heart 
(mammary-derived growth inhibitor) 
206283_s_at up 2.09 TAL1 ENSG000001
62367 
T-cell acute lymphocytic leukemia 1 
206806_at up 2.05 DGKI ENSG000001
57680 
diacylglycerol kinase, iota 
207145_at up 2.09 MSTN ENSG000001
38379 
myostatin 
209291_at up 2.74 ID4 ENSG000001
72201 
inhibitor of DNA binding 4, dominant negative 
helix-loop-helix protein 
209292_at up 2.65 ID4  Inhibitor of DNA binding 4, dominant negative 
helix-loop-helix protein 
209700_x_at up 2.08 PDE4DI
P 
 phosphodiesterase 4D interacting protein 
212805_at up 2.02 PRUNE2 ENSG000001
06772 
prune homolog 2 (Drosophila) 
213496_at up 3.05 LPPR4 ENSG000001
17600 
plasticity related gene 1 
213543_at up 2.30 SGCD  sarcoglycan, delta (35kDa dystrophin-
associated glycoprotein) 
213904_at up 3.58    
213906_at up 2.09 MYBL1 ENSG000001
85697 
v-myb myeloblastosis viral oncogene 
homolog (avian)-like 1 
214285_at up 2.69 FABP3 ENSG000001
21769 
fatty acid binding protein 3, muscle and heart 
(mammary-derived growth inhibitor) 
215995_x_at up 2.38    
216007_at up 2.15    
218723_s_at up 2.26 C13orf15 ENSG000001
02760 
chromosome 13 open reading frame 15 
221211_s_at up 2.09 C21orf7 ENSG000001
56265 
chromosome 21 open reading frame 7 




microtubule-associated protein 1 light chain 3 
gamma 
223800_s_at up 2.01 LIMS3  LIM and senescent cell antigen-like domains 
3 
226322_at up 2.09 TMTC1 ENSG000001
33687 
transmembrane and tetratricopeptide repeat 
containing 1 
226933_s_at up 2.03 ID4  Inhibitor of DNA binding 4, dominant negative 
helix-loop-helix protein 
227061_at up 2.13    
228343_at up 4.01 POU2F2 ENSG000000
28277 
POU class 2 homeobox 2 




228697_at up 4.08 HINT3 ENSG000001
11911 
histidine triad nucleotide binding protein 3 
228731_at up 2.55    
229339_at up 2.32    





229951_x_at up 2.01    
230560_at up 2.35 STXBP6 ENSG000001
68952 
syntaxin binding protein 6 (amisyn) 
232268_at up 2.05    
234136_at up 2.05    
235276_at up 2.43 EPSTI1  Epithelial stromal interaction 1 (breast) 
236302_at up 2.03 PPM1E ENSG000001
75175 
protein phosphatase 1E (PP2C domain 
containing) 
236335_at up 2.60    
237290_at up 2.26    
238451_at up 2.31 MPP7 ENSG000001
50054 
membrane protein, palmitoylated 7 (MAGUK 
p55 subfamily member 7) 
238621_at up 2.09 FMN1  formin 1 
239787_at up 2.04 KCTD4 ENSG000001
80332 
potassium channel tetramerisation domain 
containing 4 
240512_x_at up 2.19 KCTD4 ENSG000001
80332 
potassium channel tetramerisation domain 
containing 4 




solute carrier family 25, member 42 
243813_at up 2.25    
243864_at up 2.17 CCDC80 ENSG000000
91986 
coiled-coil domain containing 80 
244511_at up 2.06    
1554012_at up 2.42 RSPO2 ENSG000001
47655 
R-spondin 2 homolog (Xenopus laevis) 
1554997_a_
at 
up 3.17 PTGS2 ENSG000000
73756 
prostaglandin-endoperoxide synthase 2 
















Down‐regulated genes in NSCs migrating towards 4T1 conditioned medium 











Ensembl Gene Title 
228737_at down -16.18 TOX2 ENSG000001
24191 
TOX high mobility group box family member 2 
219730_at down -7.65 MED18 ENSG000001
30772 
mediator complex subunit 18 
210432_s_at down -4.88 SCN3A ENSG000001
53253 
sodium channel, voltage-gated, type III, alpha 
subunit 
242321_at down -4.21    
219927_at down -3.66 FCF1 ENSG000001
19616 
FCF1 small subunit (SSU) processome 
component homolog (S. cerevisiae) 
235977_at down -3.60 LONRF2 ENSG000001
70500 
LON peptidase N-terminal domain and ring 
finger 2 
217590_s_at down -3.48 TRPA1 ENSG000001
04321 
transient receptor potential cation channel, 
subfamily A, member 1 
1558680_s_at down -3.43 PDE1A ENSG000001
15252 
phosphodiesterase 1A, calmodulin-dependent 
223939_at down -3.39 SUCNR1 ENSG000001
98829 
succinate receptor 1 
1558515_at down -3.36    




probable ubiquitin-conjugating enzyme E2 
FLJ25076 
238755_at down -3.12    





1567044_s_at down -3.01    
239132_at down -2.92 NOS1  Nitric oxide synthase 1 (neuronal) 
230585_at down -2.92    
233231_at down -2.91 MCCC2  Methylcrotonoyl-Coenzyme A carboxylase 2 
(beta) 
228625_at down -2.89 CITED4 ENSG000001
79862 
Cbp/p300-interacting transactivator, with 
Glu/Asp-rich carboxy-terminal domain, 4 
241955_at down -2.85 HECTD1 ENSG000000
92148 
HECT domain containing 1 
211022_s_at down -2.75 ATRX ENSG000000
85224 
alpha thalassemia/mental retardation 
syndrome X-linked (RAD54 homolog, S. 
cerevisiae) 
208396_s_at down -2.72 PDE1A ENSG000001
15252 
phosphodiesterase 1A, calmodulin-dependent 




probable ubiquitin-conjugating enzyme E2 
FLJ25076 
202291_s_at down -2.66 MGP ENSG000001
11341 
matrix Gla protein 
231916_at down -2.65 EXOSC6  exosome component 6 
206306_at down -2.64 RYR3 ENSG000001
98838 
ryanodine receptor 3 
239123_at down -2.63    
203796_s_at down -2.61 BCL7A ENSG000001
10987 
B-cell CLL/lymphoma 7A 




sulfotransferase family, cytosolic, 1C, member 
2 
217373_x_at down -2.59 MDM2 ENSG000001
35679 
Mdm2 p53 binding protein homolog (mouse) 
1560775_at down -2.58    
198 
 
204988_at down -2.57 FGB ENSG000001
71564 
fibrinogen beta chain 
236843_at down -2.57 NOX4  NADPH oxidase 4 
219976_at down -2.57 HOOK1 ENSG000001
34709 
hook homolog 1 (Drosophila) 
231200_at down -2.52 LSM14B ENSG000001
49657 
LSM14B, SCD6 homolog B (S. cerevisiae) 
1562836_at down -2.52    
235122_at down -2.49 HIVEP3 ENSG000001
27124 
human immunodeficiency virus type I 
enhancer binding protein 3 
243489_at down -2.49    
204867_at down -2.48 GCHFR ENSG000001
37880 
GTP cyclohydrolase I feedback regulator 
220586_at down -2.47 CHD9  chromodomain helicase DNA binding protein 9 
221986_s_at down -2.47 KLHL24 ENSG000001
14796 
kelch-like 24 (Drosophila) 
227450_at down -2.46 ERP27 ENSG000001
39055 
endoplasmic reticulum protein 27 
216238_s_at down -2.45 FGB ENSG000001
71564 
fibrinogen beta chain 
1558173_a_at down -2.44 LUZP1 ENSG000001
69641 
leucine zipper protein 1 
232132_at down -2.43 PARD6G ENSG000001
78184 
par-6 partitioning defective 6 homolog gamma 
(C. elegans) 
226548_at down -2.42 SBK1 ENSG000001
88322 
SH3-binding domain kinase 1 
240757_at down -2.41 CLASP1  Cytoplasmic linker associated protein 1 




heterogeneous nuclear ribonucleoprotein U-
like 2 




ankyrin repeat domain 44 
241724_x_at down -2.28    
202840_at down -2.28 TAF15 ENSG000001
72660 
TAF15 RNA polymerase II, TATA box binding 
protein (TBP)-associated factor, 68kDa 
239262_at down -2.27    




zinc finger CCCH-type containing 11A 




zinc finger protein 385D 




tumor necrosis factor (ligand) superfamily, 
member 18 
212650_at down -2.26 EHBP1 ENSG000001
15504 
EH domain binding protein 1 
231213_at down -2.25 PDE1A  phosphodiesterase 1A, calmodulin-dependent 
212095_s_at down -2.25 MTUS1 ENSG000001
29422 
mitochondrial tumor suppressor 1 
201340_s_at down -2.24 ENC1 ENSG000001
71617 
ectodermal-neural cortex (with BTB-like 
domain) 
218211_s_at down -2.23 MLPH ENSG000001
15648 
melanophilin 
202880_s_at down -2.23 CYTH1 ENSG000001
08669 
cytohesin 1 
242741_x_at down -2.23    
242518_at down -2.21    
1554199_at down -2.21 PTPRO  protein tyrosine phosphatase, receptor type, O 
235321_at down -2.19    
215891_s_at down -2.19 GM2A ENSG000001
96743 
GM2 ganglioside activator 




amyloid beta (A4) precursor protein-binding, 
family B, member 1 interacting protein 





226655_at down -2.18 STX17  syntaxin 17 
202879_s_at down -2.18 CYTH1 ENSG000001
08669 
cytohesin 1 
1557227_s_at down -2.18 TPR ENSG000000
47410 
translocated promoter region (to activated 
MET oncogene) 




coiled-coil domain containing 88A 
233547_x_at down -2.17 PDE1A ENSG000001
15252 
phosphodiesterase 1A, calmodulin-dependent 




family with sequence similarity 149, member A 
1560100_at down -2.17 DLX1 ENSG000001
44355 
distal-less homeobox 1 
1555564_a_at down -2.16 CFI ENSG000002
05403 
complement factor I 
206932_at down -2.16 CH25H ENSG000001
38135 
cholesterol 25-hydroxylase 
212382_at down -2.15 TCF4 ENSG000001
96628 
transcription factor 4 
235282_at down -2.15    
230964_at down -2.15 FREM2 ENSG000001
50893 
FRAS1 related extracellular matrix protein 2 
244419_at down -2.15 FRZB  Frizzled-related protein 




histone cluster 1, H2bg 
210119_at down -2.10 KCNJ15 ENSG000001
57551 
potassium inwardly-rectifying channel, 
subfamily J, member 15 





232861_at down -2.10 PDP2 ENSG000001
72840 
pyruvate dehydrogenase phosphatase 
isoenzyme 2 
212909_at down -2.08 LYPD1 ENSG000001
50551 
LY6/PLAUR domain containing 1 
202827_s_at down -2.08 MMP14 ENSG000001
57227 
matrix metallopeptidase 14 (membrane-
inserted) 
1556325_at down -2.08 FILIP1  filamin A interacting protein 1 
229033_s_at down -2.07 MUM1  melanoma associated antigen (mutated) 1 
230865_at down -2.07 LIX1 ENSG000001
45721 
Lix1 homolog (chicken) 
217370_x_at down -2.07 NR1H3 ENSG000000
89280 
nuclear receptor subfamily 1, group H, 
member 3 




204638_at down -2.06 ACP5 ENSG000001
02575 
acid phosphatase 5, tartrate resistant 
1564962_at down -2.06 ZNF92 ENSG000001
46757 
zinc finger protein 92 
209258_s_at down -2.05 SMC3 ENSG000001
08055 
structural maintenance of chromosomes 3 
221985_at down -2.05 KLHL24 ENSG000001
14796 
kelch-like 24 (Drosophila) 
203698_s_at down -2.05 FRZB ENSG000001
62998 
frizzled-related protein 




histone cluster 1, H2bg 




protein phosphatase 1, regulatory (inhibitor) 
subunit 9A 
206259_at down -2.02 PROC ENSG000001
15718 
protein C (inactivator of coagulation factors Va 
and VIIIa) 
1553304_at down -2.02 LSM14B ENSG000001
49657 
LSM14B, SCD6 homolog B (S. cerevisiae) 
209652_s_at down -2.00 PGF ENSG000001
19630 




Supplementary Table 3. Overlapping between affected genes detected in NSCs migrated 
towards 4T1 and U87 conditioned medium 








































prostaglandin-endoperoxide synthase 2 









diacylglycerol kinase, iota 
20929
1_at 
up 4.28 2.74 ID4 ENSG00
0001722
01 








up 2.20 3.58    
21390
6_at 





v-myb myeloblastosis viral oncogene 
homolog (avian)-like 1 
21600
7_at 


















chromosome 21 open reading frame 7 
22632
2_at 














up 2.82 2.13    
22836
7_at 













histidine triad nucleotide binding protein 3 
22873
1_at 
up 2.81 2.55    
22933
9_at 
up 4.30 2.32    
22976
1_at 














syntaxin binding protein 6 (amisyn) 
23226
8_at 
up 3.27 2.05    
23527
6_at 
up 4.18 2.43 EPS
TI1 
 Epithelial stromal interaction 1 (breast) 
23633
5_at 
up 2.84 2.60    
23729
0_at 










membrane protein, palmitoylated 7 (MAGUK 
p55 subfamily member 7) 
23862
1_at 
up 2.22 2.09 FMN
1 
 formin 1 
23978
7_at 



















up 5.93 2.25    
24386
4_at 





coiled-coil domain containing 80 
24451
1_at 









prostaglandin-endoperoxide synthase 2 
















































Ensembl Gene Title 
202880
_s_at 















down -4.19 -2.57 FGB ENSG000
00171564 
fibrinogen beta chain 
206306
_at 




ryanodine receptor 3 
208396
_s_at 






















retardation syndrome X-linked 
(RAD54 homolog, S. cerevisiae) 
212095
_s_at 
















down -5.62 -2.45 FGB ENSG000
00171564 
fibrinogen beta chain 
218211
_s_at 



















hook homolog 1 (Drosophila) 
220117
_at 




zinc finger protein 385D 
221009
_s_at 











succinate receptor 1 
226612
_at 





enzyme E2 FLJ25076 
226618
_at 





enzyme E2 FLJ25076 
227450
_at 








down -3.97 -2.92    
230925
_at 




amyloid beta (A4) precursor 
protein-binding, family B, 
member 1 interacting protein 
230964
_at 




FRAS1 related extracellular 
matrix protein 2 
231213
_at 
down -2.89 -2.25 PDE1
A 




down -3.08 -2.65 EXO
SC6 
 exosome component 6 
233547
_x_at 












human immunodeficiency virus 




down -2.26 -2.57 NOX
4 
 NADPH oxidase 4 
238755
_at 





down -3.86 -2.92 NOS
1 




down -2.20 -2.27    
241955
_at 




HECT domain containing 1 
242321
_at 
down -2.59 -4.21    
155419
9_at 
down -2.95 -2.21 PTP
RO 
 protein tyrosine phosphatase, 
receptor type, O 
155868
0_s_at 








down -2.61 -2.17 DLX1 ENSG000
00144355 
distal-less homeobox 1 
 
 
 
 
 
 
 
 
 
 
 
